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Abstract 
The Hippo tumour suppressor pathway regulates tissue growth by co-ordinating cell 
death, proliferation and differentiation. The central Hippo core cassette consists of 
MST1/2, LATS1/2, NDR1/2 and MOB1, with recent studies of MOB1 knockout mice 
indicating MOB1 functions as the central hub of Hippo signalling. However, it has 
remained unknown which interactions of MOB1 with the Hippo core cassette kinases 
MST1/2, LATS1/2 and NDR1/2 are required for normal life and tumour suppression. 
Therefore, my PhD project focused on deciphering the complex protein-protein 
interactions of MOB1 with MST1/2, LATS1/2 and NDR1/2. To do so, we generated a 
series of MOB1 variants that are selectively impaired in their binding to NDR1/2 (Trc), 
MST1/2 (Hippo), or LATS1/2 (Warts) in human (fly) cells. Using these selective loss-
of-interaction (SLOI) variants we studied the effects of MOB1 overexpression on the 
proliferation and anchorage-independent growth of human cancer cell lines, thereby 
establishing which MOB1 interactions are required for the tumour suppressive role of 
MOB1. Equally importantly, we found that human MOB1 can restore the survival of 
mats loss-of-function (LOF) in Drosophila. By generating and studying transgenic flies 
expressing our SLOI MOB1 variants combined with Mats LOF, we discovered that the 
Hippo/MOB1A interaction is dispensable for fly development and reproduction, while 
the Trc/MOB1A and Wts/MOB1A interactions are essential. Taken together, my PhD 
thesis defined a completely novel panel of MOB1 SLOI variants to study the importance 
of MOB1 interactions. By studying transgenic human cells lines and flies expressing 
these SLOI variants we delineated which MOB1 interactions are essential for life of a 
complex multicellular organisms and for tumour suppression in human cancer cells. 
Collectively, our findings suggest that the Hippo/MOB1 interaction is neither required 
for life nor for tumour suppression, while the other interactions of MOB1 with Hippo 
core cassette kinases are essential in a context-dependent manner. 
  
iii | P a g e  
 
Acknowledgements 
First of all, I would like to thank so much to Alex, for being such a supportive, 
motivational supervisor, for giving me an opportunity I would have never obtained in 
my life to work in such a motivating scientific environment and for being such a 
patient and tolerant to my “weak” English at the very beginning. I remember the first 
time I came in to meet Alex about my PhD project. At that time, Alex was outlining 
the PhD project and I remember well that I did not understand even one single word. 
Then, I remembered the famous saying from Richard Branson “If someone offers you 
an amazing opportunity and you are not sure you can do it, say YES, and then learn 
how to do it later”. All of a sudden, someone came in and asked Alex “Who is he”, 
after seeing me. He replied, “He is a new PhD student”. She answered, “Oooo, he is 
a new victim, then”, while smiling Alex replied again, “No, he is a new victor”. And, 
I started thinking, like “Am I going to achieve it?”. My gut feeling was telling me, 
“Yes, you can”. And I listened to my gut feeling. 
Also, I would like to thank all the members of the Hergovich Lab, especially 
to Ramazan, for being such a friendly and supportive. Also, my big thanks go to Nic 
Tapon, Ivana Bjedov, and Maxine Holder for being such a helpful in my Drosophila 
studies. 
Lastly, my big thanks go to the folks of Arnos grove house for being 
supportive. It would be shame for me if I forget to thank Ufuk Ucar for supporting 
me physiologically.    
 
 
 
  
iv | P a g e  
 
Turkish Acknowledgements 
Değerli Annecim, Babacım ve Amcacım (Metin Kulaberoglu), 
Size nasıl teşekkür edeceğimi gerçekten bilmiyorum. Daha doğrusu size ne kadar 
teşekkür etsem, bu yeterli olmaz. Anadolu lisesine kazandığımda, daha iyi eğitim 
alabilmem için, yediklerinden kısarak beni özel okula gönderdiğinizi, anneciğimin 
altınlarını satıp, bizlerin eğitimine verdiğini unutamam. Alinlerin terleriyle 
kazandıkları kazançları, eğitimime yatirdiğiniz hiç unutulur mu? Yaptığınız bu 
fedakârlıklar her zaman aklımda ve hiç unutmayacağım. Bende sizlerin bu 
fedakârlıklarına karşılık, Allah şahittir, canimi dişime takip calistim ve elimden 
geleni yaptım. Hiç şüpheniz olmasın, size utandıracak hiçbir şey yapmadım. 
Dünyanın en iyi 25. Üniversitesinde yüksek lisans eğitimimi tamamladım ve 
dünyanın en iyi 10. Üniversitesinde, an itibariyle doktora eğitimimi bitirmek 
üzereyim. Ve dünyanın en iyi 4. Üniversitesi olan Cambridge Üniversitesinden 3 
sene, post-doc teklifi aldım. Bu basarilari elde ederken, Allah`tan başka kimseden 
yârdim talep etmedim.  
Baba yarim olan, Metin amcamın, ailemin bu zorlu süreçlerinde hem maddi hem de 
manevi olarak yanında olmasını da unutmak çok büyük vefasızlık olur. Amca, bu 
elde edilmiş başarılarda, senin de çok büyük payın var ve sana nasıl teşekkür 
edeceğimi bilmiyorum!!! Ve bu basarilari elde etmemde, maddi ve manevi olarak 
yanımda olan, Yasin abimi, kardeşim Beyza’yı, babaannemi, Gülay yengemi 
unutmak ise büyük vefasızlık olur. Hepinizi çok seviyorum ve teşekkür ediyorum… 
Son olarak, Aziz Türkiye Cumhuriyeti Devleti`ne, bana sponsorluk yaptığı için çok 
teşekkür ediyorum. Aziz milletimin, alin terlerinden akıtarak vermiş olduğu 
vergilerle almış olduğum eğitimle, basta insanlığa sonra Aziz Türk milletine hizmet 
edeceğimden kimsenin kuskusu olmasın. 
 
  
v | P a g e  
 
Abbreviations 
AGC…………………………………… Protein kinase A (PKA)/PKG/PKC-like. 
AS…………………………………….... Activation segment motif 
CRB……………………………………. Crumbs 
DKO……………………………………. Double knock-out 
EMT…………………………………….. Epithelial-mesenchymal transition 
ErbB4……………………………………. Receptor tyrosine-protein kinase erbB-4 
Ex………………………………………… Expanded 
GPCR…………………………………….. G-protein coupled receptor 
HID……………………………………….. Head involution defective 
HIPK……………………………………… Homeodomain interacting protein kinase 
HM………………………………………... Hydrophobic motif 
HP…………………………………………. Hematoporphrin 
Hpo………………………………………... Hippo 
Hppy………………………………………. Happyhour 
IAP……………………………………….... Inhibitors of apoptosis protein 
KO…………………………………………. Knock-out 
LATS1/2…………………………………… Large tumour suppressor 1/2 
LIFR……………………………………….. Leukemia inhibitory factor receptor 
LPA………………………………………... serum-borne lysophosphatidic acid 
MAP……………………………………… Microtubule affinity-regulating kinase 1 
MAP4K…………………………………... Mitogen-activated protein kinase 
mats………………………………………. Mob as a tumour suppressor 
MEN……………………………………… Mitotic exit network 
vi | P a g e  
 
MOB1…………………………………….. Mps-one binder 1 
MST1/2………………………… Mammalian Ste20-like serine/threonine kinases 1/2 
NDR……………………………………… Nuclear dbf2 related 
NF2……………………………………….. Neurofibromatosis-2 
NTR………………………………………. N-terminal regulatory domain 
OA………………………………………… Okadaic acid 
PAR……………………………………….. Protease-activated receptors 
PP2A………………………………………. Protein phosphatase type 2A 
PPI…………………………………………. Protein-protein interaction 
RASSF……………………………………... RAS association domain family 
RUNX1/2…………………………………... Runt-related transcription factor 1 
S1P…………………………………………. Sphingosine 1-phosphate 
SAV………………………………………... Salvador 
SIK…………………………………………. Salt-inducible kinase 
SIN…………………………………………. Septation initiation network 
TAO1………………………………………. Serine/threonine-protein kinase 
 TAZ………………………… Transcriptional co-activator with PDZ-binding motif  
TBX5……………………………………… T-box transcription factor 5 
TEAD……………………………………… TEA domain family member 
Trc………………………………………….. Tricornered 
TSG………………………………………… Tumour suppressor gene 
VGLL4……………………………………... Vestigial-like family member 4 
 VP………………………………………….. Verteporfin 
Wts………………………………………….. Warts 
vii | P a g e  
 
YAP………………………………………… Yes associated protein 
Yki…………………………………………... Yorkie 
β-TrCP………………. beta-transducin repeat containing E3 ubiquitin protein ligase 
 
 
 
 
 
 
 
  
viii | P a g e  
 
Table of Contents 
1. Introduction ......................................................................................................................... 1 
1.1. General introduction ..................................................................................................... 1 
1.2. The Core kinase network of the Hippo Pathway .......................................................... 4 
1.3. Upstream regulators of the Hippo pathway ............................................................... 12 
1.4. Hippo signalling in diseases ........................................................................................ 14 
1.4.1. The Hippo pathway and cancer ........................................................................... 14 
1.4.2. Hippo signalling in non-cancer pathologies ......................................................... 18 
1.4.3. Hippo Signalling as a therapeutic target .............................................................. 20 
1.5. MOB Proteins .............................................................................................................. 23 
1.5.1. MOB proteins in budding and fission yeast ......................................................... 24 
1.5.2. MOB proteins in Drosophila ................................................................................. 26 
1.5.3. MOBs in mammalian cells .................................................................................... 31 
1.5.4. Regulation of MOB1/Mats Proteins in Drosophila and Mammals ...................... 32 
1.5.4. Mats/MOB1A in cancer ........................................................................................ 36 
1.6. Research Aims ............................................................................................................. 40 
2. Materials and Methods ...................................................................................................... 41 
2.1. Materials ..................................................................................................................... 41 
2.1.1. Reagents ............................................................................................................... 41 
2.1.2. Antibodies ............................................................................................................ 47 
2.1.3. Buffers and Solutions ........................................................................................... 48 
2.1.4. Plasmids ............................................................................................................... 60 
2.1.5. Oligonucleotides .................................................................................................. 61 
2.2. Methods ...................................................................................................................... 63 
2.2.1. Molecular Biology Techniques ............................................................................. 63 
2.2.2. Biochemistry methods ......................................................................................... 79 
2.2.3. Cell biology methods ............................................................................................ 85 
2.2.4. Structural Studies Methods (performed in collaboration with the Wu Laboratory)
 ....................................................................................................................................... 90 
2.2.5. Fly genetics ........................................................................................................... 92 
3. Results .............................................................................................................................. 104 
3.1. Structural and biochemical definition of the importance of MOB1A-NDR, MOB1A-
LATS, and MOB1A-MST complex formation .................................................................... 104 
3.1.1. Abstract .............................................................................................................. 104 
3.1.2. Introduction ....................................................................................................... 105 
ix | P a g e  
 
3.1.3. Results - Structural definition of MOB1-NDR2 and MOB1-LATS1 complex 
formations .................................................................................................................... 107 
3.1.4. Results - Characterization of MOB1A mutants with selective binding to 
MST/NDR/LATS kinases in mammalian cells ................................................................ 115 
3.1.5. Discussion ........................................................................................................... 123 
3.2. Defining the importance of complex formation of MOB1A with the Hpo, Wts, and Trc 
kinases in fly cells ............................................................................................................. 126 
3.2.1. Abstract .............................................................................................................. 126 
3.2.2. Introduction ....................................................................................................... 127 
3.2.3. Results - Characterization of MOB1A mutants with selective binding to the 
Hpo/Wts/Trc kinases in fly cells ................................................................................... 128 
3.2.4. Discussion ........................................................................................................... 134 
3.3. Defining phosphorylation patterns of our MOB1A variants by human MST1/2 and fly 
Hpo kinases ...................................................................................................................... 135 
3.3.1. Abstract .............................................................................................................. 135 
3.3.2. Introduction ....................................................................................................... 136 
3.3.3. Results - Testing selective MOB1A mutants as MST1/2 substrates .................. 137 
3.3.4. Results - Testing selective MOB1A mutants as Hpo substrates ......................... 144 
3.3.5. Discussion ........................................................................................................... 147 
3.4. Defining the tumour suppressive roles for MOB1A interactions with Hippo core 
kinases in human cancer cells .......................................................................................... 148 
3.4.1. Abstract .............................................................................................................. 148 
3.4.2. Introduction ....................................................................................................... 149 
3.4.3. Results ................................................................................................................ 151 
3.4.4. Discussion ........................................................................................................... 156 
3.5. Defining the tumour suppressive roles of MOB1A interactions with the Hippo core 
kinases in Drosophila melanogaster ................................................................................ 158 
3.5.1. Abstract .............................................................................................................. 158 
3.5.2. Introduction ....................................................................................................... 159 
3.5.3. Results – The characterisation of Mats loss-of-function and transgenic flies 
expressing MOB1A variants ......................................................................................... 161 
3.5.4. Results – The characterisation of transgenic flies expressing MOB1A variants in 
mosaic fly tissues ......................................................................................................... 165 
3.5.3. Discussion ........................................................................................................... 176 
4. Final discussion ................................................................................................................ 179 
4.1. Final discussion - from structural biology to cell culture .......................................... 179 
4.2. Final discussion - from human cells and Drosophila melanogaster .......................... 182 
4.3. Future outlook .......................................................................................................... 185 
x | P a g e  
 
5. References ....................................................................................................................... 187 
Supplementary Data ............................................................................................................ 200 
Supplementary Table S1 Data collection and refinement statistics. ............................... 200 
Appendix 1 ........................................................................................................................... 205 
Appendix 2 ........................................................................................................................... 215 
 
  
xi | P a g e  
 
Table of Figures 
Figure 1.1. The involvement of the Hippo pathway in different cellular processes. .............................. 2 
Figure 1.2.  Schematic illustration of the human Hippo pathway. ......................................................... 9 
Figure 1.3. Schematic illustration of the Drosophila Hippo pathway. ................................................ 11 
Figure 1.4.  Hippo (MST1/2) loss-of-function phenotypes in Drosophila and mice. ........................... 14 
Figure 1.5. Conservation of the Mats gene. ......................................................................................... 30 
Figure 1.6. A proposed model for Wts activation. ............................................................................... 34 
Figure 1. 7. The implications of the Mats loss-of-function in cancer-related phenotypes. .................. 37 
Figure 2.1. Cloning of MOB1A into pcDNA3.1_myc. _______________________ 71 
Figure 2.2. The cloning of myc-MOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, 
HA-Trc, HA-Warts into pENTR3C. ______________________________________ 73 
Figure 2.3. The cloning of myc-hMOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, 
HA-Trc, HA-Wts into pAW. ____________________________________________ 74 
Figure 2.4. The cloning of MOB1A cDNAs into pMAL-2C. ___________________ 76 
Figure 2.5. The cloning of MOB1A cDNAs into PKC26W pUbi. _______________ 78 
Figure 2.6. A Schematic representation of ΦC31-mediated insertion. ___________ 94 
Figure 2.7. Differences between wild type and TM6B balancer flies. ___________ 95 
Figure 2.8. The generation of the balanced flies. ___________________________ 96 
Figure 2. 9. Recombination of Roo transposon. ____________________________ 97 
Figure 2.10. Recombination of FRT sites. ________________________________ 99 
Figure 2.11. The FLP/FRT system. _____________________________________ 102 
Figure 3.1. The MOB1A/NDR2 structure reveals that MOB1A and NDR2 interact 
through conserved interfaces. _________________________________________ 108 
Figure 3.2. NDR2 and LATS2 bind to MOB1A through different key 
residues/mechanisms. _______________________________________________ 111 
Figure 3. 3.  Characterization of MOB1A(D63V) and MOB1A(K104E/K105E) 
binding to NDR2, LATS1 and MST2 by gel filtration chromatography. ________ 113 
Figure 3.4. Characterization of the interaction of MOB1A variants with MST1/2. 116 
Figure 3.5. Characterization of the interaction of MOB1A variants with the LATS1/2 
kinases. __________________________________________________________ 118 
Figure 3.6. Characterization of the interaction of MOB1A variants with NDR1/2. 119 
Figure 3.7. Generation of MOB1A variants to dissect the importance of MOB1A 
interactions with mammalian Hippo core cassette kinases. __________________ 122 
Figure 3.8. Characterization of the interaction of MOB1A variants with the fly Hippo 
kinase____________________________________________________________ 129 
xii | P a g e  
 
Figure 3.9. Characterization of the interaction of MOB1A variants with the Wts 
kinase. ___________________________________________________________ 130 
Figure 3.10. Characterization of the interaction of MOB1A variants with the Trc 
kinase____________________________________________________________ 131 
Figure 3.11. Generation of MOB1 variants to dissect the importance of MOB1 
interactions with Drosophila Hippo core cassette kinases. __________________ 133 
Figure 3.12. Bacterially expressed and purified MAL-MOB1A variants. _______ 137 
Figure 3.13. Phosphorylation of MOB1A mutants by MST1/2. _______________ 138 
Figure 3.14. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in 
the context of MST1/2-mediated phosphorylation of MOB1A. ________________ 140 
Figure 3.15. Characterization of the MST1/2-mediated phosphorylation of MOB1A 
variants. __________________________________________________________ 142 
Figure 3.16. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in 
the context of Hippo-mediated phosphorylation of MOB1A. _________________ 144 
Figure 3.17. Characterization of the MST1/2(Hippo)-mediated phosphorylation of 
MOB1A variants. __________________________________________________ 145 
Figure 3.18. MOB1A functions as tumour suppressor by decreasing cell 
proliferation. ______________________________________________________ 152 
Figure 3. 19.  MOB1A can suppress proliferation and anchorage-independent 
growth of human cancer cells through different interactions with Hippo core cassette 
kinases. __________________________________________________________ 154 
Figure 3.20. Confirmation of the homozygous lethality caused by Mats loss-of-
function. _____________________________________________________________  
Figure 3. 21. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) 
rescues larval lethality of Mats deficient flies. ____________________________ 163 
Figure 3.22. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) 
rescues tissue overgrowth phenotype driven by Mats loss-of-function __________ 166 
Figure 3.23. Ubiquitous expression of the MOB1A(wt) transgene restores expanded 
upregulation in Mats
roo
 mutant clones in wing imaginal discs. _______________ 168 
Figure 3.24. Ubiquitous expression of MOB1A(wt) transgene rescues Expanded 
upregulation in Mats
roo
 mutant clones in the eye imaginal discs. _____________ 170 
Figure 3.25.  Expression of MOB1A(KEKE) restores normal Ex levels in Mats
roo
 
mutant clones in the wing imaginal disc, while expression of MOB1A(DV) or 
MOB1A(DVKEKE) does not. _________________________________________ 172 
xiii | P a g e  
 
Figure 3.26. Expression of MOB1A(KEKE) restores normal Ex levels in Mats
roo
 
mutant clones in the eye imaginal disc, while expression of MOB1A(DV) or 
MOB1A(DVKEKE) does not. 174 
 
Figure 2.1. Cloning of MOB1A into pcDNA3.1_myc. .......................................................................... 71 
Figure 2.2. The cloning of myc-MOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, HA-Trc, HA-Warts 
into pENTR3C. ..................................................................................................................................... 73 
Figure 2.3. The cloning of myc-MOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, HA-Trc, HA-Wts 
into pAW. .............................................................................................................................................. 74 
Figure 2.4. The cloning of MOB1A cDNAs into pMAL-2C. ................................................................. 76 
Figure 2.5. The cloning of MOB1A cDNAs into PKC26W pUbi. ......................................................... 78 
Figure 2.6. A Schematic representation of ΦC31-mediated insertion. ................................................ 94 
Figure 2.7. Differences between wild type and TM6B balancer flies................................................... 95 
Figure 2.8. The generation of balanced stocks. ................................................................................... 96 
Figure 2.9. Recombination of Roo transposon. .................................................................................... 97 
Figure 2.10. Recombination of FRT sites. ............................................................................................ 99 
Figure 2.11. The FLP/FRT system. .................................................................................................... 102 
 
Figure 3.1. The MOB1A/NDR2 structure reveals that MOB1A and NDR2 interact through conserved 
interfaces. ........................................................................................................................................... 108 
Figure 3.2. NDR2 and LATS2 bind to MOB1A through different key residues/mechanisms. ............ 111 
Figure 3. 3.  Characterization of MOB1A(D63V) and MOB1A(K104E/K105E) binding to NDR2, 
LATS1 and MST2 by gel filtration chromatography. ......................................................................... 113 
Figure 3.4. Characterization of the interaction of MOB1A variants with MST1/2. ........................... 116 
Figure 3.5. Characterization of the interaction of MOB1A variants with the LATS1/2 kinases. ....... 118 
Figure 3.6. Characterization of the interaction of MOB1A variants with NDR1/2. .......................... 119 
Figure 3.7. Generation of MOB1A variants to dissect the importance of MOB1A interactions with 
mammalian Hippo core cassette kinases. ........................................................................................... 122 
Figure 3.8. Characterization of the interaction of MOB1A variants with the fly Hpo kinase. ........... 129 
Figure 3.9. Characterization of the interaction of MOB1A variants with the Wts kinase.................. 130 
Figure 3.10. Characterization of the interaction of MOB1A variants with the Trc kinase ................ 131 
Figure 3.11. Generation of MOB1 variants to dissect the importance of MOB1 interactions with 
Drosophila Hippo core cassette kinases. ........................................................................................... 133 
Figure 3.12. Bacterially expressed and purified MAL-MOB1A variants. .......................................... 137 
Figure 3.13. Phosphorylation of MOB1A mutants by MST1/2. ......................................................... 138 
Figure 3.14. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in the context of 
MST1/2-mediated phosphorylation of MOB1A. ................................................................................. 140 
Figure 3.15. Characterization of the MST1/2-mediated phosphorylation of MOB1A variants. ........ 142 
Figure 3.16. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in the context of 
Hippo-mediated phosphorylation of MOB1A. .................................................................................... 144 
Figure 3.17. Characterization of the MST1/2(Hippo)-mediated phosphorylation of MOB1A variants.
............................................................................................................................................................ 145 
Figure 3.18. MOB1A functions as tumour suppressor by decreasing cell proliferation. ................... 152 
Figure 3. 19.  MOB1A can suppress proliferation and anchorage-independent growth of human 
cancer cells through different interactions with Hippo core cassette kinases.................................... 154 
Figure 3.20. Confirmation of the homozygous lethality caused by mats loss-of-function. ................. 161 
Figure 3.21. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) rescues larval 
lethality of mats deficient flies. ........................................................................................................... 163 
xiv | P a g e  
 
Figure 3.22. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) rescues tissue 
overgrowth phenotype driven by Mats loss-of-function ..................................................................... 166 
Figure 3.23. Ubiquitous expression of the MOB1A(wt) transgene restores ex upregulation in mats
roo
 
mutant clones in wing imaginal discs. ................................................................................................ 168 
Figure 3.24. Ubiquitous expression of MOB1A(wt) transgene rescues Ex upregulation in mats
roo
 
mutant clones in the eye imaginal discs. ............................................................................................ 170 
Figure 3.25.  Expression of MOB1A(KEKE) restores normal Ex levels in mats
roo
 mutant clones in the 
wing imaginal disc, while expression of MOB1A(DV) or MOB1A(DVKEKE) does not. ................... 172 
Figure 3.26. Expression of MOB1A(KEKE) restores normal Ex levels in mats
roo
 mutant clones in the 
eye imaginal disc, while expression of MOB1A(DV) or MOB1A(DVKEKE) does not. ..................... 174 
 
 
 
 
 
 
 
 
 
 
  
xv | P a g e  
 
Publications 
Bold and # indicate first or equally contributed authorship. 
Hoa, L.#, Y. Kulaberoglu#, R. Gundogdu, D. Cook, M. Mavis, M. Gomez, V. Gomez and A. 
Hergovich. "The Characterisation of Lats2 Kinase Regulation in Hippo-Yap 
Signalling." Cellular Signalling 28, no. 5 (2016): 488-497. 
Kulaberoglu, Y.#,Gundogdu, R., and Hergovich, A. Role of p53/p21/p16 in DNA damage 
signalling and DNA repair. Genome Stability (in press). 
http://store.elsevier.com/Genome-Stability/isbn-9780128033098/ 
Kulaberoglu, Y.#, Gomez, M., Assefa Shifa, B., Hoa, L., Tapon, N. and Hergovich, A. The 
functional characterisation of the regulatory MOB1 interactions in Hippo kinase 
signalling reveals essential roles for MOB1-containing complexes. (planned submission 
to Nature Structural and Molecular Biology (in 2016) 
 Chisnall, B., C. Johnson, Y. Kulaberoglu and Y. W. Chen. "Insoluble Protein Purification with 
Sarkosyl: Facts and Precautions." Methods Mol Biol 1091,  (2014): 179-86. 
 
 
Conference attended 
2015 (between 21
th
 and 24
th
 August): Oral Presentation, 4th National Molecular 
biology and Biotechnology Conference, Afyonkarahisar, Turkey 
 
Leadership experiences 
2014-2015:   Personal tutor for Onur Kahraman and Mustafa Taher (Master students 
in UCL Cancer Institute) 
2015-2016:   Personal tutor for Annabel Tran and Angela Li (Master students in 
UCL Cancer Institute) 
2014-2015:   Supervision for Merdiye Mavis (Master student in UCL cancer 
Institute, passed with Merit, Thesis title: Biochemical and Structural Definition of 
MOB1 Loss of Interaction Variant 
i | P a g e  
 
Awards 
 A full scholarship for Master and PhD study abroad awarded by Ministry of 
National Education of Turkey 
 Post-doctorate research associate, sponsored by Cancer-Research UK for 3 
years, under supervision of Dr Ewan St. John Smith, University of 
Cambridge in the department of pharmacology ( Expected start date: 6 
October 2016) 
 
Outreach/public engagement activities 
2014 – Present: Exhibitor at London Innovation Society in Inspiring Science 
Scheme 
 I am exhibitor of London Innovation Society (LIS) and run public 
engagement activity named “Who do you think you are?” in collaboration 
with LIS. The public engagement activity takes 55 minutes and includes the 
following hands-on activities; 
 Building up the model DNA using play-dough 
 Extracting pupil`s DNA from their saliva and sequencing their DNA 
 Tracing their possible ancestor using sequence analysis 
 The public engagement activities performed so far are listed below; 
 2015: North London Grammar School (NLGS), student aged 11-16. 
 2016: King Fahad Academy, Girls Grade 9G1 (Yr 10)  
 2016: King Fahad Academy, Boys Grade 9B1 (Yr 10) 
 2016: Ashmole Academy, Student year 10 
 
 
 
 
  
1 | P a g e  
 
1. Introduction 
1.1. General introduction 
The regulation of cell proliferation, death and differentiation is regarded as 
one of the most fundamental biological processes not only to ensure proper 
organ size during development but also to sustain tissue homeostasis during 
postnatal life. The coordination of these processes is considered crucial for 
physiological and pathological conditions (Galliot and Ghila 2010). Cell 
proliferation and differentiation is needed to ensure proper organ size and 
differentiation of multiple cell types, allowing to function accurately, during 
development (Gomez, Gomez et al. 2014). In adult animal, most tissues are 
subjected to continuous cell turnover to sustain functionality. Aged and/or 
damaged cells undergo apoptosis (also known as programmed cell death), 
followed by replacement of these aged and/or damaged cells by 
differentiating adult stem cells, which can replenish dysfunctional cells. 
Under normal conditions, wound healing and organ regeneration is tightly 
controlled and regulated by cell division and differentiation of tissue 
specific progenitor cells. However, deregulation of cell proliferation and 
death result in hyperplasia or tumorigenesis (Yu and Guan 2013). Intensive 
research efforts have been invested to uncover the detailed mechanism 
underlying cell proliferation, death and differentiation. However, how 
multicellular organisms coordinate the growth of their individual cells and 
the size of their organs is poorly understood. 
Research carried out over the past decade has discovered the Hippo 
pathway as an evolutionally and functionally conserved signalling network, 
which has been shown to be a master regulator of cell proliferation, death 
and differentiation (Yu and Guan 2013, Gomez, Gomez et al. 2014). Current 
evidence strongly suggests that the Hippo pathway may play pivotal roles in 
coordinating these cellular processes (Figure 1.1). 
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Figure 1.1. The involvement of the Hippo pathway in different cellular processes. 
The Hippo pathway can regulate cell proliferation, differentiation, and death. The modulation of these 
cellular processes by the Hippo pathway may contribute to different physiological and pathological 
conditions including development, tissue homeostasis, and cancer development (Adapted from (Yu 
and Guan 2013). 
 
The Hippo pathway is a highly conserved growth inhibitory 
signalling cascade. This pathway was initially discovered in D. 
melanogaster by genetic mosaic screens to identify genes whose loss-of-
function mutations result in severe overgrowth phenotype (Meng, Moroishi 
et al. 2016). For example, genetic inactivation of Hippo components, such 
as Warts (Wts) (Justice, Zilian et al. 1995, Xu, Wang et al. 1995), Hippo 
(Hpo) (Harvey, Pfleger et al. 2003, Wu, Huang et al. 2003), Salvador (Sav) 
(Tapon, Harvey et al. 2002), and Mats (Lai, Wei et al. 2005), all lead to 
similar severe overgrowth phenotype. Significantly, follow up studies 
revealed that the Hippo pathway is highly conserved from flies to human. 
Each member of the Hippo pathway in D. melanogaster possesses 
functional orthologs in mammals. In flies, Hpo (Harvey, Pfleger et al. 2003, 
Jia, Zhang et al. 2003, Pantalacci, Tapon et al. 2003, Udan, Kango-Singh et 
al. 2003, Wu, Huang et al. 2003), Sav (Kango-Singh, Nolo et al. 2002, 
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Tapon, Harvey et al. 2002), Wts (Justice, Zilian et al. 1995, Watson 1995, 
Xu, Wang et al. 1995, Justice, Woods et al. 1999, Tapon, Harvey et al. 
2002)  and Mats  (Lai, Wei et al. 2005) organize a kinase network which 
phosphorylates and negatively regulates Yki, which together with Sd (Hong 
and Guan 2012) mediates the major physiological functions of the pathway. 
In mammals, a classical view of the core of the Hippo pathway organizes a 
kinase network in which mammalian Ste20-like serine/threonine kinases 1/2 
(MST1/2) (Dan, Watanabe et al. 2001) are activated by multiple upstream 
branches. The activated MST1/2 then interact with their scaffolding partner 
SAV (Avruch, Zhou et al. 2012), which is in turn followed by 
phosphorylation of the large tumour suppressor 1/2 serine/threonine protein 
kinases (LATS1/2) (Hergovich, Stegert et al. 2006, Praskova, Xia et al. 
2008, Li, Li et al. 2014, Meng, Moroishi et al. 2015, Hoa, Kulaberoglu et al. 
2016) and MOB1 (Hergovich 2011), leading to increased LATS/MOB1 
complex formation and ultimately LATS1/2 activation. Phosphorylation of 
YAP/TAZ by activated LATS1/2 kinases result in YAP/TAZ cytoplasmic 
retention and/or degradation (please see Table 1.1 for the nomenclature of 
core components of the Hippo pathway in Drosophila and mammals). 
While this traditional linear signalling network has been serving for 
the initial studies of Hippo signalling, recent studies have identified the 
AGC serine/threonine NDR1/2 kinases (Zhang, Tang et al. 2015) and 
members of the Ste-like MAP4K as a new members of the core Hippo 
pathway (Meng, Moroishi et al. 2015). More specifically, in addition to 
MST1/2 kinases, members of MAP4K kinases can induce the 
phosphorylation and activation of LATS1/2 to negatively regulate 
YAP/TAZ via LATS1/2-stimulated-phosphorylation (Hergovich 2016). 
Furthermore, a recent study revealed that NDR1/2 can act as YAP kinases 
(Zhang, Tang et al. 2015). Taken together, MST1/2 as well as members of 
MAP4K kinases can regulate and activate NDR1/2 and LATS1/2 kinases, 
consequently negatively regulating YAP/TAZ (Hergovich 2016). 
Following the identification of MAP4K as new upstream regulator 
of LATS1/2 and NDR1/2 kinases, another recent study discovered the ste-
20 kinase Happyhour (Hppy) (counterpart of mammalian MAP4K kinases) 
4 | P a g e  
 
as an alternative kinase which phosphorylates and activates Wts in 
Drosophila (Zheng, Wang et al. 2015).    
 
Table 1.1. Hippo core components in humans and D. melanogaster (adapted from (Johnson and 
Halder 2014) 
 
 
1.2. The Core kinase network of the Hippo Pathway 
The mammalian Hippo pathway consists of a core kinase cassette 
compromising mammalian sterile 20-like serine/threonine kinases 1 and 2 
(MST1 and MST2, also known as STK4 and STK3), MAP4Ks (Mitogen-
activated kinases), the large tumour suppressor 1 and 2 (LATS1/2) 
serine/threonine protein kinases, nuclear dbf2-related kinases 1 and 2 
(NDR1/2), the adaptor protein Salvador homologue 1 (SAV1, also known as 
WW45), the signal transducer Mps-one binder 1 (MOB1), and the 
downstream effectors compromising the transcriptional co-activators Yes-
associated protein  and transcriptional co-activator with PDZ-binding motif 
(TAZ). The physiological output of Hippo signalling is to negatively 
regulate the activities of YAP and TAZ (Gomez, Gomez et al. 2014). 
MST1/2, MAP4Ks, LATS1/2, NDR1/2, SAV1, MOB1, and YAP/TAZ 
correspond to Hpo, Hppy, Wts, Trc, Sav, Mats, and Yki in flies, 
respectively. The inactivation of YAP/TAZ plays an important role in 
maintaining cell quiescence. Dysregulation of YAP/TAZ activities 
significantly contributes to cancer initiation and development (Figure 1.1) 
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through various mechanisms (Meng, Moroishi et al. 2016). The main 
mediator of YAP/TAZ is believed to be TEAD1-4 transcription factors, 
though other transcription factors, such as RUNX1/2, p63/p73, ErbB4, can 
also associate with YAP/TAZ (Hansen, Moroishi et al. 2015).          
Our traditional understanding of the regulation of core Hippo 
signalling can be summarised as follows: the Hippo pathway is activated by 
pro-apoptotic kinases MST1/2 by the binding of SAV1 through the SARAH 
domains (Hwang, Ryu et al. 2007). MST1/2 (Hippo) can be activated 
through different mechanisms. The activation of MST1/2 is also performed 
by binding to Ras association domain family (RASSF) proteins (Oh, Lee et 
al. 2006). Furthermore, recent studies have revealed that the thousand-and-
one (TAO) amino acids kinase or TAOK1-3 can also phosphorylate and 
activate Hpo or MST1/2 (Boggiano, Vanderzalm et al. 2011, Poon, Lin et al. 
2011). In contrast to mammals, Drosophila homologous RASSF has been 
shown to inhibit Hpo (homologues of human MST1/2), possibly owing to 
competition with Sav for Hpo binding (Polesello, Huelsmann et al. 2006) 
and the recruitment of the dSTRIPAK-PP2A complex (Figure 1.3) (Ribeiro, 
Josue et al. 2010). Following the activation of MST1/2, LATS2 is in turn 
phosphorylated at Thr1041 (known as hydrophobic motif (HM) site) (Hoa, 
Kulaberoglu et al. 2016). MOB1 is phosphorylated by MST1/2 at Thr12 and 
Thr35 sites, which leads to an enhanced affinity of MOB1 for LATS1/2, 
leading to the phosphorylation of LATS1/2 at Ser872 (known as T loop) and 
Thr1041 (HM sites) (Praskova, Xia et al. 2008, Hoa, Kulaberoglu et al. 
2016). Activated LATS1/2 in turn phosphorylates YAP in HXRXXS motif 
at Ser127 residue (Yorkie at Ser168 residue), creating a 14-3-3 binding site, 
which result in cytoplasmic retention of YAP. (Gomez, Gomez et al. 2014). 
TAZ is regulated in a similar fashion as YAP. TAZ is phosphorylated by 
LATS2 in HXRXXS motif at Ser89, generating a 14-3-3 binding site, 
therefore resulting in its inactivation (Figure 1.2) (Johnson and Halder 
2014). YAP and TAZ do not contain any DNA binding domain. However, 
they are able to bind to the vicinity of promoters of target genes by 
associating with DNA-binding transcriptional factors, such as TEAD1-4 
(Goulev, Fauny et al. 2008), Smad1/2/3 (Alarcon, Zaromytidou et al. 2009), 
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p63/p73 (Strano, Munarriz et al. 2001), T-box transcription factor 5 (TBX5) 
(Murakami, Nakagawa et al. 2005), RUNT-related factor 1 and 2 
(RUNX1/2) (Murakami, Nakagawa et al. 2005) . The association of 
YAP/TAZ with the transcriptional factors triggers changes in the expression 
of  genes involved in cell proliferation, cell death, differentiation (Meng, 
Moroishi et al. 2016). 
In addition to traditional regulation of core Hippo signalling, recent 
studies discovered new additional kinases MAP4Ks and NDR1/2 as novel 
members of the core cassette of Hippo signalling. More specifically, 
MAP4Ks were shown to function as important physiological LATS-
activating kinases in addition to MST1/2 kinases (Meng, Moroishi et al. 
2015). Furthermore, the involvement of NDR1/2 kinases in core Hippo 
signalling made the regulation more and more complex. NDR1/2 interact 
with MOB1 (Bichsel, Tamaskovic et al. 2004, Hergovich, Bichsel et al. 
2005, Hergovich, Kohler et al. 2009) and act as YAP kinases (Zhang, Tang 
et al. 2015). Interestingly, it was shown that NDR1/2 is regulated by MST1, 
MST2, and MST3 (Stegert, Hergovich et al. 2005, Cornils, Kohler et al. 
2011). More interestingly, recent studies revealed that MAP4Ks are the 
upstream regulator of NDR1/2 kinases (Selimoglu at al., 2014). Taken 
together, NDR1/2 can be regulated by MST kinases and function as 
upstream regulator of YAP. Furthermore, MOB1-NDR1/2 and MOB1-
LATS1/2 complex formation seems to play pivotal role for the regulation of 
Hippo signalling (Figure 1.2). In addition to MST kinases, MAP4Ks can 
also act as upstream regulator of NDR1/2 as well as LATS1/2. NDR1/2 and 
LATS1/2 kinases initiate the phosphorylation of YAP to negatively regulate 
YAP (Figure 1.2).       
Phosphorylation of YAP and TAZ at Ser127 and Ser89, respectively, 
plays a pivotal role in generating the 14-3-3 binding side, leading to their 
cytoplasmic sequestration and subsequent inactivation. In addition, YAP 
and TAZ are phosphorylated by LATS1/2 at Ser381 and Ser311, 
respectively, which primes YAP and TAZ for subsequent phosphorylation 
by CK1 (casein kinase 1), which generates a phospho-degron that can 
recruit β-TrCP (beta-transducin repeat containing E3 ubiquitin protein 
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ligase) and hence promote YAP and TAZ ubiquitination and degradation 
(Liu, Zha et al. 2010, Zhao, Li et al. 2010, Huang, Lv et al. 2012). 
YAP/TAZ can be also phosphorylated at other serine sites by LATS1/2 
(YAP on Ser61, Ser109, Ser164, TAZ on Ser66, Ser89, Ser117, Ser311). 
However, their functions are unknown. In addition to the phosphorylation-
dependent degradation, YAP and TAZ also can be suppressed through 
phosphorylation-independent manner by protein-protein interactions with 
transmembrane complexes-related proteins, leading to YAP and TAZ 
cytoplasmic sequestration (see section 1.3) (Figure 1.2) (Santucci, 
Vignudelli et al. 2015). 
The regulation of the Hippo pathway is highly conserved from 
Drosophila to mammals. In tradition to fashion as observed in mammals, 
the Drosophila Hippo pathway is “turned on” by the activation of Hpo, in 
association with an adaptor protein Sav, which in turn phosphorylates and 
activates the kinase Wts. Furthermore, Mats is then phosphorylated by Hpo, 
leading to enhanced binding of Mats for Wts. The activated Wts then 
phosphorylates Yki as downstream effector, which in turn leads to its 
cytoplasmic retention via 14-3-3 (Figure 1.3) (Meng, Moroishi et al. 2016). 
As reported in mammalian Hippo signalling, the regulation of Drosophila 
core Hippo signalling is also more complex than it has been thought. Recent 
research discovered Tricornered (Trc) and Happyhour (Hppy) as novel 
components of core Drosophila signalling. Trc and Hppy correspond to 
NDR1/2 and MAP4Ks in mammals. There are some connections that link 
Trc to the regulation of core Drosophila Hippo signalling. First connection, 
Hippo (counterpart of human MST1/2) functions as upstream regulator of 
Trc and Wts in fly neurons (Emoto, Parrish et al. 2006). Second connection, 
Trc and Wts mutant cells exhibit increased levels of F-actin (He, Emoto et 
al. 2005, Fang and Adler 2010), a phenotype also detected upon Yki 
overexpression or Hippo loss-of-function (Fang and Adler 2010). Third 
connection, Trc and Wts mutant cells display upregulation of DE-Cadherin 
expression, which was also reported in Mats mutant cells (Fang and Adler 
2010). Fourth connection, Trc as well as Wts have been shown to physically 
and genetically associate with Mats (He, Emoto et al. 2005, Lai, Wei et al. 
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2005). Furthermore, the complex formation of Wts or Trc with Mats might 
play important roles in fly wing development. These findings suggest that 
Trc and Wts, together with Mats, might function together to phosphorylate 
and ultimately inactivate Yki (Figure 1.3). However, it has not been 
addressed yet whether Trc could directly phosphorylate and inactivate Yki. 
On the other hand, another key player Hppy was identified as novel 
component of core Drosophila Hippo signalling (Zheng, Wang et al. 2015). 
Hppy was found to function as upstream regulator of Wts by 
phosphorylating the hydrophobic motif of Wts (Zheng, Wang et al. 2015).   
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Figure 1.2.  Schematic illustration of the human Hippo pathway. 
The Hippo pathway is activated by pro-apoptotic kinases MST1/2 by the binding of SAV1 
through the SARAH domains. The activation of MST1/2 is also performed by binding to 
Ras association domain family (RASSF) proteins. Furthermore, recent studies have 
revealed that the thousand-and-one (TAO) amino acids kinase or TAOK1-3 can also 
phosphorylate and activate MST1/2. Following the activation of MST1/2, LATS2 is in turn 
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phosphorylated at Thr1041. MOB1A is phosphorylated by MST1/2 at Thr12 and Thr35 
sites, which leads to an enhanced affinity of MOB1A for LATS1/2, leading to the 
phosphorylation at Ser872 and Thr1041. Activated LATS1/2 in turn phosphorylates YAP in 
HXRXXS motif at Ser127 residue, creating a 14-3-3 binding site, which lead inactive 
Ser127-phosphorylated YAP to be sequestered in the cytoplasm. TAZ is regulated in 
similar fashion with YAP. The association of YAP/TAZ with the transcriptional factors 
triggers changes in the expression of genes involved in cell proliferation, cell death, and 
differentiation. MAP4Ks function as important physiological LATS-activating kinases in 
addition to MST1/2 kinases. Furthermore, the involvement of NDR1/2 kinases in core 
Hippo signalling made the regulation more and more complex. NDR1/2 interacts with 
MOB1 and act as YAP kinases. NDR1/2 is regulated by MST1, MST2, and MST3. Recent 
studies revealed that MAP4Ks can be the upstream regulator of NDR1/2 kinases.  
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Figure 1.3. Schematic illustration of the Drosophila Hippo pathway. 
At the centre of the Hippo signalling pathway in Drosophila is a kinase cascade which 
consists of Wts and Hpo. This kinase cascade, together with their co-factors Sav and Mats, 
forms the core of the Hippo signalling pathway in Drosophila. The functional output of this 
core kinase cascade is to regulate the Yki transcriptional co-activator. Mechanistically, Hpo 
forms a complex with Sav. The Hpo-Sav complex phosphorylates Warts at Thr1077 and 
Mats at Thr12/35. Phosphorylation residues of Mats are conserved from Drosophila to 
human. The activated Warts, together with Mats, then phosphorylates Yki, thus leading to 
cytoplasmic retention and ultimately degradation of Yki by binding to 14-3-3 
phosphopeptide binding proteins. Mats also genetically interacts with serine/threonine-
protein kinase Trc, the second NDR/LATS kinase in flies. The Drosophila Hippo signalling 
pathway is also regulated by multiple upstream branches. 
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1.3. Upstream regulators of the Hippo pathway 
So far, more than 20 upstream regulators have been discovered which 
somehow affect either Hippo core signalling or downstream targets of the 
Hippo pathway (Harvey, Zhang et al. 2013). Here, we provide an overview 
of selected upstream regulators. 
Research performed over last 10 years has showed that YAP/TAZ 
(Yki in Drosophila) is directly or indirectly controlled by multiple upstream 
branches of the Hippo signalling pathway. These upstream regulators 
mainly regulates the Hippo pathway in 2 major pathways: by initiating the 
activation of the core kinase cassette which ultimately suppresses YAP/TAZ 
(Yki); and by bypassing and interfering with the core kinase cassette by 
directly forming physical complexes with YAP/TAZ(Yki), thereby 
sequestering them at cell-cell junctions and leading to nuclear exclusion 
(Harvey, Zhang et al. 2013). 
The Kibra-Expanded-Merlin Complex: Merlin (also termed NF2 for 
neurofibromatosis-2) and Expanded are members of the FERM (4.1, Ezrin, 
Radixin, and Moesin) domain-containing family of proteins. In Drosophila, 
both Merlin and Expanded loss-of-function resulted in severe overgrowth 
phenotype similar to that of Hpo mutants (Hamaratoglu, Willecke et al. 
2006). Following that, Kibra (a WW and C2 domain containing protein) was 
discovered to physically associate with both Merlin and Expanded. 
Moreover, it has been shown that Sav and Hpo physically interact with 
Merlin and Expanded and Kibra associates with Wts, thereby activating Wts 
in a cooperative manner (Baumgartner, Poernbacher et al. 2010, Genevet, 
Wehr et al. 2010, Yu, Zheng et al. 2010) (Figure 1.3). In mammals, Kibra 
interacts with Merlin, leading to enhanced phosphorylation of LATS1/2 in 
vitro (Xiao, Chen et al. 2011). Association of Kibra with LATS2 prevents 
LATS ubiquitination and subsequent proteasomal degradation, thus 
resulting in decreased proliferation (Xiao, Chen et al. 2011).  
Apical-basal polarity proteins: Crumbs (CRB, a transmembrane apical-
basal polarity determinant) has been classified as a cell surface regulator of 
the Hippo pathway in Drosophila (Robinson, Huang et al. 2010). In 
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Drosophila, CRB interacts with Expanded. The complex formation of CRB 
and Expanded regulates the localization and stability of Expanded, thereby 
modulating the activity of the Hippo pathway kinases and Yki (Figure 1.3) 
(Chen, Gajewski et al. 2010). 
 Upstream regulators of the Hippo core kinase cassette: Hippo signalling 
can be also activated by TAO (thousand and one amino acid protein) 
kinases and the cell polarity kinase MAP/microtubule affinity-regulating 
kinase 1 (MARK1; also termed PAR1). TAO kinases have been shown to 
phosphorylate the activation loop of MST1/2, thereby regulating the activity 
of the core kinase cassette (Figure 1.2 and 1.3) (Yu and Guan 2013). 
Additionally, two groups of MAP4Ks (mitogen-activated protein kinase), 
MAP4K1/2/3/5 and MAP4K4/6/7 have been shown to enhance 
phosphorylation of LATS1/2 at HM, resulting in LATS1/2 activation (Li, Li 
et al. 2014, Meng, Moroishi et al. 2015, Zheng, Wang et al. 2015). In this 
context, triple knock-out of MAP4K4/6/7 in HEK293A cells resulted in the 
phosphorylation of YAP/TAZ more dramatically comparing to that of 
MST1/2 double knock-out (Meng, Moroishi et al. 2016), suggesting that 
MAP4Ks are the main regulators of YAP phosphorylation in the tested cell 
lines. 
GPCR Signalling: Recent studies have reported that GPCR signalling can 
mediate the Hippo pathway activity in cultured cells by serum-borne 
lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) (Miller, 
Yang et al. 2012). As a mechanism of action, they showed that LPA or S1P 
bind to their corresponding GPCRs and act through Rho GTPase to initiate 
the activation of YAP/TAZ. Thrombin, known to activate protease-activated 
receptors (PARs; a GPCR), has also been shown to stimulate YAP/TAZ 
activity through Rho GTPase (Figure 1.2) (Miller, Yang et al. 2012, Yu, 
Zhao et al. 2012). In contrast, activation of GPCRs by epinephrine and 
glucagon can boost LATS kinase activities and subsequently inactivate 
YAP/TAZ in a Protein Kinase A (PKA) dependent manner (Yu, Zhang et al. 
2013). Thus, GPCRs can either stimulate or restrain LATS kinase activities 
to trigger or repress YAP activity dependent on the nature of GPCRs.   
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1.4. Hippo signalling in diseases 
1.4.1. The Hippo pathway and cancer 
Several lines of evidence show that the disruption of the Hippo pathway is 
related to several human cancers as well as tumour formation/tissue 
overgrowth in Drosophila (Figure 1.4). Indeed, dysregulation of Hippo 
signalling has been shown at a high frequency in different carcinomas 
(Table 1.2), such as lung, colorectal, ovarian, liver and prostate cancer 
(Harvey, Zhang et al. 2013). 
 
 
Figure 1.4.  Hippo (MST1/2) loss-of-function phenotypes in Drosophila and mice. 
Scanning electron micrographs (SEM) of a wild-type (wt) Drosophila (panel a) and a 
Drosophila with clonal loss of hpo (panel b) are indicated. Drosophila with loss of hpo 
exhibits overgrowths in head cuticle. Panel c indicates a mice liver from wt animal aged 2 
months, while panel d represent a mice liver from MST1/2 conditional knock-out mice aged 
2 months. Panel e and f also shows mice livers from wt and MST1/2 conditional knock-out 
mice aged 6 months, respectively (adapted from (Johnson and Halder 2014).  
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Uncontrolled cell proliferation and ultimately dramatic overgrowth 
phenotype are regarded as a fundamental aspect of neoplasia. The loss of the 
core Hippo pathway components resulted in severe overgrowth phenotype 
in Drosophila (Figure 1.4), sparking the idea that the Hippo pathway might 
play a pivotal role in controlling organ growth and it might act as a tumour 
suppressor (Hansen, Moroishi et al. 2015). In Drosophila, loss-of-function 
of Hpo, Mats or Wts, or overexpression of Yorkie (Drosophila homolog of 
YAP and TAZ) leads to severe overgrowth of the corresponding adult 
structures, such as adult eye. It has been observed that these overgrowth 
phenotypes are caused by two defects. First, cell proliferation was 
deregulated; proliferation of mutant clones are faster than that of wild type 
clones and after organ size have reached their proper size, mutant cells 
continue to proliferate while wild type clones stop proliferating. Second, 
mutant clones are resistant to the apoptotic signals that usually trigger 
removal of extra wild-type cells (Johnson and Halder 2014). 
 
Table 1.2. Hippo signalling deregulation in cancer (adapted from Harvey et al., 2013) 
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This is further supported by recent researches performed in mice, 
which showed that loss of MST1/2 (Camargo, Gokhale et al. 2007, Dong, 
Feldmann et al. 2007, Zhou, Conrad et al. 2009, Lu, Li et al. 2010, Zhou, 
Zhang et al. 2011), SAV (Lee, Kim et al. 2008), or MOB1 (Nishio, Hamada 
et al. 2012, Nishio, Sugimachi et al. 2016) in mice lead to the development 
of different tumour types (Figure 1.4), while YAP overexpression has been 
implicated in a wide range of human cancers including lung cancer (Lau, 
Curtis et al. 2014), breast cancer (Di Agostino, Sorrentino et al. 2016), 
colorectal cancer (Lee, Lee et al. 2015), liver cancer (Tao, Calvisi et al. 
2014), and gastric cancer (Jiao, Wang et al. 2014). The overexpression of 
YAP and its relation to human cancer are broadly reviewed in (Zanconato, 
Cordenonsi et al. 2016)    
In addition to the roles of the Hippo pathway in the control of cell 
growth and proliferation, it has been suggested that Hippo signalling might 
also play a prominent role in tumour invasion and metastasis (Cordenonsi, 
Zanconato et al. 2011, Zhao, Li et al. 2012). Metastasis is defined as spread 
of cancer to distant parts of the body and is responsible for the majority of 
cancer-associated mortalities. Metastasis consists of multiple steps including 
an epithelial-mesenchymal transition (EMT) of cells, which confers these 
cells with the ability to resist anoikis (a form of apoptosis) during 
dissemination (Simons and Mlodzik 2008). Concordantly, it has also been 
demonstrated that overexpression of YAP has a pronounced effect on 
cellular growth by promoting EMT of cultured cells (Hao, Chun et al. 2008) 
(Overholtzer, Zhang et al. 2006), suggesting a potential role for the Hippo 
pathway in human cancer metastasis. Consistent with this notion, it has been 
shown that TAZ activity is enhanced in metastatic breast cancer comparing 
to non-metastatic breast cancer (Cordenonsi, Zanconato et al. 2011). 
Moreover, expression of LATS1/2, which can function as inhibitors of 
YAP/TAZ, was considerably decreased in metastatic prostate cancer 
comparing to non-metastatic prostate cancer (Zhao, Li et al. 2012). In 
addition, recent studies reported that overexpression of LIFR (leukemia 
inhibitory factor receptor) dramatically decreases metastases formation in 
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metastatic breast cancer cell line in collaboration with YAP-Hippo 
signalling (Chen, Sun et al. 2012).  
Although the activity of the Hippo pathway is clearly disrupted at a 
high frequency in a broad range of different human cancers, the exact 
mechanism by which dysregulation of Hippo signalling activity drives 
tumour formation remains to be answered. Considerable effect of YAP or 
Yorkie overexpression has been observed on organ size control, strongly 
suggesting that YAP or Yorkie functions as growth-promoting activity. 
Studies linking disruption of Hippo activity to human neoplasia are mostly 
based on immunohistochemical detection of nuclear YAP in the tumour 
tissue nucleus, which is likely to induce growth-promoting transcriptional 
programme. In full support for nuclear localization of YAP in different 
cancers, it has been observed that YAP is nuclear in about 60% of 
hepatocellular carcinoma, 15% of ovarian cancers, and 65% of non-small-
cell lung cancer. On the other hand, in normal tissues, YAP is infrequently 
observed in the nucleus (Johnson and Halder 2014). Although the Hippo 
pathway can modulate YAP/TAZ (Yorkie in Drosophila) by restricting their 
access to the nucleus, its cancer-related mechanism is poorly understood and 
remains to be answered.  
To date, few germline or somatic mutations of the Hippo signalling 
components have been discovered in human malignancies, with exception 
of mutations of the NF2 locus. The NF2 encodes the tumour suppressor 
protein Merlin that modulates the Hippo pathway by regulating the activity 
of the LATS kinases to mobilize them to the plasma membrane, and 
YAP/TAZ amplification (Gomez, Gomez et al. 2014, Johnson and Halder 
2014). NF2 loss of function is related to schwannomas, meningiomas, and 
mesotheliomas (Evans 2009, Harvey, Zhang et al. 2013). Loss of function of 
Merlin and the Hippo pathway components LATS2 or SAV1 is also seen in 
malignant mesothelioma (Murakami, Mizuno et al. 2011). Furthermore, 
inactivation of NF2 in the mouse liver lead to HCC, and more interestingly, 
deletion of one allele of YAP gene completely blunts tumour formation 
(Zhang, Bai et al. 2010, Johnson and Halder 2014). Last but not least, a 
recent study has revealed that mammalian Merlin represses tumorigenesis 
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by suppressing the E3 ubiquitin ligase CRL4
DCAF1
, which regulates 
transcription activity of genes including TEAD. (Li, Cooper et al. 2014). 
Mechanistically, they observed that CRL4
DCAF1
 directly associates with and 
then prime LATS1/2 to ubiquitin for proteasome-dependent degradation in 
NF2-mutants cells, thereby leading to loss of kinase activity. As a 
consequence, active YAP and TAZ accumulate in nucleus, thereby resulting 
in TEAD-dependent transcription (Li, Cooper et al. 2014). Although these 
observations suggest that YAP has a critical role for the progression of 
cancers driven by NF2 deletion, the mechanism of action is not clearly 
understood. 
 
1.4.2. Hippo signalling in non-cancer pathologies    
The role for the Hippo pathway in tumour formation is gaining more and 
more popularity. On the other hand, the research over the role of the Hippo 
pathway in non-cancer abnormalities is growing day by day. Several lines of 
evidence have linked the Hippo signalling pathway to non-cancer 
pathologies (Table 1.3, Table 1.4). These evidences are largely based on 
the manipulation of YAP/TAZ and MST1/2 (Gomez, Gomez et al. 2014).  
 
Table 1.3. The involvement of MST1/2 kinases in non-cancer mammalian pathologies 
(adapted from (Gomez, Gomez et al. 2014) 
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 Altered MST1 and YAP/TAZ activities were shown to result in 
heart defects (Table 1.3, Table 1.4). Furthermore, MST1/2 and YAP knock-
out mice were shown to exhibit defective heart development during 
embryonic development (Heallen, Zhang et al. 2011, Xin, Kim et al. 2011). 
Moreover, it was shown that the overexpression of YAP result in enhanced 
proliferation of cardiomyocytes (Del Re, Yang et al. 2013, Xin, Kim et al. 
2013). To further support the role of the Hippo signalling pathway in heart 
regeneration, Olson and colleagues have shown that YAP conditional 
knock-out in the heart impede neonatal heart regeneration (Xin, Kim et al. 
2013), while mice with heart specific LATS1/2 or SAV deletion display 
promoted regenerative capacities (Heallen, Morikawa et al. 2013). Taken 
together, these studies suggest that the Hippo pathway can play pivotal roles 
in modulating the potential of myocardial regeneration after injury. 
Therefore, an in-depth understanding of the Hippo pathway has the potential 
to significantly improve our knowledge regarding non-cancerous diseases, 
in addition to accelerating translational cancer research efforts. 
          
Table 1.4. The involvement of YAP/TAZ proteins in non-cancer mammalian 
pathologies (adapted from (Gomez, Gomez et al. 2014)) 
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1.4.3. Hippo Signalling as a therapeutic target 
The widespread involvement of the Hippo pathway in cancer (summarized 
above) makes this pathway crucial for targeting as an anti-cancer therapy. 
Given the fact that human malignancies are linked to the enhanced activity 
of YAP/TAZ, it is tempting to develop strategies that aim to suppress 
YAP/TAZ activities. However, although mounting evidence suggests that 
pharmacological manipulation of the Hippo pathway components and 
YAP/TAZ activities seems promising for anti-cancer targets, there are 
problems that needs to be solved. First is that the core components of the 
Hippo pathway negatively regulates the pathway`s transcriptional output, 
creating a conceptual problem, because pharmacological inhibitors targeting 
the core components would lead to enhanced YAP activity, thus promoting 
cancer-related properties. Another disadvantage is that manipulation of 
YAP/TAZ as well as of Hippo components might result in deleterious side 
effects in normal tissues. For example, it seems tempting to inhibit MST 
kinase activity to recover from myocardial injury. However, it needs to be 
considered that MST deficiency has detrimental effects on the human 
immune system (Abdollahpour, Appaswamy et al. 2012, Nehme, 
Pachlopnik Schmid et al. 2012). Thus, any manipulation of YAP/TAZ and 
the Hippo signalling components should be addressed very cautiously to 
ensure that any vital organs or tissues are not dramatically affected.  
Targeting GPCR signalling: GPCR signalling was shown to regulate the 
Hippo pathway activities through LAP, S1P and Thrombin to trigger YAP 
nuclear localization. Thus, agonists of LPA, S1P and thrombin-induced 
receptor signalling, such as adrenaline, glucagone, and the dopamine 
receptor agonist dihydrexidine, may lead to enhanced YAP phosphorylation 
and inactivation (Johnson and Halder 2014). Therefore, targeting GPCR, 
LPA, S1P and thrombin represent potential novel routes for therapeutic 
intervention. In this context, monoclonal antibodies highly specific to these 
molecules have been developed (Fleming, Wojciak et al. 2011). For 
example, the Sphinaomab (S1p-blocking antibody) has been found to 
attenuate lung tumour metastasis (Ponnusamy, Selvam et al. 2012). 
Additionally, Phenoxodiol, the isoflavone-derivative with SPHK1 inhibitor, 
21 | P a g e  
 
has been trialled in patient with platinum/taxane-refractory/resistant 
ovarium cancers, with limited single agent activity (de Souza, Liauw et al. 
2006, Kelly, Mor et al. 2011).           
Targeting protein-protein interactions in Hippo signalling: Extensive 
biological and clinical investigations have discovered protein-protein 
interaction (PPI) networks and nodes which play important roles in 
acquiring and maintaining cancer-related features fundamental for cellular 
transformation. In cancer, PPIs create signalling networks which deliver 
pathophysiological signals to complete an integrated biological output, 
ultimately leading to tumorigenesis, tumour progression, invasion, and/or 
metastasis (Ivanov, Khuri et al. 2013).  
  The large amount of evidence has shown that the Hippo pathway is 
involved in a large range of cancer. In this context, YAP/TAZ is regarded as 
the most attractive therapeutic in the Hippo pathway. However, 
pharmacologically inhibiting YAP/TAZ is challenging, as these proteins are 
transcriptional co-activators with no known enzymatic activity. Thus, 
YAP/TAZ needs to associate with transcription factors, such as TEAD, to 
regulate gene expression (Zhao, Ye et al. 2008). Furthermore, the 
transcription factors TEADs are largely redundant for normal development 
but necessary for YAP-driven tumorigenesis. All together, these make the 
targeting of YAP/TAZ-TEAD interaction the most direct and effective 
approach to stamp down YAP/TAZ-driven oncogenic events. To this end, 
Pan and colleagues investigated the role of YAP-TEAD interaction in 
murine tumours and found that a dominant-negative versions of TEAD2 
(TEAD-DN, DNA-binding domain has been deleted) suppress YAP-driven 
transcription and YAP`s ability to drive soft-agar growth in vitro as well as 
YAP-induced cancer in vivo without resulting in severe liver abnormalities 
(Liu-Chittenden, Huang et al. 2012).  
Having reached the conclusion that genetic disruption of the YAP-
TEAD interaction can prevent YAP`s transforming activity, Pan and 
colleagues screened 3300 FDA-approved drugs to categorize compounds 
that can directly interfere with the YAP/TAZ-TEAD interactions, and 
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thereby suppress YAP/TAZ-triggered transcriptional activity (Liu-
Chittenden, Huang et al. 2012). Significantly, they found that a group of the 
porphyrin family of compounds (Protoporphyrin IX (PPIX), 
hematoporphyrin (HP), and Verteporfin (VP) can impede the interaction of 
YAP/TEAD, ultimately inhibiting the transcription of YAP/TAZ target 
genes (Liu-Chittenden, Huang et al. 2012). Moreover, VP was shown to 
compete for TEAD to associate with YAP in vitro as well as to abolish liver 
overgrowth mediated by YAP overexpression and inactivation of 
NF2/Merlin in vivo (Liu-Chittenden, Huang et al. 2012), clearly 
demonstrating the therapeutic potential of disruption of YAP/TAZ-TEAD 
interaction.  
As another alternative to target YAP/TAZ-TEAD interaction, one 
should take Vestigial-like (VGLL) proteins into account. There are four 
different VGLL proteins: VGLL1, VGLL2, VGLL3, and VGLL4. These 
proteins are transcriptional co-factors that are first identified in Drosophila 
as a master regulator of wing development (Zhang, Gao et al. 2014). 
Importantly, recent studies revealed that VGLL1 protein family increases 
cell proliferation (Pobbati, Chan et al. 2012). Similarly, VGLL3 is amplified 
in soft tissue sarcoma and its inhibition was shown to result in decreased 
cell proliferation and migration (Helias-Rodzewicz, Perot et al. 2010). 
However, VGLL4 seems to function differently. VGLL4 proteins are 
defined as a new group of TEAD-binding partners involved in 
tumorigenesis. Very interestingly, VGLL4 proteins were shown to promote 
apoptosis by negatively modulating inhibitors of apoptosis proteins (IAPs) 
(Jin, Park et al. 2011). Furthermore, recent research uncovered that VGLL4 
associates with TEADs by competing for YAP, thereby suppressing lung 
cancer growth and progression (Zhang, Gao et al. 2014). 
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1.5. MOB Proteins 
Considerable efforts have been invested to understand the regulation of 
Hippo signalling in Yeast, Drosophila and human. Recent studies have 
uncovered that MOB1A/Mats play essential role in the regulation of the 
Hippo core cassette through their regulatory interactions with NDR/LATS 
kinases in Drosophila and human.       
The family of Mps One binder (MOB) co-activator proteins are 
evolutionally conserved from insects to human and constitute signal 
transducers in essential signalling network via their interactions with 
NDR/LATS kinases (Hergovich 2011). To date, several different MOB 
proteins have been discovered in every eukaryote. At the very beginning, 
key roles for Mob1p and Mob2p were revealed in the regulation of mitotic 
exit and cell morphogenesis. Four different MOB proteins (dMOB1A, 
dMOB2, dMOB3, and dMOB4) are encoded by Drosophila, with dMOB1 
(also known as Mats) being the heart of the Hippo pathway and regulating 
cell proliferation and apoptosis (Lai, Wei et al. 2005, Staley and Irvine 
2012). At least six different MOB proteins (MOB1A, MOB1B, MOB2, 
MOB3A, MOB3B, MOB3C) are expressed in mammalian genome, with 
MOB1A functioning as a master regulator of NDR/LATS kinases in 
mammalian Hippo signalling (Hergovich 2016) (Figure 1.5). We will 
summarize current knowledge of this emerging protein family from yeast to 
human. 
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Figure 1.5. Phylogenetic tree and sequence similarity within the MOB protein family.  
(Top) Phylogenetic tree can be divided into three subgroups. Saccharomyces cerevisiae 
Mob1a (scMob1a) and Schizosaccharomyces pombe Mob1a (spMob1p) in budding and 
fission yeast, respectively, are grouped together with dMOB1 and MOB1A/B in MOB1 
subgroup. scMob2p and spMob2p are classified together with dMOB2 and hMOB2 in 
MOB2 subgroup. dMOB3 fall into MOB3 subgroup together with MOB3A/B/C. (Bottom) 
Sequence similarities within the MOB protein family (adapted from (Hergovich 2012).  
 
1.5.1. MOB proteins in budding and fission yeast 
The MOB proteins were first identified in yeast by screening for novel 
interactors with Mps1p kinases, which is Mob1p typifying Mps one binder 
1p (homologues of Drosophila Mats and Human Mob1) (Luca and Winey 
1998). It has been reported that Mob1p has far reaching effects in yeast, 
such as the survival of cells, spindle pole body duplication, as well as the 
mitotic exit network (MEN) (Frenz, Lee et al. 2000) in budding yeast or 
septation initiation network (SIN) in fission yeast (Bardin and Amon 2001). 
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In summary, these studies (summarized in Hergovich, 2011) showed that 
the stimulation of Cdc15p kinase (counterpart of human MST1/2 and 
Drosophila Hippo) increases the activity of Mob1p towards Dbf2p or Sid2p 
(counterpart of human LATS1/2 and Drosophila Warts), which in turn 
phosphorylates the phosphatase Cdc14p, thus inducing mitotic exit of yeast 
cells (Figure 1.6). 
 
 
Figure 1.6.  MOB-regulated intracellular signalling in S.cerevisiae. 
(a) Mob1p is phosphorylated by Cdc15p. Phospho-Mob1p then activates the Dbf2p 
NDR/LATS kinase. Complex formation of Mob1p and Dbf2p subsequently phosphorylates 
Cdc14p, which in turn trigger mitotic exit of yeast cells. (b) Cooperation of Mob2p and 
Kic1p stimulates the Cbk1p NDR/LATS kinase. The association between Mob2p and 
Cbk1p targets Ace2p for phosphorylation to regulate Ace2p activity and cellular 
morphogenesis (RAM). 
  
MOB1p has also been shown to play crucial roles in controlled exit 
of mitosis in Schizosaccharomyces pombe (Bardin and Amon 2001). SIN is 
also regulated by a similar signalling network as shown for MEN in S. 
pombe. Mob1p associates with the kinase Sid2p (counterpart of yeast Dbf2), 
thereby controlling and ultimately affecting the subcellular localisation of 
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Clp1p (Chen, Feoktistova et al. 2008) (Figure 1.6). Taken together, 
association of Mob1p with the NDR/LATS kinases Dbf2p or Sid2p plays 
essential role in the functionality of MEN or SIN (Bardin and Amon 2001).  
Importantly, in addition to establishing the first function of Mob1p, 
Mob2p was reported as a non-essential protein in yeast (Luca and Winey 
1998). However, research uncovered that Mob2p is essential for the 
regulation of asymmetry in budding yeast by mediating Ace2p daughter-
specific genetic programs (Colman-Lerner, Chin et al. 2001, Weiss, 
Kurischko et al. 2002). Additionally, association of Mob2p with Cbk1p (the 
second NDR/LATS kinase S. cerevisiae) regulates polarized growth in S. 
cerevisiae, which is termed RAM (Regulation of Ace2p and cellular 
Morphologies) (Jansen, Barry et al. 2006) (Figure 1.6). Similarly, it was 
shown that Mob2p associates with the second NDR/LATS kinase Orb6p 
(Hou, Wiley et al. 2003). Research showed that Mob2p in complex with the 
Orb6p regulates a morphogenesis network in S. pombe (Hou, Wiley et al. 
2003, Kanai, Kume et al. 2005).  
Taken together, two different MOB proteins (Mob1p, Mob2p) are 
expressed in budding and fission yeast (Figure 1.6). Association of Mob1p 
with Dbf2p and Sid2p, respectively, plays a central role in the control of exit 
from mitosis in yeast. On the other hand, Mob2p in complex with Cbk1p 
and Orb6p, respectively, play a pivotal role in the regulation of cell 
morphogenesis networks. Importantly, Mob1p does not associate with 
Orb6p, and Mob2p does not interact with Sid2p (Hou, Guertin et al. 2004, 
Kanai, Kume et al. 2005). Thus, yeast Mob1p and Mob2p regulate two 
separate biological processes by their association with the corresponding 
yeast NDR/LATS kinases (Figure 1.6). 
 
1.5.2. MOB proteins in Drosophila 
In Drosophila genome, three different MOB proteins are expressed by 
independent genes (Figure 1.5), namely dMOB1 (aka Mats), dMOB2, 
dMOB3, with Mats functioning as key regulator of the Hippo pathway in 
Drosophila Hippo signalling. Mats (known as Mob as a tumour suppressor) 
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is a protein-coding gene, corresponding to Mob1p in yeast and MOB1A in 
human. In the Drosophila genome, the Mats gene is located in third 
chromosome (3R:22421161..22423302, cytoplasmic map is 94A12). The 
Mats gene has 3 annotated transcripts and 3 polypeptides (Figure 1.7). To 
date, nearly 15 mutant alleles of Mats have been reported whose phenotypes 
manifest in wing; denticle; trichogen cell; mesothoracic tergum; adult 
mushroom body; wing hair; imaginal disc (Table 1.5) (Attrill, Falls et al. 
2016). dMOB2 is required for regulating neuromascular junctions and 
photoreceptor morphology (Campbell and Ganetzky 2013), while the 
biological role(s) of dMOB3 is not known. 
 
 
Figure 1.7. Schematic representation of the mats gene neighbouring nop56 in the 
Drosophila chromosome. 
The Mats gene is located in 3.chromosome and its gene sequence location is 
3R:22421161..2242330. The cytological map location of mats is 94A12. The Mats gene 
has 3 annotated transcripts (Mats RA, RB, RC) and 3 polypeptides (Mats PA, PB, PC) 
(Generated from http://flybase.org/ ). 
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Table 1.5. Mats alleles reported so far (adapted from http://flybase.org/ ) 
Number  Allele 
(Symbol) 
Mutagen Reference(s) 
1 mats
e235
  P-element activity (Lai, Wei et al. 2005) 
2 mats
roo
 transposable element 
activity 
(Lai, Wei et al. 2005) 
3 mats
PBrv
 piggyBac activity (He, Emoto et al. 2005) 
4 mats
unspecified
 - (Schuldiner, Berdnik et 
al. 2008) 
5 mats
S113416
 P-element activity (Deak, Omar et al. 1997) 
6 mats
A33
  ethyl methanesulfonate (Liu, Zheng et al. 2016) 
7 mats
e03078
 piggyBac activity (Thibault, Singer et al. 
2004) 
8 mats
e03077
 piggyBac activity (He, Emoto et al. 2005) 
9 mats
Scer\UAS.cLa
 in vitro construct (Lai, Wei et al. 2005) 
10 mats
GD8136
 in vitro construct (Neely, Kuba et al. 2010) 
11 mats
KK100140
 in vitro construct (Rauskolb, Pan et al. 
2011) 
12 mats
JF03246
 in vitro construct (Jia, Soylemez et al. 
2015) 
13 mats
HMS00475
 in vitro construct (Jia, Soylemez et al. 
2015) 
14 mats
e17
 Delta2-3 transposase (Yang, Gupta et al. 2008) 
15 mats
2236.T:Avic\GFP
 in vitro construct (Yang, Gupta et al. 2008) 
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After understanding the importance of Mob1p in yeast, Lai et 
al.(2005) embarked on the hunt for understanding the functions of MOB 
proteins in multicellular organism and found that Mats (the counterpart of 
human MOB1) is required for cell proliferation and death as central part of 
the Hippo pathway in Drosophila by functioning as an activator of Wts, one 
of two NDR/LATS kinases (Lai, Wei et al. 2005).  Furthermore, Mats has 
been shown to be an essential gene which modulates proper mitotic 
division, possibly due to the requirement of Mats for proper chromosomal 
segregation (Shimizu, Hot et al. 2008). Even more interestingly, they 
showed that Mats and MOB1A proteins share 87% sequence identity and 
the loss of Mats is rescued by human MOB1A expression in the Drosophila 
eye (Figure 1.8), suggesting that the function of Mats proteins is highly 
conserved from Drosophila to human (Lai, Wei et al. 2005). However, the 
current picture is getting more and more complicated, as recent studies 
showed that Mats can directly associate with Trc, the second NDR/LATS 
kinase in Drosophila (He, Emoto et al. 2005). Intriguingly, flies with Trc 
deficiency has enhanced negative phenotype in Mats mutant cells, 
indicating that Mats not only specifically associates with Wts and ultimately 
controls Wts signalling but also is required for Trc signalling in flies 
(Figure 1.3) (He, Emoto et al. 2005). 
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Figure 1.5. Conservation of the Mats gene. 
(A) Illustration of the conservation of the Mats protein across species. Mats is highly 
conserved from Drosophila to human. Human MOB1 and Drosophila Mats proteins share 
87% sequence identity. (B) Panel showing that MOB1A can rescue for Mats loss-of-
function. Eyes with wild-type clones are shown as control. Eyes with mats mutant is shown 
to be larger and develop tumour formation. Mats expression in mats mutant clones is shown 
to suppress defective eye phenotype and tumour formation. MOB1A expression in mats 
mutant clones shows that MOB1A can rescue defective eye phenotype, as does Mats 
expression. (A is t generated from http://www.ebi.ac.uk/Tools/msa/clustalo/ ) and B is 
adapted from (Lai, Wei et al. 2005).  
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In addition to Mats (dMOB1), two additional and different MOB 
proteins (dMOB2, dMOB3) are expressed in flies. Little is known about the 
biological roles of dMOB2 and dMOB3. On the one hand, it was shown that 
dMOB2 is required for regulating neuromuscular junctions and 
photoreceptor morphology (Campbell and Ganetzky 2013). On the other 
hand, dMOB2 was shown to associate with Trc, thereby regulating wing 
hair morphogenesis (He, Emoto et al. 2005). Significantly, the biological 
functions of dMOB2 seem to be different from that of Mats, as mutations in 
the dMOB2 gene seem not to synergise with loss or gain of Trc kinase in the 
enhanced morphological phenotype (He, Emoto et al. 2005). However, 
overexpression of dMOB2 results in fly wing phenotype similar to the Trc 
mutant (He, Emoto et al. 2005), indicating a potential dominant-negative 
role in flies. In this context, it is tempting to speculate that Trc signalling is 
negatively regulated by dMOB2, as reported for human counterpart (see 
section 1.5.3). Therefore, the mechanism of action of dMOB2 is yet to be 
determined. The biological functions of dMOB3 are currently not known. 
  
1.5.3. MOBs in mammalian cells 
Comparing to yeast and Drosophila, the complexity is higher in mammals, 
as mammals express at least six different MOB proteins (MOB1A, MOB1B, 
MOB2, MOB3A, MOB3B, and MOB3C) (Figure 1.5). 
MOB1A and MOB1B ( also termed as MOB1) can associate with 
NDR/LATS kinases (Bichsel, Tamaskovic et al. 2004, Ponchon, Dumas et 
al. 2004, Hergovich, Bichsel et al. 2005, Hergovich, Schmitz et al. 2006, 
Hergovich, Kohler et al. 2009, Kohler, Schmitz et al. 2010, Hoa, 
Kulaberoglu et al. 2016). Interestingly, a conserved domain in NDR/LATS 
kinases mediates these interactions (Hergovich, Stegert et al. 2006). 
Furthermore, MOB1A has been shown to interact with various proteins, 
such as DOCK8, Praja2, and S100A8 (Ewing, Chu et al. 2007, Lignitto, 
Arcella et al. 2013, Rock, Lim et al. 2013).  
MOB2 can associate with NDR1/2 kinases, not LATS1/2 kinases (Bothos, 
Tuttle et al. 2005, Hergovich, Schmitz et al. 2006, Kohler, Schmitz et al. 
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2010). Importantly, MOB2 associates with the same domain on NDR1/2 as 
MOB1 and seems to compete for NDR1/2 interaction with MOB1 and 
negatively regulate NDR1/2 signalling (Hergovich 2013).  
MOB3A/B/C (also termed as MOB3) does not interact with and 
activate NDR1/2 and LATS1/2, despite of high sequence identity between 
MOB3A/B/C and MOB1 (Figure 1.5). MOB3B seems to bind to Mitogen 
activated protein kinase p38 alpha (MAPK14) (Bandyopadhyay, Chiang et 
al. 2010), DNK2/KSR2 (Ewing, Chu et al. 2007), and NT5C2 (Rual, 
Venkatesan et al. 2005). These interactions have not tested experimentally 
yet. 
 
1.5.4. Regulation of MOB1/Mats Proteins in Drosophila and 
Mammals 
At the centre of the Hippo pathway in Drosophila is a kinase cascade which 
consists of the Ste20-like kinase Hpo, the nuclear Dbf2-related (NDR) 
family kinase Wts. This kinase cascade, together with a co-factor Sav 
(Salvador) and a key signal transducer  Mats (Mob as a tumour suppressor), 
forms the core of the Hippo pathway in Drosophila (Yu and Guan 2013). 
The functional output of this core kinase cascade is to negatively regulate 
the Yorkie (Yki) transcriptional co-activator. Mechanistically, Hpo forms a 
complex with Sav (Wu, Huang et al. 2003). The Hpo-Sav complex activates 
Wts and Mats by phosphorylation (Wu, Huang et al. 2003). The activated 
Wts, together with Mats, then phosphorylates Yki, thus leading to 
cytoplasmic retention and ultimately degradation of Yki by binding to 14-3-
3 phosphopeptide binding proteins (Meng, Moroishi et al. 2016). 
However, recent studies have revealed that the current picture of the 
core Drosophila Hippo pathway is more complicated, as Mats also can 
genetically interacts with serine/threonine-protein kinase tricorner (Trc) (the 
counterpart of human LATS1/2), the second NDR/LATS kinase in flies, and 
is required for Trc signalling in flies (Hergovich 2011, Hergovich 2016), 
indicating that Trc is linked to the Hippo pathway and should be considered 
as novel core component of the Hippo pathway. However, the complex 
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interactome of Mats with the Hippo core kinases Hpo, Wts, and Trc is yet to 
be determined. And, its molecular mechanism remains to be answered. 
The fact that Mats is highly conserved from Drosophila to human 
and human MOB1A can compensate for tissue overgrowth phenotype 
driven by Mats loss-of-function (Figure 1.5) suggests that the role and 
mechanism of Mats is also conserved. 
The Hippo pathway in mammals is very similar to that of 
Drosophila. The mammalian Hippo pathway creates a kinase cascade which 
consists of MST1/2, LATS1/2, and NDR1/2. A recent structural study 
proposes new molecular role for MOB1A in LATS1/2 phosphorylation (Ni, 
Zheng et al. 2015). According to this model (Ni, Zheng et al. 2015), the 
auto-phosphorylation of MST2 at its long linker results in generation of a 
phosphor-docking motif, thereby recruiting MOB1A. Subsequently, LATS1 
associates with the MOB1A-phospho-MST2 complex which ultimately 
forms the MST2-MOB1A-LATS1 ternary complex. This ternary complex 
subsequently enhances the phosphorylation of MOB1A at its N-terminal tail 
and LATS1 at its hydrophobic motif by MST2. Furthermore, auto-
phosphorylation of LATS1 is further promoted by phosphorylated MOB1A, 
as it is required for LATS1 activation (Ni, Zheng et al. 2015). The activated 
LATS then phosphorylates YAP/TAZ, thereby resulting in cytoplasmic 
retention by binding to 14-3-3 proteins and proteasome-mediated 
degradation of YAP/TAZ. Taken together, this structural study proposes 
that MOB1 binding to MST1 plays a crucial role in activating LATS1 by 
MST2 (Ni, Zheng et al. 2015). However, in a recent comprehensive study, 
Stuhl et al. challenged the notion that the association of MOB1 with MST1 
(the counterpart of fly Hpo) is crucial for the activation of LATS (the 
counterpart of Wts). They showed using conformation sensors that 
Wts/Mats complex formation is required for Wts activation, while the 
Hpo/Mats interaction seem to be dispensable (Struhl et al., 2015) (Figure 
1.6). 
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Figure 1.6. A proposed model for Wts activation. 
(Step 1A) Hpo is activated by upstream components. (Step 1B) The conformation state of 
Wts is shifted from closed state to open state by the binding of Mats to Wts. (Step 2) Hpo 
associates with Wts as well as Mats and phosphorylates the Wts hydrophobic motif and 
Mats. (Step 3) This enhances Mats-Wts association and Hpo is then disassociated from the 
ternary complex. (Step 4) A further Mats-mediated allosteric change to Wts subsequently 
initiates activation loop phosphorylation. Active wts can initiate the phosphorylation of its 
substrate, such as Yki (Manning and Harvey 2015).  
 
On the other hand, recent studies have revealed that the AGC 
serine/threonine NDR1/2 kinases (also termed as STK38/STK38L) function 
as novel members of the core cassette of the Hippo pathway, suggesting that 
the mammalian Hippo pathway is more diverse and complex. The first NDR 
serine/threonine kinaseDbf2p was identified in budding yeast (Johnston, 
Eberly et al. 1990). Follow up research then discovered NDR1/2 in human 
cells (Millward, Cron et al. 1995), while the Trc , the fly homolog of 
mammalian NDR1/2 kinases, was discovered later (Geng, He et al. 2000). 
To date, extensive efforts have been invested to reveal the molecular 
regulation of NDR1/2 kinases (Hoa, Kulaberoglu et al. 2016). It was shown 
that MST1/2 and MST3, another member of the MST kinase family, can 
initiate phosphorylation of NDR1/2 on Thr444/442 (Stegert, Hergovich et 
al. 2005, Hergovich, Kohler et al. 2009), while binding of MOB1 to the 
NTR domain of NDR1/2, which is located to the catalytic domain NDR1/2, 
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mediates the autophosphorylation of NDR1/2 at Ser281/282 in their T-loop 
(summarised in (Hergovich 2013). The overexpression of NDR1/2 did not 
lead to changes in YAP phosphorylation in the cultured mammalian cells, 
unlike LATS1/2 overexpression (Hao, Chun et al. 2008). Thus, it was 
thought that NDR1/2 does not regulate YAP kinases in mammalian cells. 
However, Zhang et al. discovered that NDR1/2 can directly mediate 
phosphorylation of YAP at Ser61/109/127/164, which is also 
phosphorylated by LATS1/2 (Zhao, Wei et al. 2007, Hao, Chun et al. 2008), 
strongly establishing that NDR1/2 functions as novel bona fide upstream 
kinases of YAP in mammalian cells. Intriguingly, NDR1/2-stimulated 
phosphorylation of YAP at Ser127 gave rise to cytoplasmic retention and 
ultimately inactivation of YAP (Zhang, Tang et al. 2015), as shown for the 
LATS1/2-stimulated phosphorylation of YAP at Ser127 (Zhao, Wei et al. 
2007). Although it has been established that NDR1/2 functions as key 
upstream kinase of YAP, the exact molecular mechanism is yet to be 
determined. Therefore, it is significant to understand complex protein-
protein interaction networks involving MST-SAV-MOB1A-LATS-NDR 
signalling.       
In this context, Struhl and colleagues have recently reported that the 
activation of Wts by Mats does not appear to be dependent on 
phosphorylation by Hpo and is essential for Hippo signalling in flies. 
Furthermore, they also showed that the association of Mats with Hpo seems 
to be dispensable for activation of Wts (Vrabioiu and Struhl 2015). In 
contrast to these findings, it was shown that phosphorylation of MOB1 at 
Thr12 and Thr35 by MST1/2 is essential for the formation of NDR/MOB1 
and LATS/MOB1 complexes (Praskova, Xia et al. 2008, Ni, Zheng et al. 
2015). Although MOB1 has clearly been interconnected with NDR/LATS 
(Trc/Wts) signalling in mammalian cells and fly tissues, future studies are 
needed to uncover the biological importance of MOB1 associations with the 
MST1/2, NDR1/2 and LATS1/2 kinases in the Hippo pathway.   
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1.5.4. Mats/MOB1A in cancer 
Loss-of-function of Mats in Drosophila results in homozygous lethality at 
early second larval stage and tumours (tissue overgrowth) in mosaic clones 
(Lai, Wei et al. 2005), leading an idea that Mats might play an important 
role in controlling cancer-related properties, such as cell proliferation and 
survival. To further support this idea, it was shown that these overgrowth 
phenotypes arise because of two main mechanisms (Johnson and Halder 
2014). Firstly, they observed that mats mutant clones generated in larval eye 
disc has increased Yki activity and they proliferate exponentially when mats 
wild type clones quiescence. Furthermore, they also observed that mats 
mutant clones induced in larval eye disc overexpress diap1, making mats 
mutant clones resistant to the apoptotic signals which are triggered to get rid 
of the extra cells (Lai, Wei et al. 2005). The combination of deregulated cell 
proliferation and survival therefore results in dramatic overgrowth 
phenotypes (Figure 1.10), ascribing a tumour suppressor role to Mats. Even 
more interestingly, Lai et al. (2005) showed that expression of MOB1A in 
Mats mutant clones generated in larval eye disc compensates for the Mats 
loss-of-function, further suggesting that the function of Mats is highly 
conserved from Drosophila to human. 
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Figure 1. 7. The implications of the Mats loss-of-function in cancer-related phenotypes. 
(A)(B)(C)(D) From mosaic flies with mats clones, large tumour in the head, notum, shoulder area and 
eye can be induced, respectively. (D) shows reduced eye phenotype due to hid-induced photype.(E) 
shows reduced eye phenotype in Mats mutant clones (Taken from (Lai, Wei et al. 2005). In addition 
to these phenotypes, Mats loss-of-function causes embryonic lethality. Matse235 and Matsroo are two 
independent alleles which cause Mats loss-of-function. Matse235 failed to complement the recessive 
lethality of Matsroo. 
 
Similarly, in mice, MOB1 loss-of-function has been linked to 
cancer. Recent studies revealed that MOB1 deficient mice display the most 
severe phenotype comparing to that of other Hippo component (Nishio, 
Hamada et al. 2012). Moreover, it was also shown that MOB1B 
heterozygous mice lacking MOB1A result in partial embryonic lethality and 
tumour formation in liver, while MOB1A heterozygous mice lacking 
MOB1B are all embryonically viable and free of liver tumours (Nishio, 
Hamada et al. 2012), implying that MOB1A might be key protein and more 
important than MOB1B. More importantly, keratinocyte-specific 
homozygous-null mutations of MOB1A and MOB1B (kDKO) mice 
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keratinocytes displayed over-proliferation, impaired apoptosis and contact 
inhibition, enhanced centrosomes, and increased progenitor self-renewal, 
thereby driving trichilemmal carcinoma in the skin (Nishio, Hamada et al. 
2012).            
  In addition to these findings (Nishio, Hamada et al. 2012), Nishio et 
al. (2015) showed that conditional double knock-out of MOB1 in mouse 
liver cause hyperplasia of oval cells and immature cholangiocytes and half 
of mutant mice die within 3 weeks. Survival mice were observed to develop 
hepatocellular adenomas, intrahepatic cholangiocellular carcinoma (ICC), 
cholangiocarcinomas (cHC-CCs). Furthermore, they observed that liver 
conditional double knock-out of MOB1A exhibits dramatic phenotypes 
comparing to that of Nf2 (Benhamouche, Curto et al. 2010), Sav1 (Lu, Li et 
al. 2010), or Mst1/2 (Song, Mak et al. 2010) knockout mice, making 
MOB1A the most important elements of the Hippo pathway. They have also 
clarified that all these phenotypic changes in MOB1 double knock-out mice 
are genetically linked to YAP activation (Nishio, Sugimachi et al. 2016). 
Based on these results, they propose that MOB1 loss-of-function initiates 
the activation of YAP, leading to impaired cell contact-dependent growth 
inhibition, increased cell proliferation and migration, EMT, and liver 
tumour formation. However, it is unknown how MOB1 regulates YAP in 
these settings. From the general concept of the Hippo pathway (as outlined 
in section 1.2), one can conclude that LATS tumour suppressor proteins 
cannot be activated in MOB1-deficient mice. The inactive LATS proteins 
would not be able to inactivate and then inhibit YAP onco-proteins, which 
would ultimately trigger target genes leading to tumour formation. 
Furthermore, the fact that tumour formation observed in MOB1 deficient 
mice displayed more severe phenotype than those of the other Hippo 
components (MST1/2, LATS1/2, SAV) implies that MOB1 may have 
different molecular targets. In this context, the involvement of NDR1/2 
kinases in these processes cannot be ruled out, since MOB1 can interact 
with NDR1/2 as well as LATS1/2 and MST1/2 kinases (Hergovich 2011, 
Hergovich 2016) and NDR1/2 functions upstream of YAP kinases (Zhang, 
Tang et al. 2015).  
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Taken together, involvement of Mats/MOB1 in cancer-related 
properties has clearly been shown in both Drosophila and mice. The 
involvement of Mats in cancer-related properties is shown in Mats loss-of-
function Drosophila. The molecular mechanism how Mats loss-of-function 
results in overgrowth phenotype and impaired apoptosis is not completely 
known and remains to be uncovered. Importantly, the observation that Wts 
loss-of-function flies exhibit similar overgrowth phenotype implies that 
Wts-Mats signalling are important for tissue growth regulation in 
Drosophila. Even more importantly, the overgrowth phenotype in Mats 
mutant flies are stronger than Wts loss-of-function, indicating that Mats is 
master tumour suppressor in Hippo signalling.  Moreover, it was also shown 
that Mats is required for Trc functions (He, Emoto et al. 2005). More 
importantly, Vrabioiu et al. showed that complex formation between Wts 
and Mats is required for Wts activation. On the other hand, they also 
showed that Hippo-Mats interactions seem to be indispensable. In this 
context, experimental evidence using full-length proteins carrying selective 
manipulations is yet outstanding and will help us to understand how tissue 
growth is regulated in Drosophila.     
Involvement of MOB1 has been linked to human cancer (Gomez, 
Gomez et al. 2014). MOB1 loss-of-function can play pivotal role in the 
tumour formation. Intriguingly, recent research revealed that MOB1A is 
involved in a broader range of activities including association with MST1/2, 
LATS1/2 and NDR1/2. Importantly, it was revealed that double knockout of 
MOB1 in mice represents more severe tumour formation than that of LATS, 
Sav, MST deficiency (Harvey, Zhang et al. 2013), suggesting that MOB1 
might function as tumour suppressor independent of LATS possibly 
including MOB1/MST or MOB1/NDR complexes. Complex interactions of 
MOB1 with its binding partners MST1/2, LATS1/2, and NDR1/2 are not yet 
investigated. In this context, the selected variants of MOB1A affecting 
binding properties to MST1/2, LATS1/2, and NDR1/2 will uncover the 
molecular mechanism of tumour formation driven by MOB1. 
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1.6. Research Aims 
The Hippo signalling pathway has emerged as a key signalling pathway 
regulating tissue growth and organ size during Drosophila development. 
Recent studies have identified Mats (the counterpart of human MOB1A) as 
a tumour suppressor protein which functions as a key component of the 
Hippo pathway. The same study has also shown that loss of mats gave rise 
to uncontrolled tissue overgrowth in Drosophila. Very interestingly, it has 
also been shown that loss-of-function of mats can be functionally rescued by 
expression of wild-type MOB1A to suppress tissue overgrowth in the eye. 
Moreover, Wei et al. (2007) showed that Hpo phosphorylates Mats, which 
in turn results in the activation of Mats, thus upregulating Wts kinase 
activity. MOB1A has been shown to bind to NDR1/2, LATS1/2 and 
MST1/2. However, the importance of these interactions with respect to 
biological functions has so far only been tested in isolation without 
considering the context of these diverse PPIs. More importantly, none of 
these interactions have actually been tested in the context of tumour 
suppression and the regulation of YAP (Yki). Therefore, the aim of this 
project is to decipher the key PPIs of MOB1A with the Hippo core kinases 
MST1/2(Hpo), LATS1/2(Wts), and NDR1/2(Trc) which are essential for 
tumour suppression.  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Reagents 
Molecular biology reagents 
Reagents Company Catalogue 
Number 
1kb DNA Ladder Fisher Scientific Ltd FQ-SM0311 
1.5ml PP Eppendorf 
tubes 
Fisher UK 10509691 
2.0ml PP Eppendorf 
tubes 
Fisher UK 10038760 
GelRed Nucleic Acid 
Gel Stain 
Biotium 41003 
Falcon Tubes (15ml and 
50 ml) 
Appleton Woods BC031 
Pfu DNA polymerase MBL / supplier Caltag 
Med 
RK-02-031-5 
QIAquick Gel 
extraction kit 
Qiagen 28706 
NucleoSpin Plasmid Fisher-MN NZ740588250 
Midi prep kit (MN) Fisher UK NZ740410100 
T4 DNA ligase NEB M0202G 
PCR Tubes VWR 732-0676  
BamH I - HF New England Biolabs R3136M 
Dpn I New England Biolabs R0176L 
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EcoR I - HF New England Biolabs R3101L 
EcoR V - HF New England Biolabs R3195L 
Hind III New England Biolabs R0104S 
Kpn I - HF New England Biolabs R3142S 
Not I New England Biolabs R0189S 
Pme I New England Biolabs R0560L 
Xho I New England Biolabs R0146L 
Taq DNA polymerase New England Biolabs M0273L 
Alkaline phosphatase 
CIP 
New England Biolabs M0290S 
5ml pipettes sterile Fisher UK – Corning TKV-670-051R 
10ml pipette sterile Fisher UK – Corning TKV-670-071L 
25ml pipette sterile Fisher UK – Corning TKV-670-091F 
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Biochemistry reagents 
Reagents  Company Catalog Number 
ProtoGel (30%) 
Acrylamide 
Fisher Scientific UK 12381469 
Ammonium persulphate Sigma A3678-100G 
Ampicillin Sigma A9393-25G 
2-mercaptoethanol Sigma M3148-100ml 
1.6ml plastic cuvettes Fisher UK 11547692 
Luminol Sigma 123072-25G 
pCoumaric acid Sigma C9008-10G 
H2O2 30% solution VWR 23622.260 
X-ray films SLS MOL7016 
EDTA Sigma(fluka) 10617201 
Ethanol VWR 20827.365 
Isopropanol (2-propanol) VWR 1.09634.1000 
Kanamycin Sigma K1377-5G 
LB broth base Sigma L3022-1KG 
LB agar Sigma L2897-1KG 
MgSO4 Sigma M7506-1KG 
Glycine Sigma G7126-5KG 
Boric acid Sigma B6768-1KG 
Borax Sigma 71998-250G 
NaCI Sigma S3014-5KG 
Na2HPO4 Sigma S3264-500G 
KCl Sigma P9541-500G 
EGTA Sigma E3889-100G 
IPTG Sigma I6758-10G 
Glycerol Sigma G5516-1L 
Na3VO4 Sigma S6508-50G 
Leupeptin Enzo Life Sciences ALX-260-009-
M025 
DTT Enzo Life Sciences ALX-280-001 
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Benzamidine Sigma 12072-10G 
Microcystin-LR Enzo Life Sciences ALX-350-012-
C500 
1M Hepes pH7.5 solution Invitrogen 15630-056 
10% SDS solution Fisher UK BPE2436-1 
20% SDS solution Fisher UK BPE1311-1 
Skim milk powder Sigma 70166-500G 
DMP Fisher UK PN21667 
ATP (adenosine 5'-
triphosphate) 
Fisher UK - GE 
Healthcare 
GZ27100603 
TEMED Fisher UK - National 
Diag. 
ELR-420-010P 
Bio-Rad protein assay Bio-rad 500-0006 
gamma-P32-ATP Hartmann Analytic SRP-301/37 
Peptone from casein Sigma 70172-500G 
Yeast Extract Sigma 70161-500G 
Citric acid monohydrate Sigma C1909-500g 
PMSF Sigma P7626-5G 
NP40 substitute Sigma 74385-1L 
Coomassie Brilliant Blue Sigma B4921-20TAB 
Tween 20 Bio-rad 170-6531 
NaF Sigma S7920-500G 
Triton X-100 Sigma T9284-1L 
Crystal violet Sigma C3886-100G 
NaOH Sigma S5881-1KG 
EDTA (IDRANAL) Sigma 31064-1KG 
Ponceau S Sigma P7170-1L 
Protein A sepharose CL-
4B beads 
VWR 17-0780-01 
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Cell biology reagents 
Reagents Company Catalog Number 
DMEM Sigma D6429-24X500ML 
DMSO Sigma D8418-1L 
15ml PS tubes (for TC) VWR - BD Falcon 734-0450 
Tetracycline Sigma 87128-25G 
Gelatin Fisher UK G/0150/53 
Polybrene/hexadimethrine 
bromide 
Sigma H9268-5G 
Lipofectamine 2000 Invitrogen 11668-019 
Opti-MEM Invitrogen 31985-047 
Fetal Bovine Serum (tet 
tested) 
Invitrogen 16000-044 
Trypsin 0.25% Invitrogen 25050-014 
D-MEM powder Invitrogen 52100-039 
D-PBS Invitrogen 14040-174 
Schneider's Drosophila 
medium 
Invitrogen 21720-024 
Penicillin G potassium salt VWR A1837.0010 
Streptomycin sulfate VWR A1852.0025 
Fugene-6 Roche 11814443001 
Metafectene Pro CamBio - Biontex 
UK 
T040-1.0 or 2.0 or 5.0 
Puromycin Autogen - 
Invivogen 
ant-pr-1 
Zeocin Autogen - 
Invivogen 
ant-zn-5 
Hygromycin B Autogen – 
Invivogen 
ant-hm-1 
Blasticidin S Autogen – 
Invivogen 
ant-bl-1 
G418 - Geneticin Autogen - ant-gn-5 
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Invivogen 
RPMI 1640 with L-
Glutamine 
Invitrogen 21875034 
D-PBS Ca/Mg free Invitrogen 14190-169 
Horse Serum Invitrogen 16050122 
DMEM/F12 medium 
Hepes 
Invitrogen 31330038 
EGF Peprotech AF-100-15-1000 
Hydrocortisone Sigma H0888-10G 
Cholera toxin Sigma C8052-1MG 
Insulin Sigma I1882-100MG 
0.05% trypsin plus 
0.53mM EDTA 
Invitrogen 25300096 
Effectene transfection 
reagent 
Qiagen 301425 
HI-FBS Invitrogen 10082147 
Lipofectamine 
RNAiMAX 
Invitrogen 13778150 
Tissue culture 60mm dish 
6cm 
Appleton Woods BC151 
175cm tissue culture 
flasks T175 
Greiner 660175 
12-well TC plate VWR 391-0006 
6-well TC plates VWR 734-1596 
24-well TC plates Fisher UK -
Corning 
TKT-520-090B 
6cm TC plates Fisher UK -
Corning 
TKV-160-034S 
10cm TC plates Fisher UK -
Corning 
TKV-160-049F 
CryoTubes 2.0ml Sarstedt 72.380.992 
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2.1.2. Antibodies 
 
  
Primary 
Antibody 
Species  Usage Supplier Catalog 
Number 
Blocking 
Solution 
HA-tag 
(C29F14) 
Rabbit 1:1000 Cell 
Signalling 
3724 5% Milk 
HA-tag 
(42F13) 
Mouse 1:500 Home-made  5% Milk 
Myc-tag 
(71D10) 
Rabbit 1:1000 Cell 
Signalling 
2278 5% Milk 
Myc-tag 
(9E10) 
Mouse 1:50 Home-made  5% Milk 
Alpha-tubulin 
(YL1/2) 
Rat 1:100 Home-made  5% Milk 
YAP (total) Rabbit 1:1000 Cell 
Signalling 
4912 5% Milk 
Phospho-
YAP(S127) 
Rabbit 1:1000 Cell 
Signalling 
4911S 5% Milk 
Phospho-
YAP(S397) 
Rabbit 1:1000 Cell 
Signalling 
13619 5% Milk 
Anti-Actin (I-
19) 
Goat 1:1000 Santa Cruz sc-1616 5% Milk 
Anti-GAPDH 
(6C5) 
Mouse 1:1000 Millipore Mab374 5% Milk 
Anti-MOB1 Rabbit 1:250 Home-made  5% Milk 
anti-MOB1 
(T12-P) 
Rabbit 1:1000 NEB 8843 5% Milk 
anti-MOB1 
(T35-P) 
Rabbit 1:1000 NEB 8699 5% Milk 
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2.1.3. Buffers and Solutions 
Unless otherwise stated, buffers and solutions were kept at room 
temperature 
 
5 x Laemmli SDS Sample buffer
 
Main Stock Amount Taken  Final Concentration 
1 M Tris-HCI pH 6.8 12.5ml 125mM 
20% SDS solution 25ml 5) 
autoclaved ddH2O 57.5ml  57.5% 
beta-mercaptoethanol 5ml 0.05 
Total Volume 100ml  
 
 
Western blot stripping solution
* 
Main Stock Amount Taken Final Concentration 
Glycine 1.877 g 25mM 
20% SDS solution 50ml 1% SDS 
autoclaved ddH2O Fill up to 1000 ml  
Total Volume 1000ml  
* pH is adjusted to 2.5 with 37% HCI 
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Standard 150mM Lysis Buffer
* 
Main Stock Amount Taken Final Concentration 
1 M Tris pH 8.0 20 ml 20 mM 
5 M NaCl 30 ml 150 mM 
100 ml pure glycerol 100 ml 10% 
10 % NP-40 100 ml 1% 
0.5 M EDTA pH 8.0 10 ml 5 mM 
0.5 M EGTA pH 8.0 1 ml 0.5 mM 
0.5 M NaF 100 ml 50 mM 
beta-glycerophosphate 4.32 g 20 mM 
200 mM Na3VO4 5 ml 1 mM 
autoclaved ddH2O Fill up to 1000 ml  
Total Volume 1000 ml  
*Store at 4 oC, Protease and phosphatase inhibitors; 1 mM benzamidine, 4 µM leupeptin, 0.5 mM 
phenylmethylsulfonyl fluoride [PMSF], and 1 mM dithiothreitol [DTT] were freshly added into buffer to 
prevent proteolysis, dephosphorylation and denaturation of proteins. 
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Standard 1M lysis buffer (for IP washing)* 
Main Stock Amount Taken Final Concentration 
1 M Tris pH 8.0 20 ml 20 mM 
5 M NaCl 100 ml 1 M 
100ml pure glycerol 100 ml 10% 
10 % NP-40 100 ml 1% 
0.5 M EDTA pH 8.0 10 ml 5 mM 
0.5 M EGTA pH 8.0 1 ml 0.5 mM 
0.5 M NaF 100 ml 50 mM 
beta-glycerophosphate 4.32 g 20 mM 
200 mM Na3VO4 5 ml 1 mM 
autoclaved ddH2O Fill up to 1000 ml  
Total Volume 1 000ml  
*Store at 4 oC, Protease and phosphatase inhibitors; 1 mM benzamidine, 4 µM leupeptin, 0.5 mM 
phenylmethylsulfonyl fluoride [PMSF], and 1 mM dithiothreitol [DTT] were freshly added into buffer to 
prevent proteolysis, dephosphorylation and denaturation of proteins. 
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MILB (low stringency MST Interaction Lysis Buffer)
* 
Main Stock Amount Taken Final Concentration 
1 M HEPES pH 7.4 30 ml 30 mM 
beta-glycerophosphate 4.32 g 20 mM 
1 M KCl 20 ml 20 mM 
0.5 M EGTA pH 8.0 2 ml 1 mM 
0.5 M NaF 4 ml 2 mM 
200 mM Na3VO4 5 ml 1 mM 
Pure TX-100 10 ml 1% 
autoclaved ddH2O Fill up to 1000 ml  
Total Volume 1000 ml  
*Store at 4 oC, Protease and phosphatase inhibitors; 1 mM benzamidine, 4 µM leupeptin, 0.5 mM 
phenylmethylsulfonyl fluoride [PMSF], and 1 mM dithiothreitol [DTT] were freshly added into buffer to 
prevent proteolysis, dephosphorylation and denaturation of proteins. 
 
 
10× MST1/2 (Hippo) kinase assay buffer
* 
Main Stock Amount Taken Final Concentration 
1 M Tris pH7.5 2.5 ml 5 mM 
beta-glycerophosphate 0.27 g 2.5 mM 
0.5 M EGTA 1 ml 1 mM 
0.2 M Na3VO4 2.5 ml 1 mM 
1 M MgCl2 2 ml 4 mM 
*1M DTT is freshly added to buffer at the final concentration of 0.01 mM. Store at 4 oC 
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Kinase Master Mix (KMM) 
Main Stock Amount Taken 
10x Kinase Assay Buffer 1V 
1 mM ATP 2V 
ddH2O 2V 
 
 
For SDS-PAGE 
SDS Resolving Gel (for 10ml) 
 8% 10% 12% 
ddH2O 4.6 ml 4.0 3.3 ml 
30% Acrylamide mix 2.7 ml 3.3 4.0 ml 
1.5 M Tris-HCl [pH 8.8] 2.5 ml 2.5 2.5 ml 
10% SDS 0.1 ml 0.1 0.1 ml 
10% APS 0.1 ml 0.1 0.1 ml 
TEMED 0.006 ml 0.004 0.004 ml 
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Stacking gel (3 ml per gel) 
ddH2O 2.1 ml 
30% Acrylamide mix 0.5 ml 
1.0 M Tris-HCl [pH 6.8] 0.38 ml 
10% SDS 0.03 ml 
10% APS 0.03 ml 
TEMED 0.003 ml 
 
 
10 x SDS Running Buffer (for 2000ml)   
Main Stock Amount Taken  Final Concentration 
Glycine 288.2 g 1.92 M 
Tris base 60.6 g 250 mM 
20% SDS solution 100 ml  
autoclaved ddH2O Fill up to 2000 ml  
 
 
For Western Blotting 
Tris-buffered saline-tween (TBS-T) 
Tris-HCI [pH 7.5] 50 mM 
NaCl 150 mM 
Tween 20 0.1% 
 
 
 
  
54 | P a g e  
 
Chemiluminescent detection substrates 
Solution 1 
Tris-HCI [pH 8.5] 1 M 
Luminol 250 mM 
pCoumaric acid 90 mM 
 
Solution 2 
Tris-HCI [pH 8.5] 1 M 
H2O2 30% 
 
 
Coomassie staining solution 
MeOH 25% (v/v) 
Acetic acid 10% (V/V) 
Coomassie 0.25% (w/v) 
 
 
Destaining solution for Coomassie staining    
 
 
 
 
10 x Western Blot Transfer Buffer (for 2000ml) 
Main Stock Amount Taken Final Concentration 
Glycine 288.2 1.92 M 
Tris base 60.6 250 mM 
autoclaved ddH2O Fill up to 2000 ml  
 
 
  
EtOH 10% 
Acetic acid 10% 
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10 x Tris-buffered saline (TBS) pH 7.4  (2000ml) 
Main Stock Amount Taken Final 
Concentration 
NaCl 175.32 g 3 M 
Tris base 121.14 g 1 M 
37% HCl 75 ml  
autoclaved ddH2O Fill up to 2000 ml  
 
 
TBS-T (0.05 %) 
Main Stock Amount Taken 
10x TBS 200 ml 
Tween 10 ml 
autoclaved ddH2O Fill up to 2000 ml 
 
 
10 x TBE (2000ml) 
Main Stock Amount Taken Final 
Concentration 
Tris base 216 g 0.89 M 
Boric acid 110 g 0.89 M 
0.5M EDTA pH8.0 80 ml 20 mM 
autoclaved ddH2O Fill up to 2000 ml  
 
 
1000 x Leupeptin stock (4mM)
* 
Main Stock Diluted in 
25 mg (Mw=475.6) 13.13 ml autoclaved ddH2O 
*Store at -20 
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1000 x DTT stock (1M)
* 
Main Stock Diluted in 
5 g (Mw=154.2) 32.43 ml autoclaved ddH2O 
*Store at -20 
 
1000 x Benzamidine stock (1M)
* 
Main Stock Diluted in 
10 g (Mw=120.15) 83.23 ml autoclaved ddH2O 
*Store at -20 
 
1000 x PMSF (0.5M)
* 
Main Stock Diluted in 
5 g (Mw=174.19) 57.4 ml DMSO 
*Store at -20 
 
0.2M Sodium Orthovanadate stock (0.2M Na3VO4)
* 
Main Stock Diluted in 
9.2 g (Mw=183.91) 200 ml autoclaved ddH2O 
* Adjust pH to 10.0 with 37% HCl, Boil solution until it turns colourless; cool down to RT, Readjust pH to 
10.0 with NaOH, Repeat boiling-cooling-adjusting procedure until the solution remains colourless with a 
stable pH of 10.0. 
 
200mM MBP lysis buffer (500ml) 
Main Stock Amount Taken Final 
Concentration 
20 mM Tris-HCI pH 7.5 10 ml 1 M 
1 mM EDTA 1 ml 0.5 M 
200 mM NaCl 20 ml 5 M 
autoclaved ddH2O Fill up to 500 ml  
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1M MBP column washing buffer (500ml) 
Main Stock Amount Taken Final 
Concentration 
20 mM Tris-HCI pH 7.5 10 ml 1 M 
1 mM EDTA 1 ml 0.5 M 
1 M NaCl 100 ml 5 M 
autoclaved ddH2O Fill up to 500 ml  
 
0.2 M boric acid
* 
Main Stock Diluted in 
6.183 g (Mw=61.83) 500 ml autoclaved ddH2O 
*Adjust pH to 4.0 with HCI, store at 4 oC 
 
0.05 M Na-Borax
* 
Main Stock Diluted in 
10.06 g (Mw=201.22) 1000 ml autoclaved ddH2O 
* Heat up in order to solve Borax completely 
 
0.2M Na-Borate buffer pH 9.0 (100ml)
* 
Main Stock Diluted in 
9 ml 0.2 M boric acid (pH4.0) 90 ml 0.05 M Borax 
*Adjust pH to 9.0 
 
0.2 M Ethanolamine pH 8.0 (500 ml)
* 
Main Stock Dissolved in 
6 ml 16.6 M ethanolamine solution (99%) 450 ml autoclaved ddH2O 
* Adjust pH to 8.0 with HCl 
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Bacteria culture buffers 
LB medium
*
 (1000 ml) 
Main Stock Amount Taken 
Tryptone 10 g 
Yeast Extract 5 g 
NaCI 10 g 
autoclaved ddH2O Fill up to 1000 ml 
*Adjust pH to 7.0 with NaOH and autoclave. Store at 4 oC. To prepare plates with amphicilin or kanamycin 
containing plates, add 100 mg/ml of amphicilin or 50 mg/ml of kanamycin. 
 
2 x YT medium
*
 (1000 ml) 
Main Stock Amount Taken 
Tryptone 16 g 
Yeast Extract 10 g 
NaCI 5 g 
autoclaved ddH2O Fill up to 1000 ml 
*Adjust pH to 7.0 with NaOH and autoclave. Store at 4 OC. 
 
IGB buffer
*
 (for competent E.coli) (500 ML) 
Main Stock Amount Taken Final Concentration 
PEG4000 50 g 10% (w/v) 
MgSO4 6.15 g 50 mM 
MgCI2 5.08 g 50 mM 
DMSO 25 ml 5% (v/v) 
*Dissolve solid chemicals in 400 ml LB medium, add DMSO, adjust pH to 6.5, and filter sterilise. Store at 4 
OC 
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LB plates
* 
Main Stock Amount Taken 
LB base 25 g 
Agar 15 g 
MgSO4 1.204 g 
10N NaOH 400 µl 
autoclaved ddH2O Solve in 1000 ml 
*Adjust pH to 7.2-7.3 and autoclave. After autoclave, let it cool down to 45-50 and then store at 4 oC. To 
prepare plates with ampicilin or kanamycin containing plates, add 100 mg/ml of ampicilin or 50 mg/ml of 
kanamycin after cooling down to 45-50 oC.  
 
1000 x Ampicilin stock
*
 (100 mg/ml)  
Main Stock Diluted in 
1 g Ampicilin (349.41 g/mol) 9 ml autoclaved ddH2O 
*Store at -20 
 
1000 x Ampicilin stock
*
 (50 mg/ml) 
Main Stock Diluted in 
0.5 g Kanamycin (484.499g/mol) 9 ml autoclaved ddH2O 
*Store at -20 
 
100 mM IPTG
* 
Main Stock Diluted in 
10 g IPTG (238.3 g/mol) 419.6 ml autoclaved ddH2O 
*Store at -20 
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2.1.4. Plasmids 
The following plasmids were kindly provided by the Hergovich Laboratory; 
pCMV(R)neo_new MCS (New multiple cloning sides (MCS) were inserted 
into BamHI/XhoI to get new MCS: BamHI - MluI - PmeI - KpnI - HpaI - 
BglII – XhoI). 
pcDNA3_neo_myc  (with the myc-tag being in frame into KpnI/BamHI)  
pcDNA3_neo_HA  (with the HA-tag being in frame into KpnI/BamHI) 
pMAL-2c_hMOB1A wt 
pMAL-2c_hMOB1A T12A 
pMAL-2c_hMOB1A T35A 
pMAL-2c_hMOB1A E51K 
pMAL-2c_hMOB1A D63V 
pMAL-2c_hMOB1A K104E/K105E 
pMAL-2c_hMOB1A E51K/K104E/K105E 
pMAL-2c_hMOB1A D63V/K104E/K105E 
pSuper.retro.puro shhMOB1A#1/shhMOB1B#3 
pSuper.retro.puro shhMOB1A#4/shhMOB1B#3 
pSuper.retro.puro_shLuc 
pcDNA3_myc-RFP 
pcDNA3_myc-RFP NDR1 1-80 
pcDNA3_myc-RFP NDR1 18-82 
pENTR-3C 
pcDNA3_myc-RFP NDR1 20-82 
pcDNA3_myc-RFP NDR1 22-82 
pcDNA3_myc-RFP NDR1 25-82 
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pcDNA3_myc-RFP LATS2 568-661 
pcDNA3_myc-RFP LATS2 603-661 
pcDNA3_myc-RFP LATS2 580-661 
pcDNA3_myc-RFP LATS2 590-661 
pcDNA3_myc-RFP LATS2 595-661 
pcDNA3_myc-RFP LATS2 600-661 
Drosophila cell expression plasmid pAW was kindly provided by the 
Barbara Laboratory. Transgenic drosophila generation plasmid pKC26w 
pUbiq was kind gift for the Tapon Laboratory. The plasmid pSMT3-
hMOB1A (33-216) was kindly provided by the Rice Laboratory. The 
plasmids pLEX (gateway casette inserted) were kind gift from the 
Rodriquez-Viciana Laboratory. 
 
2.1.5. Oligonucleotides 
Primers (5` to 3`) Sequence 
Universal T7  TAATACGACTCACTATAGGG  
SP6 ATTTAGGTGACACTATAG  
MOB1A (E51K) F TTGCCTGAGGGAAAGGATCTCAATGAATGG
ATTGC 
MOB1A (E51K) R TCATTGAGATCCTTTCCCTCAGGCAACATAA
CAGC 
MOB1A (D63V) F GCTGTGAACACTGTGGTTTTCTTTAACCAGA
TCAACATGTTA 
MOB1A (D63V) R GATCTGGTTAAAGAAAACCACAGTGTTCAC
AGCAATCCATTCA 
MOB1A 
(K104E/K105E) F 
ACTAATATTGAAGAGCCAATCAAATGTTCT
GCACC 
MOB1A 
(K104E/K105E) R 
TTTGATTGGCTCTTCAATATTAGTACCATCT
GCCC 
Roo Internal 1 R GCCGCTCAAGATAGCCAGAT 
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Roo Internal 2 R TATCTAAGGCGACATGGGTGC  
Roo Internal 
Forward primer 4 
ATCTGGCTATCTTGAGCGGC 
Roo Internal 
Reverse Primer 4 
CTAAGGCGACATGGGTGCAT 
Roo Internal 
Forward primer 5 
AATGGCCTACGGAGACCTAC  
Roo Internal 
Reverse Primer 5 
GCCGCTCAAGATAGCCAGAT  
Primer 97  GCACACTTCCTGGAACCGCTCGCATC  
Neo2 f AGAGGCGCTTCGTCTACGGAGCGACA  
hsp70_FRT r  CGGCAAGCAGGCATCGCCATGGGTC  
pKC26-pUbiq F CCCCAGCCAGGAAGTTAGTTTC  
SV40 R GGCATTCCACCACTGCTCCC  
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2.2. Methods 
2.2.1. Molecular Biology Techniques 
2.2.1.1. Preparation of Competent Cells 
The E. coli strains XL1-Blue or BL21 were used to produce competent 
cells. XL1-Blue or BL21 were aseptically plated out on LB agar plates 
without any antibiotics, which in turn were incubated at 37 
o
C overnight. 
Single colonies were picked and inoculated into 5 ml of 2x YT. The 
following day, the overnight cultures were diluted into 500 ml 2x YT 
(1:100), which were then incubated in a shaking incubator at 37 
o
C until the 
optical density (OD) of the culture reached 0.4 at 600nm. The cultures were 
then centrifuged at 112 x g at 4 
o
C for 5 minutes. After removing the 
supernatant, the cell pellet was re-suspended in 1/10 volume ice cold IGB 
buffer. Then, cells were aliquoted into precooled tubes in a cold room at 4 
o
C, snap frozen in dry ice and stored at -80 
o
C. 
2.2.1.2. Transformation of Competent cells  
Bacterial transformation were performed as described by (Cohen, Chang et 
al. 1972), which reported that bacteria take up plasmids when treated with 
ice-cold CaCl2 and subjected to a brief heat shock. Pre-prepared competent 
E.coli cells were thawed on ice. 1 µl of plasmid DNA were added to 100 µl 
competent cells and then incubated on ice for 30 minutes. The cells-DNA 
mixture was then heat-shocked at 42 
o
C by placing in pre-arranged 
thermomixer for 45 seconds, which were immediately transferred on ice for 
5 minutes. Following the incubation on ice, 500 µl of LB medium without 
any antibiotics were added to the cells-DNA mixture and then incubated at 
37 
o
C for 30 minutes. This so-called recovery step was only applied to the 
transformation after ligation. After the incubation at 37 
o
C, the cells-DNA 
mixture was plated out onto LB plates with corresponding antibiotics using 
sterile techniques. The plates were incubated at 37 
o
C overnight.      
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2.2.1.3. Preparation of plasmid DNA from competent E.coli cells 
2.2.1.3.1. Small Scale preparation of plasmid DNA (Mini-Prep) 
DNA minipreps were performed according to manufacturer`s instructions 
(Macherey-Nagel). Briefly, the plasmids were transformed and grown on 
LB plate with corresponding antibiotics. Single colony were then picked up 
and transferred into 3 ml LB medium in 15 ml falcon tubes with 
corresponding antibiotics and ultimately inoculated at 37 
o
C overnight with 
vigorous shaking. The following day, bacterial cells were pelleted by 
centrifugation at 12,000 x g for 1 minute. The supernatant was then 
removed and cell pellets were re-suspended in 250 µl pre-chilled buffer A1 
(50 mM Tris-HCl, 10 mM EDTA, 100 μg / mL RNase A, pH 8.0; 
resuspension solution). 250 µl of the buffer A2 (200 mM NaOH, 1 % SDS; 
lysis buffer) were then added and incubated for 5 minutes at room 
temperature. 300 µl of the buffer A3 (2.8 M KAc, pH 5.1; neutralization 
solution) were ultimately added and mixed by inversion. The mixture was 
then spun down by centrifugation at 11,000 x g for 5-10 minutes, before 
transferring the supernatant to NucleoSpin® Plasmid column, followed by 
centrifugation at 11,000 x g for 1 minute to allow DNA to bind to silica 
membrane of NucleoSpin® Plasmid column. After discarding flow-through, 
silica membrane was then washed with the buffer A4 (100 mM Tris, 15% 
ethanol, 1.15 M KCl, adjusted to pH 6.3 with H3PO4, wash buffer) to 
remove  any cellular debris. The NucleoSpin® Plasmid column was placed 
in a fresh 1.5 eppendorf tubes and 50 µl of autoclaved ddH2O were added 
and finally centrifuged at 11,000 x g to elute DNA.  
2.2.1.3.2. Large-scale preparation of plasmid DNA (Midi-prep)      
DNA midipreps were performed according to manufacturer`s instructions 
(Macherey-Nagel). Briefly, the plasmids were transformed and grown on 
LB plate with corresponding antibiotics. Single colony was then picked up 
and transferred into 100 ml LB medium in 1000 ml Erlenmeyer flask with 
corresponding antibiotics and ultimately inoculated at 37 
0
C overnight with 
vigorous shaking. After the incubation overnight, bacterial cells were 
transferred to Nalgene® Centrifuge Tubes and then centrifuged at 5,000 x g 
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for 10 minutes at 4 
o
C. After centrifugation, the supernatant was discarded 
and cell pellets were then re-suspended in Cell Resuspension Solution (50 
mM Tris-HCL (pH 7.5), 10 mM EDTA (pH 8.0), 100 µg/ml RNase A). Cell 
Lysis Solution (CLS) (0.2 M NaOH, %1 SDS) was added to the cell 
suspension and mixed by gently inverting the tube 3-5 times. After 
incubating the cell suspension-CLS mixture for 3 minutes at room 
temperature, Neutralization Solution (4.09 M guanidine hydrochloride (pH 
4.2), 759 mM potassium acetate, and 2.12 M glacial acetic acid) were added 
to the lysed cells and mixed by gently inverting the tubes 3-5 times. The 
mixture was then centrifuged at 15,000 x g for 15 minutes to pellet the bulk 
of the cellular debris. During the centrifugation, a column stack was 
assembled by assembling a PureYield
TM
 Clearing Column (PCC) into the 
top of a PureYiald
TM
 Binding Column (PBC), which were ultimately placed 
onto the vacuum manifold. After centrifugation, the cleared lysate was 
decanted into PCC and the vacuum was applied to allow to not only pass 
through the clearing membrane in the PCC but also plasmid DNA to bind to 
the binding membrane in the PBC. To clean the PBC, 5 ml of Endotoxin 
Removal Wash was added and the vacuum was applied to allow the vacuum 
to remove the solution through the column. As a last step of washing, the 
PBC was washed with 20 ml of Column Wash Solution (60% Ethanol, 60 
mM potassium acetate, 8.3 mM Tris-HCL and 0.04 mM EDTA). To elute 
plasmid DNA, 1.5 ml Eppendorf tube was placed in the base of the 
Eluator
TM
 Vacuum Elution Device in which PBC was previously placed. 
The Eluator
TM
 Device assembly were the placed into a vacuum manifold. 
400 µl of Nuclease-Free Water were then added to the Eluator
TM
 Device 
Assembly to elute plasmid DNA into 1.5 ml eppendorf tubes. 
2.2.1.4. Quantification of nucleic acids  
The concentration of DNA was measured using NanoDrop
TM
 ND-1000. 
After setting up with Blank (Nuclease-Free Water), the concentration was 
quantified at 260nm. For example, a value of 39.019 at 260nm corresponded 
to 1950 ng of DNA per µl.  
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2.2.1.5. Agarose gel electrophoresis of nucleic acids   
Agarose gel electrophoresis is widely used as a method of separating a 
mixed population of DNA based on length and size of DNA fragments. 
Negatively charged DNA molecules are run on an agarose matrix, with 
small DNA fragments running faster than large DNA fragment, when 
electric field is applied. DNA fragments were separated and visualized using 
agarose gel electrophoresis containing the Nucleic Acid Red Dye (VWR, 
cat# 730-2958). Nucleic Acid Red Dye helps to detect DNA or RNA with 
the reduced rate of mutagenicity, which make it safer than ethidium 
bromide. The agarose gels were prepared by mixing appropriate amount of 
agarose powder (see Table 2.1) (Sigma, cat# A2576) into appropriate 
amount of 10x TBE buffer, which were in turn microwaved to dissolve agar. 
Following cooling the agarose solution, appropriate amount of Nucleic Acid 
Red Dye (1:1000) were added into the solution to have DNA visualized 
after electrophoresis. The solution was then poured into a casting tray with a 
comb, subsequently allowing the solution to solidify for at least 20 minutes. 
After solidification of the gel, it was placed into electrophoresis chamber, 
immersed in 1x TBE and the comb was then removed. Appropriate amount 
of 6x DNA Loading Buffer was mixed with samples, which were 
subsequently loaded into wells. 1 µg of 1kb DNA Ladder (Fermentas, cat# 
SM0311) were exploited as a molecular weight marker. Electrophoresis was 
run at a constant voltage of 100 V for 50 minutes. The DNA were then 
visualized under UV light using Syngene G:BOX F3 Fluorescence Imaging 
System. 
Table 2. 1 
Percentage agarose gel (w/v) DNA size resolution (kb=1000) 
0.5% 1kb to 30 kb 
0.7% 800 base pairs to 12 kb 
1.0% 500 base pairs to 10 kb 
1.2% 400 base pairs to 7 kb 
1.5% 200 base pairs to 3 kb 
2.0% 50 base pairs to 2 kb 
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2.2.1.6. Restriction endonuclease digestion, extraction and ligation 
of DNA fragments 
In order to screen for inserts, right orientation of insert, or prepare for PCR 
products and plasmid DNAs for ligation, DNAs were digested in 
appropriate buffer with specific restriction endonucleases (please see Figure 
2.1, 2.2, 2.3). For ligation of insert into vector backbones, 5 µg of inserts or 
vector backbones were digested in appropriate buffer with specific 
restriction endonucleases at the recommended temperature overnight. After 
the incubation overnight, the samples were run on appropriate percentage of 
agarose gel using electrophoresis. Following the separation of DNA 
fragments on agarose gel, QIAquick Gel Extraction Kit (Qiagen, cat#28704) 
was used to extract DNA if needed for subsequent cloning stages, according 
to the manufactures’ protocol (Qiagen). Briefly, the DNA fragments were 
excised from the agarose gel with a clean and sharp scalpel. The gel slice 
was then weighed. According to weight, 3 volumes of Buffer QG were 
added to 1 volume gel (100 mg gel ~ 100 µl). The mixture was then 
incubated at 50 
o
C for 10 minutes. After the incubation, 1 volume of 
isopropanol was added to the sample and mixed. A QIAquick spin column 
was placed in a provided 2 ml collection tube. The sample were then applied 
to the QIAquick column and centrifuged at maximum speed for 1 minute to 
bind DNA. Then, flow-through was discarded and 750 µl of Buffer PE were 
added to the QIAquick column and centrifuged at maximum speed for 1 
minute to wash. After the washing, the QIAquick column was placed into a 
clean 1.5 ml Eppendorf tube. To elute DNA, 50 µl of autoclaved ddH2O 
were added and centrifuged at maximum speed for 1 minute. Following the 
extraction of DNA fragments (vector backbones, inserts or PCR products), 
100 ng/µl of vector backbone and 10 µl of DNA inserts (5-10 ng) were 
mixed with 10 µl of 2X RLB and 1 µl of T4 DNA ligase (NEB, cat# 
M0202L) and the mixture was then incubated at room temperature for 20 
minutes to ligate the insert into vector backbones. The ligation mixture was 
transformed into XL1-Blue E.coli to amplify the newly-ligated plasmid. 
After isolation of newly-ligated plasmids from XL1-Blue E.coli, the 
plasmids were screened for right insert using appropriate restriction 
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endonucleases. For example, as shown in Figure 1, plasmid C were digested 
with KpnI/XhoI in Buffer 4 overnight and run on agarose to screen for 
hMOB1 insert. The constructed plasmids were then sent for sequencing. 5 
µl (100 µg/µl) of DNA and 5 µl (5 nmol) of necessary primers were sent for 
sequencing by SourceBioscience. For sequence analysis, the sequence 
results sent by SourceBioscience were blasted with corresponding cDNA 
sequence using ClustalW2 program. 
2.2.1.7. Standard Polymerase Chain Reaction (PCR) 
 PCR is a most commonly used method in molecular biology as a tool of 
amplifying a single or several copies of a piece of DNA. PCR can be used to 
integrate specific restriction digestion sides to generate new multiple 
cloning sides in plasmid DNA. Briefly, all standard PCRs were performed 
as pointed in Table 2.2. 
 
Table 2.2. Standard PCR reaction mix 
Reagent Volume per reaction 
36 µl Autoclaved ddH2O 
5 µl 10 x buffer 
5 µl 2.5mM dNTPs 
1 ul template (at 100 ng/µl) 
1 µl Forward primer (100 µM) 
1 µl Reverse primer (100 µM) 
1 µl Pfu DNA polymerase (2.5 U/µl) 
 
 
PCR procedure consists of 3 main steps including denaturation, annealing, 
and extension, as pointed in 
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 Table 2.3. Pfu PCR cycles* 
*The temperature for Denaturation, Annealing, and Extension may vary according to the different 
enzymes. This PCR cycle is only for Pfu enzymes 
 
2.2.1.8. Site-directed PCR mutagenesis 
Site-directed PCR mutagenesis is an in vitro molecular biology technique 
which introduces specific mutations into a vector at a particular position. All 
mutations created in this project were generated on pcDNA3.1- based 
plasmids and the mutant versions of cDNAs were then subcloned into other 
plasmids as specified. All site-directed mutagenesis were performed as 
pointed in Table 2.2.  
Step Temperature Time Description 
Denaturation 98 
o
C 1 
minute 
dsDNA is exposed to high 
temperature, leading dsDNA to 
melt by disrupting the 
hydrogen bonds between 
complementary bases, thus 
generating single-stranded 
DNA. 
Annealing 55 
o
C 1 
minute 
The temperature is reduced to 
55 
0
C to enable the primers to 
anneal specifically and bind to 
the ssDNA. The temperature 
might differ according to 
primers. The best annealing 
temperature can be checked at 
http://tmcalculator.neb.com/#!/.  
Extension 72 
o
C 2 
minute 
per kb 
of 
template 
DNA polymerases generate 
new DNA complementary to 
DNA template by adding the 
dNTPs to complementary base 
pairs on ssDNA.   
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Following the standard PCR procedure, 1 µl of DpnI enzyme (20 U/µl) were 
added to PCR products, mixed thoroughly and incubated for 2 hours at 37 
o
C to eliminate methylated DNA templates and select for newly-generated 
DNA including the desired mutation. 10 µl of DpnI-digested PCR products 
were then loaded on the corresponding percentage of agarose gel and 
subjected to electrophoresis at 80 V for 1 hour to detect the presence of the 
mutated DNA, as all non-mutated DNAs were digested and eliminated by 
DpnI enzyme. Ultimately, PCR products were transformed into E.coli 
competent cells (Section 2.2.1.2), and miniprep DNAs were prepared for 
the analysis of single clones (Section 2.2.1.3.1). Full length of coding 
region was sequenced and analysed to confirm the desired mutations, as 
described in Section 2.2.1.6.  
2.2.1.9. DNA vectors 
2.2.1.9.1. Plasmids used for cloning and expression of hMOB1A 
variants, NDR1/2, MST1/2 and LATS1/2 cDNAs in COS-7 cells 
and HEK293 cells 
All human NDR1/2, MST1/2, LATS2 and MOB1A cDNAs were subcloned 
into pcDNA3 and pcDNA3 derivatives containing a hemagglutinin(HA) or 
myc epitope using BamHI/XhoI restriction sites as described (Hergovich, 
Bichsel et al. 2005). Human LATS1 was subcloned into pcDNA3 
containing a hemagglutinin (HA) epitope as described (Hergovich, Schmitz 
et al. 2006). All mutants of MOB1A were generated by PCR-based 
mutagenesis using pcDNA3-myc-hMOB1A(wt) as a template as outlined in 
section 2.2.1.8. The generated hMOB1A plasmids (Figure 2.1) were used 
for transient expressions in COS-7 and HEK-293 cells. 
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Figure 2.1. Cloning of MOB1A into pcDNA3.1_myc. 
 A (backbone) and B (insert) were digested with BamHI and XhoI restriction enzymes and 
B was ligated into A to generate pcDNA3.1_myc-MOB1A (C). Plasmid C was used as a 
template to generate all MOB1A mutant versions. This figure is for representative purpose 
only. All plasmids are circular. 
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2.2.1.9.3. Plasmids used for cloning and transient expression of 
hMOB1A variants, Mats, Hpo, Warts and Trc cDNAs in S2R+ 
Drosophila cells 
All fly Mats, Hpo, Trc and human MOB1A cDNAs were subcloned into 
pENTR-3C plasmids using KpnI/XhoI restriction sides. Fly Warts was 
subcloned into pENTR-3C using KpnI/NotI restriction sides. Following the 
construction of pENTR-3C-based plasmids, Gateway LR reactions were 
performed between pENTR-3C-based plasmids and pAW plasmid 
(destination plasmid). Gateway LR reactions are based on the recombination 
of ENTRY clone including attL sides with destination vector including attR 
sides, which results in the insertion of gene of interest placed in ENTRY 
clone between attL1 and attL2 into destination vector. The generated 
plasmids (Figures 2.2 and 2.3) were used for transient expression in 
Drosophila S2R+ cells. 
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Figure 2.2. The cloning of myc-MOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, HA-
Trc, HA-Warts into pENTR3C. 
 Plasmid A and Plasmid B were digested with KpnI and XhoI restriction enzymes. The 
insert isolated from plasmid B were then ligated into plasmid A, resulting in Plasmid C. 
Drosophila Mats cDNA, Hpo, Trc and MOB1A mutant versions were generated with the 
same procedure. Drosophila Wts were subcloned into pENTR3C using KpnI/NotI 
restriction enzymes. The figure only shows MOB1A cDNA as an insert. This also applies 
to MOB1A mutant cDNAs, Drosophila myc-Mats, HA-Hpo, HA-Trc, HA-Wts. This figure 
is for representative purpose only. All plasmids are circular. 
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Figure 2.3. The cloning of myc-MOB1A cDNAs, Drosophila myc-Mats, HA-Hpo, HA-
Trc, HA-Wts into pAW. 
Gateway LR reaction were performed between plasmid A and B, resulting in plasmid C. 
The figure only shows MOB1A cDNA as an insert. This also applies to hMOB1A mutant 
cDNAs, drosophila myc-Mats, HA-Hpo, HA-Trc, HA-Warts. This figure is for 
representative purpose only. All plasmids are circular.  
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2.2.1.9.4. Plasmids used for cloning and stable expression of 
MOB1A cDNAs in MCF-7 
All human MOB1A variants were subcloned into pCMV(R)neo_new MCS 
retroviral plasmids using PmeI/XhoI restriction sides. Also, all human 
MOB1A variants were subcloned into pENTR plasmids using KpnI/XhoI 
restriction sides, which were then subcloned into pLEX lentiviral plasmids 
using Gateway LR Reaction approach. The generated plasmids were used 
for stable expression of tagged MOB1A variants in MCF-7. 
2.2.1.9.5. Plasmids used for cloning and recombinant protein 
production of MOB1A cDNAs in E.coli (BL21) 
All human MOB1A variants were subcloned into pMAL-c2 (NEB) using 
BamHI/SalI restriction sides. The generated plasmids (Figure 2.4) were 
used for protein production in BL21 DE3 E.coli, and the purified 
recombinant proteins were subsequently used in kinase assays. 
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Figure 2.4. The cloning of MOB1A cDNAs into pMAL-2C. 
Plasmid A and B were digested with BamHI/SalI and BamHI/XhoI, respectively. Then, the 
insert isolated from plasmid B were ligated into plasmid A, resulting in plasmid C. The 
figure only shows MOB1A cDNA as an insert. This also applies to MOB1A mutant 
cDNAs. This figure is for representative purpose only. All plasmids are circular.  
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2.2.1.9.6. Plasmids used for the generation transgenic flies 
expressing fly selected MOB1A variants in D. Melanogaster 
All pENTR-3C-based plasmids of human MOB1A variants (Figure 2.2) 
were inserted into pKC26w pUbiq plasmids using Gateway LR reaction. All 
the generated plasmids (Figure 2.5) were screened for MOB1A inserts 
using KpnI/XhoI enzymes (see section 2.1.6). After confirming the inserts, 
the identity of gene of interest was verified by sequencing using pUbiq and 
SV40 primers (see section 2.2.1.6). Ultimately, the generated plasmids were 
expressed in S2R+ cells using Effectene Transfection (See section 
2.2.3.4.2), confirming the functionality of promoters. The generated 
plasmids were sent to BestGene Inc to generate transgenic Drosophila 
manipulating human MOB1A variants (Figure 2.5) (More information can 
be found in section 2.2.5). 
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Figure 2.5. The cloning of MOB1A cDNAs into PKC26W pUbi. 
Gateway LR reaction were performed between plasmid A and B, resulting in plasmid C. 
The figure only shows MOB1A cDNA as an insert. This also applies to MOB1A mutant 
cDNAs. This figure is for representative purpose only. All plasmids are circular. 
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2.2.2. Biochemistry methods  
2.2.2.1. Cell lysis for protein extraction 
Cells were gently washed with ice-cold PBS -Ca/-Mg, ice-cold 150 mM 
lysis buffer or MILB buffer was then added, which were subsequently 
followed by collecting cells in the lysis buffer using policeman scrapper. 
The cells were then transferred into pre-chilled 1.5 eppendorf tubes and 
incubated for 30 minutes on ice. After the incubation, the eppendorf tubes 
were centrifuged at 25,000 x g for 10 minutes at 4 
o
C, before supernatants 
were transferred into fresh-labelled eppendorf tubes on ice. The 
supernatants containing the cell lysate were used for either western blot 
analysis or processing as required (co-IP, Kinase assay). 
2.2.2.2. Determination of protein concentrations using Bradford 
assay 
Protein concentrations were determined by Spectrophotometer using 
Bradford assay. Briefly, Bradford reagent (Bio-Rad) was diluted in 1:5 ratio 
with distilled water. 5 µl of protein lysate or lysis buffer was mixed with 1 
ml of the diluted Bradford reagent in spectrophotometer cuvettes, which 
were then measured at 595nm in spectrophotometer. 
2.2.2.3. Preparation of Protein A-sepharose 
Protein A-Sepharose CL-4B (1.5 g) (Fisher UK - GE Healthcare, cat#17-
0780-01) was incubated overnight with 50 ml autoclaved ddH2O at 4C on 
roller shaker. The following day, the beads were spun down by 
centrifugation at 1,100 x g for 4 minutes at 4C. Then, the supernatant was 
removed without touching the beads, before being washed twice with 
ddH2O and with PBS minus, respectively. After washing the beads with 
PBS minus, they were transferred into 15 ml falcon tubes, which were in 
turn washed once with PBS minus, followed by centrifugation at 4 
o
C for 2 
min at 1,100 x g and PBS minus was removed. Lastly, 3 ml PBS minus, 2 
ml ethanol and 100 µl Na-Azide were added into 5 ml swollen beads to 
obtain slurry of 50% sepharose A beads, which was stored at 4 
o
C. 
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2.2.2.4. Anti-HA 12CA5 antibody coupling with Protein A-
sepharose 
To covalently couple anti-HA 12CA5 antibody with protein A-sepharose, 
anti-HA 12CA5 hybridoma supernatant (provided by the Hergovich 
Labaratory) was incubated with protein A-sepharose at 4 
o
C in 1 ml 10% 
NP-40 solution. Next day, beads were washed two times with PBS minus 
and three times with 0.2 M Na-Borate (pH: 9.0). 51.8 mg of dimethyl 
pimelimidate.2 HCL (DMP, from Fisher UK – Pierce, cat# PN21667) 
dissolved in 5 ml 0.2 M Na-Borate (pH: 9.0) was then added to antibody-
beads slurry and incubated for at least 1 hour at room temperature. After the 
incubation, beads were washed twice with 0.2 M ethanolamine (pH: 8.0) 
and incubated for 3-4 hours at room temperature with 10 ml 0.2 M 
ethanolamine (pH: 8.0). Following the incubation, beads were washed twice 
with PBS minus and were kept at 4 
o
C in PBS minus containing 0.2% Na-
Azide. 
2.2.2.5. Co-immunoprecipitation (Co-IP) 
Co-IP is a commonly used approach to study protein-protein interactions. In 
our studies, DNA sequences coding for short peptide tags, namely HA- and 
myc-tags, were inserted into N-terminus of our proteins of interest. After 
manipulation of the genes of interest in HEK293 cells, protein extracts were 
prepared in MILB buffer as described in Section 2.2.2.1. After preparation 
of protein extracts, 20 µl of the input lysate were collected into new tubes 
for equal loading, followed by denaturating at 95 
o
C with appropriate 
amount of Laemmli buffer. The remaining protein extracts were subjected to 
pre-clearing to remove unspecific binding to HA-beads. In the pre-clearing 
step, the protein lysate was incubated with Protein-A sepharose for 1 hour, 
rolling at 4 
o
C. After the incubation, the protein extract-Protein-A sepharose 
mixture was centrifuged at 25,000 x g at 4C for 1 minute. The supernatant 
was then transferred into pre-chilled tubes containing protein A sepharose 
coupled to anti-HA 12CA5 antibody (see section 2.2.2.4), which were in 
turn incubated rolling overnight at 4 
o
C. The following day, the protein 
extract- anti-HA 12CA5 mixture was centrifuged at 25,000 x g for 30 
seconds. After centrifugation, supernatant was removed without touching 
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the beads. The beads were then washed 3 times with MILB lysis buffer 
containing benzamidine, DTT, leupeptin and PMSF, before being 
denaturated at 95 
o
C with 20 µl of laemmli buffer. 
2.2.2.6. Production of recombinant MAL-MOB1A variants 
All pMAL-c2-based plasmids (see Figure 2.4) were re-transformed into 
BL21 DE3 E.coli as described in Section 2.2.1.2. The following day, one 
single colony was inoculated and incubated in 3 ml LB medium containing 
ampicillin for 8 hours at 37 
o
C with vigorous shaking. After 8 hours, the 
cultures were diluted in 100 ml LB medium containing ampicillin (see 
section 2.1.3) and were then incubated overnight at 37 
o
C with vigorous 
shaking. The following day, the cultures were again diluted in LB medium 
at a 1:10 ratio and then incubated for 1 hour, before IPTG (100 µM) (see 
section 2.1.3) was added and bacteria were incubated for another 3 hours at 
37 
o
C. After 3 hours, the cultures were spin down by centrifugation at 1,400 
x g for 10 minute, followed by processing each 1 litre culture with 50 ml 
lysis buffer. The suspension was then sonicated at 70% amplitude (Sonics 
Vibra Cell
TM
, model:VCx 130), and the supernatant was clarified by 
filtration (40 µm cell strainer) before adding 2 ml amylose-resin (Biolabs, 
cat# E8021L), before the incubation overnight, rolling at 4C. The following 
day, protein-amylose resin mix were collected in yellow Bio-Rad columns 
(Bio-Rad, cat#737-4152) and washed with 20 ml 0.2 M Column Buffer, 10 
ml 1M Column Buffer, 20 ml 0.2M Column Buffer. After the washing step, 
the elution of MAL bound proteins were performed in 2 ml maltose-
containing buffer, followed by dialysis of eluted proteins overnight with 20 
mM Tris pH 7.5 buffers. As a final step, 10% of glycerol was mixed with 
the collected proteins and the amount of proteins were analysed by SDS-
PAGE running 1 µl, 5 µl and 10 µl of the purified proteins versus 0.1 µg, 
0.5 µg, 1 µg and 2 µg of BSA.  
Coomassie Staining and LiCor scan (680nM) were performed to 
quantify proteins. Briefly, LiCor macnine was used to scan acrylamide gel 
with the setting 700: 5; 800: 5 by including 100ng/500ng/1ug/5ug BSA as a 
reference. The quantified proteins were then stored until further use as a 
substrate for kinase assay. 
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2.2.2.6. In vitro kinase assays 
In vitro kinase assays were used to identify phosphorylation status of 
MOB1A variants as MST1/2 (Hpo) substrate. In our project, two different 
approaches were used to identify the phosphorylation status: (1) Radioactive 
in vitro kinase assay and (2), anti-phospho-antibody-based in vitro kinase 
assay. First approach is based on transferring a radioactive phosphate group 
from ATP to a substrate via [-32P]-ATP (Hartmann Analytic, cat# SRP-
301). The second approach is based on anti-phospho antibodies which are 
specific to human MOB1A proteins, which are phospho-MOB1A (Thr12) 
and phospho-MOB1A (Thr35).  
In radioactive in vitro kinase assays, bacterially expressed and 
purified MAL- hMOB1A variants (kindly provided by Belul Assefa Shifa) 
were mixed with MST1 kinase buffer (50mM Tris,pH:7.5, 25 mM beta-
glycerophosphatase, 10 mM EGTA,pH:8.0, 10 mM Na3VO4, 40 mM 
MgCI2, 0.1 mM DTT). The mixture was then resuspended in 10 μl kinase 
buffer including 200 μM [ϒ-32P] ATP, 20 ng/μl GST-MST1 (Sigma, cat# 
M9697) or GST-MST2 (Sigma, cat# S6573) (recombinant kinases 
expressed in insect cells; purchased from Sigma). After 30 min incubation at 
30 
oC, reactions were stopped with 20 μl SDS-Laemmli buffer, and samples 
were separated by SDS-PAGE, gels dried and finally analysed by 
autoradiography. 
In anti-phospho-antibody-based in vitro kinase assays, we checked 
how hMOB1A mutants at Thr12 and Thr35 sites behave as substrate for 
both MST1/2 and Hpo using recombinant MOB1As, MST1/2 and S2R+-
expressed HA-Hpo. To check the phosphorylation status of hMOB1A 
mutants by MST1/2, 500 ng of the bacterially expressed and purified MAL-
MOB1A variants and 1× MST1/2 kinase assay buffer were mixed in a pre-
chilled eppendorf tubes to a total volume of 10 µl. 1 µl of 10x kinase assay 
buffer and 2 µl of 2 mM ATP stock (f.c.200 µM ATP) were added to the 
mixture, before adding 500 ng of the bacterially expressed and purified 
GST-MST1 and GST-MST2 and 4.5 µl of ddH2O. KMM (see section 
2.1.3) were finally added to all reactions, which were then incubated for 30 
minutes at 30 
o
C. After 30 minutes, all reactions were stopped by adding 20 
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µl of laemmli buffer and then were separated by SDS-PAGE and analysed 
by Western Blotting. To check the phosphorylation status of hMOB1A 
mutants by Hpo, HA-Hpo were transiently expressed in Drosophila S2R+ 
cells using Effectene Transfection (Section 2.2.3.4.2) and the transfected 
cells were lysed and immunoprecipitated with anti-HA 12CA5 antibody as 
described in (Section 2.2.2.5). After immunoprecipitating with anti-HA 
12CA5 antibody, the beads were washed twice with 150 mM standard lysis 
buffer. The beads were then incubated with 1 M lysis buffer for 1 hour, 
rolling at 4 
o
C. After 1 hour incubation, the beads were washed once more 
with 150 mM lysis buffer and twice with 1x kinase assay buffer, followed 
by adding 500 ng of the bacterially expressed and purified MAL-MOB1A 
variants and ddH2O to give a total volume of 15 µl. KMM were then added 
to IP-substrate mixture, which were then incubated for 30 minutes at 30 
o
C, 
followed by stopping the reaction with appropriate amount of laemmli 
buffer. The samples were separated by SDS-PAGE and analysed by western 
blotting.   
2.2.2.8. Separation of proteins by SDS-PAGE 
SDS-PAGE is routinely used to separate proteins based on their sizes. After 
the preparation of different percentage of SDS-PAGE gel (see Table 2.4), 
gels were clasped into a MINIPROTEAN II electrode assembly and 
electrophoresis chamber (BIO-RAD). Equal amount of protein samples 
heat-denatured with Laemmli buffer at 95 
o
C for 5 minutes were loaded into 
the wells alongside pre-stained molecular marker (NEB), which were then 
run at 80V till samples had passed the stacking gel and reached to the 
resolving gel. The voltage was then increased to 100 V to run for another 90 
minutes. Where appropriate, the gels were then either transferred to PVDF 
membrane (Section 2.2.2.9) or incubated with Coomassie Blue for staining. 
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 Table 2.4. Gel percentage based on protein size (Adapted from Abcam.com) 
 
 
2.2.2.9. Western blotting of SDS polyacrylamide gels 
Following the separation of proteins on SDS-PAGE gels, the proteins were 
then transferred from polyacrylamide gels to PVDF membrane by Western 
blotting. Briefly, the polyacrylamide gels were soaked in transfer buffer and 
then placed on top of transfer buffer soaked-Whatman 3MM paper. PVDF 
membrane were pre-rinsed in methanol for 30 seconds, then washed with 
transfer buffer, which was subsequently placed on top of polyacrylamide 
gels, followed by more pre-soaked Whatman 3MM paper. The PVDF-
membrane “sandwich” were then placed into electro-blotting apparatus 
cassette and then immersed in transfer buffer, followed by running at 0.40 A 
(per tank) for 1 hour alongside with an ice block. After transferring proteins 
from polyacrylamide PVDF membrane, proteins were direct-stained by 
Ponceau S staining solution to check the quality of protein transfer. 
2.2.2.10. Immunodetection of proteins on Western blot 
membranes 
Following checking the quality of the protein transfer, the blotted membrane 
was then washed with ddH2O (2 times), and TBS-T (2 times), before 
blocking with 5% milk dissolved in TBS-T for at least 30 minutes. The 
membranes were then incubated overnight with primary antibody diluted in 
either 5% milk or BSA, rocking at 4 
o
C. The following day, the membranes 
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were washed three times with TBS-T at room temperature (each wash for 10 
minutes) to remove any unbound antibodies, before being incubated with 
horseradish peroxidase-linked secondary antibodies (see section 2.1.2) 
specific to primary antibodies rocking at room temperature for at least 2 
hours, followed by washing membranes three times with TBS-T (10 minutes 
per each wash). Following the washing step, chemiluminescent detection 
substrates were mixed in 1:1 ration and then added on top of membranes, 
which were then incubated for at least 30 seconds. Membranes were 
exposed to a film in the dark room and then developed by using a film 
processor (Konica Minolta, SRX-101A). 
 
2.2.3. Cell biology methods 
2.2.3.1. Tissue cell culture  
MCF-7, Cos-7, HEK-293, HEK-293T and PT67 cells were maintained in 
Dulbecco`s modified Eagle`s medium (Sigma, cat# D6429) supplemented 
with foetal calf serum (Sigma, Cat no: F7524) to a final concentration of 
10%. MCF10A (non-tumoral cell line) were cultured in a DMEM:- Nutrient 
Mixture F-12 (GIBCO® DMEM/F-12; cat# 11320-033) containing 5% 
horse serum (Gibco® HS; cat# 16050-122), 20 ng/mL epidermal growth 
factor (Peprotech EGF; cat# AF-100-15-1000), 0.5 μg/ml hydrocortisone 
(Sigma; cat# H0888-10G), 0.1 μg/ml cholera toxin (Sigma; cat# C8052-
1MG), and 10 μg/ml insulin (Sigma; cat# I1882-100MG). Drosophila S2R+ 
cells were cultured in Schneider`s Drosophila Medium (Invitrogen, cat# 
217200024) supplemented with heat-inactivated FBS (Invitrogen, cat# 
10082147). Cells were grown in the presence of 100 units/ml penicillin 
(VWR, cat#A1837.0010) and 100 mg/ml streptomycin (VWR, cat# 
A1852.0025), at 37 
o
C with 5% CO2 except for Drosophila S2R+ cells 
which were incubated at 24 
o
C. 
2.2.3.2. Passaging of cells 
After reaching approximately 80% confluency, cells were split to avoid 
overcrowding and prevent loss of epithelial morphology. Briefly, cell 
medium was removed and cells were washed once with PBS minus at 37 
o
C. 
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After removing PBS minus, a 0.25% trypsin/EDTA solution (0.05% 
trypsin/EDTA for MCF10A cells) were added to detach the cells (1 ml, 3ml 
and 5 ml of trypsin for 10cm plate, 75cm and 175cm flask, respectively). 
Briefly, trypsin was added to the cells and then trypsin-cells were incubated 
at 37 
o
C for trypsin to catalyse the reaction. Fresh medium containing serum 
was then added to the detached cells to neutralize the trypsin reaction, which 
were centrifuged at 94 x g after transferring the medium-trypsin-cell 
suspension into a 15 ml tube. After the centrifugation, the supernatant was 
aspirated and the cell pellet was resuspended in fresh medium. 
Subsequently, cells were seeded into fresh flasks or dishes at a 1:10 dilution. 
For S2R+ cells, no trypsin was used, since these cells do not attach to the 
flask so tightly. For passaging of these cells, cells were resuspended in 10 
ml of Schneider medium and seeded into fresh flasks or dishes at a 1:15 
dilution.    
2.2.3.3. Freezing and thawing of cells 
In order to store cell lines for long-term, cells were frozen. Briefly, cells 
were detached using trypsin/EDTA solution as described in Section 2.2.3.2. 
After the centrifugation, cells were then resuspended in freezing medium 
instead of complete medium. Then, 1ml of the cell suspension was aliquoted 
into cryotubes (Sarstedt, cat#72.380.992), which were immediately placed 
into Mr. Frosty before transferring to -80 
o
C. Next day, frozen cells were 
transferred to liquid nitrogen 2 in tower 10 (boxes 5 to 10).   
To thaw frozen cells, cryotubes were taken out from liquid nitrogen 
and thawed at 37 
o
C for 40 seconds, before transferred the content into 15 
ml falcon containing 5 ml complete medium. The medium with frozen cells 
was then spun down by centrifugation at 136 x g for 4 minutes. The cell 
pellet was resuspended in fresh complete medium and seeded into a flask.  
2.2.3.4. Cell transfections   
2.2.3.4.1. Fugene 6 transfection 
Transient plasmid transfection of Cos-7 and HEK-293 cells was performed 
using Fugene 6 (Promega, cat# E2692) transfection reagent as outlined by 
the manufacturer. Briefly, Cos-7 and HEK-293 cells were seeded at a 
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consistent confluence (1 x 10
6
 cells per 10-cm dish) 24 hours prior to 
transfection. Next day, plasmid DNAs mix was prepared in separate 1.5ml 
eppendorf tubes. After Fugene 6 and Optimem (Invitrogen, Cat no: 31985-
047) had reached room temperature, Fugene 6 was diluted in 500 µl of 
Optimem. Following incubation of the Fugene-Optimem mixture for 5 
minutes at room temperatures, the plasmid DNA mixture was added to the 
Fugene-Optimem mixture, which were then incubated for another 40 
minutes at room temperature. Following 40 minutes incubation, the 
transfection complex was added to cells and the cells were incubated 
overnight at 37 
o
C. The following day, transiently transfected cells were 
processed as required. 
 2.2.3.4.2. Effectene transfection 
 Transient plasmid transfection of Drosophila S2R+ cells was mediated 
through Effectene (Qiagen, cat# 301425). Namely, 1.2 x 10
6
 cells were 
seeded per well (6-well plate) 24 hours prior to transfection. On the day of 
transfection, appropriate amount of DNAs was added into 1.5ml ependorf 
tubes, followed by the addition of 150 µl of Buffer EC. The appropriate 
amount of Enhancer (the ratio of DNA to Enhancer was 1:8) was added and 
mixed by vortexing for 10 seconds. After incubating for 2-5 minutes at 
room temperature and brief centrifugation to collect drops from the top of 
the tube, 10 µl of Effectene was added to the DNA-Enhancer mixture. After 
vortexing for 10 seconds, the Effectene-DNA-Enhancer mixture was 
incubated for 30 minutes to allow transfection complex formation. Then, 
500 µl of fresh Schneider`s Drosophila Medium were added to the 
transfection complex, and subsequently added onto cells. After 48 hours, the 
cells were processed as required. 
2.2.3.5. Cell infection 
2.2.3.5.1. Retroviral infection   
To generate retroviral pools, transfection of the packaging cell line PT-67 
(Clontech, Alto, CA) was mediated through the Lipofectamine 2000 
transfection reagent (Life Technology, cat#11668-019). Briefly, 2 x 10
6
 of 
PT67 cells were seed per 10cm plate 24 hours prior to transfection. On the 
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day of transfection, two sets of 2 ml eppendorf tubes were prepared. 30 µl of 
Lipofectamine 2000 was added into the first set of tubes containing 720 µl 
of pre-warmed Optimem, which were then mixed by continuous gentle 
inversion for 30 seconds, followed by incubation for 5 minutes at room 
temperature. In the meantime, 12 µg of plasmid DNA were mixed with 
Optimem to give a total volume of 750 µl. The DNA-Optimem mixture was 
added to the Lipofectamine 2000-Optimem mixture, which were then mixed 
by continuous gentle inversion and incubated for 30 minutes at room 
temperature to allow transfection complex formation. In the meantime, the 
medium of the cells was replaced with 5 ml fresh DMEM containing 10% 
tet-free FCS (Invitrogen, cat#26140079) without Pen-Strep. After 30 
minutes incubation, the transfection complex was centrifuged briefly and 
added to the PT67 cells. 4 to 6 hours (preferentially 6 hours) after adding the 
DNA/Lipofectamine/Optimem, the medium was aspirated and replaced with 
fresh 6 ml medium DMEM containing 10% tet-free FCS without Pen-Strep, 
followed by incubation at 37 
o
C overnight. After 24 hours, supernatants 
were collected, filtered through a 0.45 μm filter (Sarstedt, cat#83.1826) in 
the presence of 0.8 μg/ml polybrene and subsequently added to 5 x 106 
target cells for infection. After 2 days, the infected cells were selected by 
treatments with appropriate antibiotics. Stable cell pools of target cells were 
maintained in media supplemented with appropriate antibiotics (see section 
2.1.3). 
2.2.3.5.2. Lentiviral Infection  
To quickly generate cell lines stably expressing transgenes of interest, a 
lentiviral approach was used by transfecting HEK-293T cells with PEI 
transfection reagent (Polysciences, Inc, cat# 23966-2). 10 x 10
6
 of HEK-
293T cells were seeded per 10cm plate 4 hours prior to transfection. The 
following plasmids were mixed per 1.5 ml eppendorf tube: 
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Table 2. 5 
 ratio µg 
pMD.G 1 2.4  
p8.91 0.3 0.8  
lentiviral vector 6 4.8 
 
After mixing the DNAs in Eppendorf tubes, 800 µl of pre-warmed Optimem 
and 32 µl of PEI were added in a specific order, followed by continuous 
gentle inversion and then incubated for 30 minutes at room temperature. 
After the incubation, the transfection complex was added to HEK-293T 
cells. The cells were then incubated overnight at 37 
o
C. The following day, 
the medium of the cells was replaced with 5 ml fresh medium. In parallel, 1 
x 10
6
 of target cells were seeded per 10 cm plate. The next day, virus 
containing supernatants were collected from the transfected HEK-293T 
cells, filtered through a 0.45μm filter (Nalgene) in the presence of 0.8 μg/ml 
polybrene and added onto the target cells after removing the medium of 
target cells. 24 hours later, the infected cells were selected by treatments 
with appropriate antibiotics (see section 2.1.3). Stable cell pools of target 
cells were maintained in media supplemented with appropriate antibiotics. 
2.2.3.6. Proliferation and colony formation assays 
For cell proliferation analysis, cells were seeded at defined densities (5 x 10
4
 
cells per well) in triplicates in 12-well plates, followed by non-invasive 
IncuCyte live cell imaging (Essen BioScience) to measure the kinetics of 
cell growth/proliferation based on area (confluence) metrics. Phase-contrast 
images were continuously collected on IncuCyte ZOOM (Essen 
BioScience) for at least one week. A specific processing definition (Phase-
contrast processing module) was applied to count objects (cells) for the 
duration of the assay. The Phase object area was expressed as relative cell 
confluency for each well at each time point and subsequently exported into 
GraphPad (Prism Software) for final analysis. To evaluate colony formation, 
1,000 cells were seeded per well (6-well format). After 8-12 days, colonies 
were fixed with methanol/acidic acid (3:1) for 5 minutes at room 
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temperature, stained with 0.5% (w/v) crystal violet for 15 minutes at room 
temperature, washed with water and finally scanned using the G:BOX HR 
gel documentation system (Syngene, cat# LCI-700-090R). Colonies 
composed of at least 50 cells were scored as positive. 
2.2.3.7. Soft agar assays for anchorage-independent growth. 
After trypsinization, cells were passed 4-5 times through a 21G syringe, 
before 1 x 10
4
 cells were resuspended in complete medium (DMEM 
containing 10% FBS and appropriate antibiotics) with 0.6% agarose 
(Thermo Fisher Scientific, cat#16520050), and subsequently cultured in 
wells (6-well format) underlaid by a layer of 1% agarose in complete 
medium and overlaid with complete medium without agarose. Top layer 
media were replenished every 72 hours. After three weeks, colonies were 
stained with 2.5 mg/ml thiazolyl blue tetrazolium blue (MTT, Sigma, 
cat#M2128), scanned, and quantified. Cell clusters of at least 50 cells were 
scored as colonies. 
 
2.2.4. Structural Studies Methods (performed in collaboration 
with the Wu Laboratory) 
2.2.4.1. Protein expression and purification for structural and 
biochemical analyses. 
cDNAs encoding human MOB1A (residues 33-216), NDR2 (residues 25-
88), human LATS1 (residues 618-697 or 640-703), human MST2 (residues 
2-392 or 2-308) were subcloned into a modified pET28a vector (Novagen), 
which were used to express N-terminally 6×His tagged proteins in the E. 
coli strain BL21 DE3. Bacteria carrying pET28a plasmids were grown at 37 
ºC until they reached an optical density of 0.6 to 1.0 at 600 nm. Protein 
expression was induced by addition of 0.2 mM IPTG and cultures were 
incubated at 16 ºC for additional 12 to 16 hours. After cell lysis with a cell 
homogenizer (JNBIO) in lysis buffer (25 mM Tris pH 8.0, 300 mM NaCl, 
and 20 mM imidazole), followed by centrifugation, supernatants were 
subjected to Ni
2+
-NTA affinity chromatography (Qiagen) as described by 
91 | P a g e  
 
the manufacturer. To form crystals of the MOB1A/NDR2 complex, NDR2 
(25-88) and MOB1A (33-216) proteins were incubated at an 1:1 molar ratio 
at 4 °C in assembly buffer (20 mM Tris pH 8.0, 200 mM NaCl, and 5 mM 
DTT), prior to loading onto a HiLoad 16/60 Superdex 200 gel filtration 
column (GE Healthcare). Peak fractions were combined and concentrated to 
10 to 15 mg/ml for crystallization experiments. Purified MOB1A (33-216) 
was phosphorylated as follows: in a total volume of 10 ml MOB1A (1 
mg/ml) was incubated with MST2 (2-308, 0.002 mg/ml) at 30ºC for 90 
minutes in phosphorylation buffer (40 mM Tris pH 7.5, 10 mM MgCl2, 5 
mM DTT, and 0.2 mM ATP). Completion of the phosphorylation reaction 
was verified by the shift of the MOB1A band in non-denaturing gel 
electrophoresis conditions (data not shown). 
2.2.4.2. Crystallization and data collection. 
Crystals of MOB1A (33-216) bound to NDR2 (25-88) were grown at 14C in 
crystallization buffer (17% PEG 3350, 0.1 M HEPES pH 7.5, and 150 mM 
magnesium chloride) by the hanging drop vapor diffusion method. Crystals 
were transferred to the crystallization buffer supplemented with 25% 
glycerol before freezing. Using an ADSC Quantum 315r CCD area detector 
an X-ray diffraction dataset at 2.10 Å was collected at the beamline 
BL17U1 at Shanghai Synchrotron Radiation Facility (Shanghai, China). 
Diffraction data were processed with the HKL2000 software (Otwinowski 
and Minor 1997). 
2.2.4.3. Structure determination, refinement and molecular 
graphics. 
The crystal belonged to the space group P212121 and contained two MOB1A 
(33-216)‒NDR2 (25-88) complexes in each asymmetric unit. MOB1 (33-
216) molecules in the complex were located by the molecular replacement 
method with the CCP4 program Phaser (Mccoy, Grosse-Kunstleve et al. 
2007)} using the published (Stavridi, Harris et al. 2003) structure of 
MOB1A (33-216) alone (PDB code: 1PI1) as the searching model. The 
model of the NDR2 (25-88) fragment was built manually with Coot (Emsley 
and Cowtan 2004). After refinement by the CCP4 program REFMAC5 
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(Winn 2003), the Rwork and Rfree factors were 15.3% and 24.4%, 
respectively. The quality of the final structure was verified by the CCP4 
program PROCHECK (Laskowski, Macarthur et al. 1993), revealing good 
stereochemistry according to the Ramachandran plot (99.0%, 0.6%, and 
0.4% for favored, allowed, and disallowed regions, respectively). The final 
models include residues 33-212 and 33-216 of MOB1A for chains A and B, 
respectively, and residues 25-85 and 25-87 of NDR2 for chains C and D, 
respectively. All figures displaying protein structures were generated with 
PyMOL (http://www.pymol.org). Sequence conservation of MOB1 mapped 
onto the surface of its crystal structure was generated by the ConSurf server 
(Landau, Mayrose et al. 2005). 
2.2.4.4. Gel filtration chromatography. 
Full-length MOB1A wild-type, D63V or K104E/K104E cDNAs were 
subcloned into the pET28a vector, expressed in bacteria and subsequently 
purified as described above for MOB1A (33-216). Purified full-length 
MOB1 proteins were incubated with NDR2 (25-88), LATS1 (618-697), or 
MST2 (2-392) protein at 4 
o
C for 20 minutes in assembly buffer, before the 
protein mixtures were loaded onto a HiLoad 16/60 Superdex 200 gel 
filtration chromatography column (GE Healthcare) and 1.4 ml fractions 
were collected. Samples from selected Superdex 200 fractions were 
analyzed by SDS-PAGE and Coomassie Blue staining. For the complex 
formation assay between MOB1A and LATS1, MOB1A protein was in vitro 
phosphorylated by MST2 (2-308) as described above before incubation with 
LATS1 (618-697). 
 
2.2.5. Fly genetics 
General Fly Husbandry 
Flies were maintained in vials of standard fly food media. Generally, genetic 
crosses were performed using 5 virgin females and 3 males. 
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Fly food recipe (18L) 
12600 ml H2O 
270g Agar 
900g Sugar 
3387 ml Extra water 
540ml Nipagin 
54 ml Propionic Acid 
1800g Yeast 
2.2.5.1. Generation of transgenic D. melanogaster 
To generate transgenic flies expressing human MOB1A cDNAs, a full 
length of cDNAs of human MOB1A variants were subcloned into pKC26w 
pUBIQ plasmids as shown in Figure 2.5. The identities of our gene variants 
of interest were verified by sequencing using pUbiq and SV40 primers. The 
plasmids were transiently expressed in S2R+ cells using Effectene 
Transfection reagent (see Section 2.2.3.4.2), confirming the functionality of 
promoters. The cloned plasmids were then sent to Best Gene (BestGene Inc 
2140 Grand Ave., Suite#205 Chino Hills, CA 91709 U.S.A.) for injection 
into the germline of fly embryos carrying an attP site inserted at cytological 
location 89E11 (Bloomington stock number 9744;  FlyBase ID: 
FBst0009744) for insertion into the Drosophila genome using the ΦC31 
integrase system. 
Site-specific integration using the Streptomyces phage ΦC31 
integrase has been developed and subsequently applied to D. melanogaster 
system (Groth, Fish et al. 2004). Unlike a transposase, ΦC31 integrase 
mediates a sequence-specific recombination in which it catalyses the 
recombination between an engineered “docking” site, a phage attachment 
site (attP), in the fly genome, and a bacterial attachment site (attB) present 
in the injected plasmid (Figure 2.6). During the recombination, a plasmid 
carrying both a transgene and attB site is co-injected with ΦC31 integrase 
mRNA into attP-containing embryos in which attP acts as the receiving site, 
thus leading to the site-specific integration of the transgene into the attP site 
(Figure 2.6). At least two independent stocks for each construct were kept.  
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Figure 2.6. A Schematic representation of ΦC31-mediated insertion.  
During the recombination, a plasmid carrying both a transgene and attB site is co-injected 
with ΦC31 integrase mRNA into attP-containing embryos in which attP acts as the 
receiving site, thus leading to the site specific integration of the transgene into the attP site 
(adapted from (Fish, Groth et al. 2007).    
 
2.2.5.2. Generation of balanced fly stocks 
Balancer chromosomes are modified chromosomes which carry multiple 
inversions, preventing the occurrence of crossing-over (genetic 
recombination) between two homologous chromosomes during meiosis. 
Balancer chromosomes used to stably maintain populations of Drosophila 
carrying homozygous lethal mutations across generations. Most balancers 
contain a dominant visible marker, which enables researchers to generate 
stocks carrying one copy of a mutation of interest over one copy of the 
balancer chromosomes. In our study, we used the balancer flies which have 
the TMB6 (Third Multiple 6B) balancer on the third chromosome. TM6B 
balancer chromosome carries Tubby (Tb) and Humeral (Hu) as dominant 
markers (see Figure 2.7).  
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Figure 2.7. Differences between wild type and TM6B balancer flies. 
(a) Wild type pupa. (b) Tubby mutant pupa. Note the shorter and thicker appearance. (c) 
Wild type fly thorax. (d) Humeral mutant fly thorax. Note the additional macrochaetae on 
the humeri (red circle). 
 
When the first progenies of transgenic flies hatched, virgin females with red 
eyes (pKC26w-pUBIQ contains the mini-white reporter gene, see section 
2.2.1.9.6) were collected and then crossed with +/TM6B balancer males 
(Figure 2.8) (kindly provided by the Bjedov Laboratory). TM6B virgin and 
male flies with red eyes were collected in the F1 generation, and 
subsequently crossed inter se to generate the balanced stocks (Figure 2.8). 
The cross scheme was as follows: 
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Figure 2.8. The generation of balanced stocks.  
Homozygous virgin flies with red eyes were collected and crossed with +/TMB6 balancer 
flies (Cross 1.1).  
 
2.2.5.3. Recombination of the mats
Roo 
allele 
The ubi>myc-hMOB1A transgenes were recombined with mats
roo
 by meiotic 
recombination as shown in Figure 2.8. 
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Figure 2.9. Recombination of Roo transposon. 
The aim of this cross scheme was to recombine mats
roo
 with ubi>myc-MOB1A. 15 
individual male progeny of the F1 cross were selected and, mated with virgin +/TMB6 to 
establish stocks. After the crosses had taken, the genomic DNA was extracted from the 
single males and subjected to PCR to genotype for the Roo transposon. The existence of 
Roo transposon was confirmed by PCR genotyping (see Supplementary data, Figure S1). 
 
Based on the fact that meiotic recombination occurs only in females, virgin 
homozygous flies with red eyes from (Figure 2.9) were selected, which 
were then crossed with male w;; +/TM6B balancer flies to allow the mats
roo
 
allele to be exchanged with the endogenous Mats allele (see Figure 2.9). In 
this crossing, there are two scenarios; 
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1- If recombination occurs, the mats
roo
 gene is recombined into the 
proximity of the chromosomal arm near on which the hMOB1A 
gene is integrated (see Figure 2.9, “If recombination occurs” 
scenario) 
2- If recombination does not occur, mats
roo
 will remain on the same 
chromosomal arm and the generated flies will have endogenous 
Mats (see Figure 2.9, “If recombination does not occur” scenario). 
The main aim of Figure 2.9 was to recombine the mats
roo
 into the proximity 
of the chromosomal arm near on which the MOB1A gene is integrated so 
that it has been tested if MOB1A can compensate for Mats loss-of-function. 
2.2.5.4. Recombination of the FRT site and Neomycin-based 
selection for FRT containing recombinants 
After the recombination of the mats
roo
 allele to our MOB1A constructs, the 
FRT82B site was recombined to the mats
roo
, ubi>myc-MOB1A stocks as 
depicted in Figure 2.10. 
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Figure 2.10. Recombination of FRT sites. 
Cross scheme to generate the FRT82B mats
roo
, ubi>myc-MOB1A recombinants. 
 
The progeny of the F1 cross were subjected to neomycin selection in order 
to select for the presence of the neomycin resistance cassette present on the 
FRT82B element (Xu and Rubin 1993).  
Crossing was set up as shown in Figure 2.10. Cross 3.2 was performed on 
medium containing 100 µl of 25mg/ml neomycin solution at 25 
o
C. When 
many eggs became visible on the surface of the food, vials were heat-
shocked at 37 
o
C for 1 hour 1-2 times per day every day until pupae 
appeared on the sides of the vials. After balancing, mats
roo
 allele and 
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FRT82B were confirmed by PCR genotyping using primers generated inside 
mats gene (See supplementary Figure S1 and S2). 
2.2.5.5. PCR genotyping  
All PCR genotyping was carried out as shown in Table 2.6. Information 
about the primers can be found in section 2.1.5. 
 
Table 2.6 
Reagent Volume per reaction 
5 µl 10X Standard Taq Reaction Buffer 
1 µl 10 mM dNTPs 
1 µl 10 mM Forward Primer 
1 µl 10 mM reverse Primer 
Variable Genomic DNA 
0.25 µl Taq DNA Polymerase 
To 50 µl Nuclease-free water 
 
  2.2.5.6. Western blotting of whole fly 
Three flies per WB lane were frozen at -80 
o
C overnight. After freezing, 
flies were homogenized on ice in 20 µl of 2 x laemmli sample buffer per fly 
(Bio rad, cat# 1610737) using a Squisher
TM
 manual homogeniser. The 
samples were then incubated for 5 minutes at 95 
o
C, followed by 
centrifugation at maximum speed in a microcentrifuge. Supernatant was 
transferred to new eppendorf tubes and the 1 in 20 v/v 1M DTT was added. 
Equal volumes of samples were analysed by SDS-PAGE, followed by 
Western blotting, as explained in (Section 2.2.2.8).  
2.2.5.7. Genomic DNA preparation from adult flies   
Genomic DNA preparations were performed using the Qiagen DNeasy 
Blood and Tissue kit according to the manufacturer`s instructions (Qiagen, 
cat#69506). Briefly, flies were collected and frozen in liquid nitrogen. The 
frozen flies were removed from liquid nitrogen and immediately crushed 
using micropestle. 180 µl of Buffer ATL was then added to the crushed 
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flies, followed by the addition of 20 µl of proteinase K before mixing 
thoroughly by vortexing. The samples were then incubated at 56C for 3 
hours while vortexing. After the incubation, 200 µl of Buffer AL and then 
ethanol (Sigma, cat# E7023-4x4L) were added and mixed by vortexing. The 
mixture was pipetted into the DNeasy Mini spin column placed in a 2 ml 
collection tube, following centrifugation at 7,000 x g for 1 minute. The 
flow-through and collection tubes were discarded. The DNeasy Mini spin 
columns were placed in new collection tubes and 500 µl of Buffer AW1 was 
added, followed by centrifugation at 7,000 x g for 1 minute. The flow-
through and collection tubes were discarded. The DNeasy Mini spin 
columns were placed in new collection tube and 500 µl of Buffer AW2 were 
added, followed by centrifugation at 21,000 x g for 3 minutes. The flow 
through and collection tubes were discarded once more. The DNeasy Mini 
columns were placed in 1.5 ml eppendorf tubes and 80 µl of Buffer AE 
were added onto the DNeasy membrane and centrifuged at maximum speed 
for 1 minute to elute the DNA. The DNA solution can be stored at -20 
o
C. 
300 ng DNA was used for PCR genotyping.  
2.2.5.8. Generation of mosaic tissues in Drosophila using the FLP-
FRT system     
Genetic mosaic techniques are powerful genetic tools that allow genetic 
manipulations of gene functions in a subset of cells in tissues (clones) 
within otherwise unperturbed organism, thus providing a platform to 
examine genetic changes, which would lead to lethality if applied to the 
entire organism (Blair 2003). 
The FLP-FRT system is one of the most commonly used genetic 
mosaic techniques. This system is created from yeast and it was first used in 
Drosophila in 1989 (Golic and Lindquist 1989). The FLP-FRT system 
makes use of the yeast FLP recombinase (FLPase), under the control of a 
heat-shock inducible promoter, to catalyse recombination between two FRT 
sites (FLPase recombination target). Thereby, this system generates mitotic 
clones of homozygous cells in heterozygous tissue. The system is described 
in Figure 2.11. 
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Figure 2.11. The FLP/FRT system. 
The pair of chromosomes contain the gene of interest residing distal to FRT transgene near 
the centromere. One chromosome carries the wild-type allele and a GFP reporter under the 
control of a given promoter, while the other chromosome bears a mutant allele. The 
expression of FLPase is induced by heat-shock, ultimately catalysing the recombination of 
FRT sites between the two homologous chromosomes, thereby generating two chimeric 
chromosomes, each bearing the two different alleles of gene X on its sister chromatids. 
Two possible outcomes are observed during the next mitosis. 1. In one possible outcome, 
two identical daughter cells are produced, each carrying one chromatid of each genotype. 
These cells are heterozygous mutant for gene X, and expressing GFP. 2. In this possible 
outcome, two different daughter cells are produced, homozygous wt cells carrying two 
chromatids with wt allele and GFP, and homozygous mutant cells carrying only X mutant 
allele. These two different daughter cells can be distinguished by GFP, since homozygous 
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wt cells express GFP, while homozygous mutant cells does not (Sidor, C., 2012, PhD 
Thesis, available at http://discovery.ucl.ac.uk/1352451/).   
           
2.2.5.9. Immunostaining of Drosophila imaginal discs 
Wing or eye imaginal discs were dissected in ice cold PBS. The dissected 
larvae were then fixed in PBS with 4% formaldehyde at room temperature 
for 30 minutes. Samples were then washed with two times (10 minutes 
each) with 0.1% PBST, permeabilised 0.3%  PBS-T for 25 minutes and pre-
blocked with 10% NGS (normal goat serum) in 0.1% PBS-T for 1 hour, 
followed by incubation with primary antibody at 4C overnight. Next day, 
the samples were washed three times (5 minutes per wash) with 0.1% PBS-
T and pre-blocked with 10% NGS in 0.1% PBS-T for 25 minutes, followed 
by incubation with secondary antibody for at least 2 hours. After the 
incubation, samples were again washed three times with 0.1% PBS-T, 
before mounting on Vectashield. 
 
 
 
  
104 | P a g e  
 
3. Results 
3.1. Structural and biochemical definition of the importance of 
MOB1A-NDR, MOB1A-LATS, and MOB1A-MST complex 
formation 
3.1.1. Abstract 
In mammals, there are six MOB proteins including MOB1A/B (usually 
collectively referred as MOB1) and four NDR/LATS kinases: NDR1/2 and 
LATS1/2. LATS1/2 are closer to Wts and phosphorylate the Yorkie 
homologue YAP in Hippo signalling; while NDR1/2 are implicated in 
regulating centrosome duplication, apoptosis, cell cycle, and Hippo 
signalling. It was found that an N-terminal domain of NDR1/2 (which 
occurs in the middle of LATS1/2) is responsible for mediating association 
with MOB1A. Furthermore, it was also shown that MOB1A can also 
interact with MST1/2 kinases. Although structures of human, Xenopus, 
yeast MOB1, and yeast Mob2-Cbk1 complex are available, it remains 
elusive how MOB differentially recognize NDR, MST, and LATS 
subfamilies of kinases. Here, we report the crystal structure of human 
MOB1A (residues 33-216) in complex with the N-terminal MOB1-binding 
domain of NDR2 (residues 25-88). Furthermore, we structurally and 
biochemically characterise the key residues of MOB1A for binding to 
MST/LATS/NDR kinases. Taken together, our data unveil crucial residues 
that are required for MOB1A binding to MST/LATS/NDR kinases. 
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3.1.2. Introduction 
Hippo signalling regulates cell proliferation, apoptosis, and cell 
differentiation from flies to mammals. The final output of the Hippo 
pathway is to inhibit the transcriptional co-activators Yorkie and YAP/TAZ 
in Drosophila and mammals, respectively (Wei, Shimizu et al. 2007). 
Essentially, core members of the Hippo pathway include the nuclear Dbf2-
related (NDR)/large tumour suppressor (LATS) family of kinases and its 
activator Mps one binder (MOB) proteins (Hergovich 2011, Avruch, Zhou 
et al. 2012). In Drosophila, Hippo kinase phosphorylates the MOB protein 
Mats and promotes its interaction with the NDR/LATS kinase Wts (Wei, 
Shimizu et al. 2007). Upon activation by Hippo and Mats, Wts 
phosphorylates and inactivates the transcriptional coactivator Yorkie 
(Avruch, Zhou et al. 2012). In mammals, there are six MOB proteins 
including MOB1A/B (usually collectively referred as MOB1) and four 
NDR/LATS kinases: NDR1/2 and LATS1/2 (Hergovich 2011). 
Mechanistically, the regulation of the mammalian Hippo pathway appears to 
function in a similar fashion with that of Drosophila. Briefly, current 
evidence suggests that MST (counterpart of Hpo kinase) initiates 
phosphorylation of MOB1A and then promotes its association with 
NDR/LATS kinases, therefore resulting in NDR/LATS activation. The 
activated NDR/LATS kinases subsequently phosphorylate and then inhibit 
the Yorkie homologue YAP (Hergovich 2013). 
It is important to note that complex protein-protein interactome of 
the Hippo pathway plays crucial role in its regulation (Hergovich 2012). In 
this context, complex interaction of MOB1A with MST/LATS/NDR kinases 
seems to be significant with regard to the regulation of the Hippo pathway. 
MOB1A can associate with all four human LATS/NDR as well as MST 
kinases (Hergovich 2012). It was only biochemically shown that N-terminal 
domains of NDR/LATS kinases are essential for the binding of MOB1A 
with LATS/NDR kinases. However, structural importance of complex 
formation of MOB1A with NDR/LATS is not known and needs to be 
addressed.   
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Here we report the complex formation of MOB1A with NDR/LATS 
kinases using structural studies. Based on our structural studies, we 
determine the key residues of MOB1A that is needed for the association 
with NDR/LATS kinases. To further support our findings from the 
structural studies, we biochemically prove the importance of the key 
residues of MOB1A with respect to binding to NDR/LATS kinase. 
Furthermore, we also report the key residues which is essential for the 
binding of MOB1A with MST1/2 kinases. 
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3.1.3. Results - Structural definition of MOB1-NDR2 and MOB1-
LATS1 complex formations 
To determine the crystal structure of human MOB1A (residues 33-216) in 
complex with the N-terminal MOB1-binding domain of NDR2 (residues 25-
88), MOB1A (33-216) and NDR2 (25-88) were bacterially expressed and 
purified as outlined in section 2.2.4.1. The crystal growth of the purified 
proteins was carried out as shown in section 2.2.4.2. The results are 
presented in Figure 3.1. 
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Figure 3.1. The MOB1A/NDR2 structure reveals that MOB1A and NDR2 interact 
through conserved interfaces. 
(a) Overall crystal structure of the complex between human MOB1A (residues 33 to 216) 
and human NDR2 (residues 25 to 88). MOB1 and NDR2 are coloured in magenta and 
green, respectively. The Zinc associated with MOB1 is indicated in grey. Secondary 
structure elements are highlighted. (b) The negatively charged surface of MOB1 recognizes 
positively charged residues on NDR2. The electrostatic surface potential of MOB1 is 
shown (red: negatively charged residues; blue: positively charged residues). NDR2 is 
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shown as a ribbon representation coloured in green. (c) The MOB1A/NDR2 binding 
surfaces are highly conserved. The residues of MOB1 are gradually coloured according to 
conservation scores (dark red: most conserved residues; dark cyan: least conserved 
residues). NDR2 is shown as a ribbon representation coloured in green. (d) Structure based 
sequence alignment of MOB1A from indicated species. MOB1A residues mediating 
interactions with NDR2 are marked with brown (main-chain hydrogen bonds), green (side-
chain hydrogen bonds) and magenta circles (van der Waals interactions). a helices are 
painted with cyan background. Thr12 and Thr35 phosphorylation sites are indicated by red 
arrows. (e,f) The interaction interfaces of MOB1A with the a1 (e) and a2 (f) helices of 
NDR2. MOB1A and NDR2 and their key interacting residues are shown in pink and green, 
respectively. Dashed lines represent hydrogen bonds. Side chain nitrogen, oxygen, and 
sulphur atoms of MOB1A and NDR2 residues are coloured in blue, red and gold, 
respectively. The hydrogen bond network connecting the a1 and a2 helices of NDR2 is also 
illustrated in f. 
 
We determined the crystal structure of human MOB1A (residues 33-216) in 
complex with the N-terminal MOB1A-binding domain of NDR2 (residues 
25-88) to 2.1 Å resolution (Supplementary data, Table S1, deposited with 
the PDB code 4ZUG). Noteworthy, the structure of MOB1A in the 
complex with NDR2 is essentially the same as the published structure of 
MOB1A in isolation (Stavridi, Harris et al. 2003), while the NDR2 (25-88) 
fragment bound to MOB1A displays a tong-shaped structure comprising 
two α helices (Figure 3.1a). MOB1A employs its negatively-charged 
surface to associate with positively-charged K25/R42/R79/K81/R82 
residues on NDR2 (Figure 3.1b). This NDR2-binding surface of MOB1A 
exhibits a striking level of conservation from yeast to human, while, in 
contrast, the other part of MOB1A that is not involved in the interaction 
with NDR2 is much less conserved (Figure 3.1c). Moreover, sequence 
alignments of MOB1A and NDR2 with their respective functional 
counterparts reveal that key residues mediating their direct association are 
highly conserved from yeast to human (Figure 3.1d). 
The recognition interface between NDR2 and MOB1A can be divided into 
two main parts. First, at the interface between the α1 helix of NDR2 and 
MOB1A, Y32 of NDR2 occupies a central position, and its side-chain 
hydroxyl group forms hydrogen bonds with Q67 and H185 of MOB1A 
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(Figure 3.1e). Moreover, K25 of NDR2 makes hydrogen bonds with the 
main-chains of L173 and Q174 of MOB1A, and residues L28, L35, and I36 
of NDR2 interacts with a cluster of residues of MOB1A 
(L36/G39/L41/A44/M70/L71) by van der Waals forces (Figure 3.1e). 
Second, at the interface between the α2 helix of NDR2 and MOB1A, L78 of 
NDR2 makes hydrophobic interactions with W56 and V59 MOB1A, in 
addition to R79 and R82 of NDR2 forming hydrogen bonds with cluster of 
residues of NDR2 MOB1A (F132/P133/K135/V138) and a salt bridge with 
E55 of MOB1A (Figure 3.1f). 
Intriguingly, analyses of the sequence alignments of the NDR/LATS 
kinases revealed that most of the MOB1A-binding residues are conserved in 
NDR/LATS kinases from yeast to humans (Figure 3.2a). However, we 
discovered a peculiar subfamily-specific residue of NDR2, namely Y32, that 
is not present in all NDR/LATS kinases (Figure 3.2a). More specifically, in 
the NDR-subfamily including human NDR1/2, Drosophila Tricornered, S. 
cerevisiae Dbf2/Dbf20/Cbk1, and S. pombe Sid2/Orb6, the residue at this 
key position is an invariant tyrosine (Figure 3.2a). In stark contrast, in the 
LATS-subfamily including human LATS1/2 and Drosophila Wts, a valine 
or isoleucine occurs at this key position (Figure 3.2 a). 
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Figure 3.2. Structure based modelling of NDR2 and LATS2 bind to MOB1A through 
different key residues/mechanisms. 
(a) Structure based sequence alignment of the conserved N-terminal regulatory domain of 
NDR/LATS kinases that is required for MOB1A binding. NDR2 residues mediating 
interactions with MOB1A are marked with red circles. Residues mediating intramolecular 
interactions of NDR2 are denoted by blue triangles. Residues conserved from yeast to 
humans are highlighted in green, while residues conserved in at least seven of the 
conserved NDR/LATS family members are marked in cyan. a helices are indicated with 
gray rods. (b) Asp63 of MOB1 is involved in LATS1 binding, but does not contribute to 
the interaction of MOB1A with NDR2. MOB1 is shown in yellow, while NDR2 and 
LATS1 are indicated in green and blue, respectively. Top panel, Phe31 of NDR2 does not 
interact with Asp63 of MOB1A. Bottom panel, His646 of LATS1 forms a hydrogen bond 
with Asp63 of MOB1A. 
 
Significantly, our analysis further determined key residues mediating the 
interaction of MOB1A with LATS1 and NDR2 (Figure 3.2). To do so, we 
also studied the recently published structure of MOB1A in complex with a 
LATS1 fragment (Kim, Tachioka et al. 2016). As shown in Figure 3.2b, 
this revealed that D63 of MOB1A is involved in LATS1-binding but not in 
NDR2-binding. Specifically, H646 of LATS1 forms a hydrogen bond with 
D63 of MOB1A, whereas F31 of NDR2, the residue of NDR2 
corresponding to H646 of LATS1 (Figure 3.2a), does not interact with D63 
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of MOB1A (Figure 3.2b). This suggests that the D63 residue of MOB1A 
plays a specific and pivotal role in the association of LATS1 with MOB1A.  
In addition to the structural analyses of NDR/MOB1A and 
LATS/MOB1A complexes (Figures 3.1 and 3.2), we also sought to 
determine key residues mediating the interaction of MOB1A with the 
MST1/2 kinases. To do so, we tested by co-immunoprecipitation assays the 
interactions of a range of MOB1A mutants with wild-type MST1/2 kinases 
(Hergovich, A., unpublished data now shown). Considering that negatively 
charged surfaces of MOB1A are responsible for the interactions with 
positively charged surfaces of NDR/LATS kinases (see Figures 3.1 and 
3.2) and that MOB1A interacts with MST1/2 kinases differently than with 
NDR/LATS (Ni, Zheng et al. 2015, Kim, Tachioka et al. 2016), we 
hypothesized that potentially positively charged residues of MOB1A are 
central for complex formation with MST1/2. Therefore, we focused our 
efforts on studying MOB1A versions carrying point mutations of arginine or 
lysine. Significantly, this approach proved successfully, since we found that 
MOB1A(K104E/K105E) does not bind to MST1/2, in contrast to all the 
other MOB1A mutants tested (Hergovich, A., unpublished data now 
shown). 
Consequently, as next step to further investigate and compare the 
importance of D63 and K104/K105 residues of MOB1A for binding to 
MST/NDR/LATS kinases, gel filtration chromatography was performed. 
The results are shown in Figure 3.3. 
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Figure 3. 3.  Characterization of MOB1A(D63V) and MOB1A(K104E/K105E) binding 
to NDR2, LATS1 and MST2 by gel filtration chromatography.  
(a-c) Indicated versions of recombinant MOB1A were incubated with recombinant wild-
type NDR2(25-88), LATS1(618-697), or MST2(2-392), before loading (BL) onto a 
Superdex 200 column. To assess LATS1 binding, MST2 phosphorylated MOB1 proteins 
were used. The indicated fractions from the Superdex 200 column were analyzed by SDS-
PAGE followed by coomassie staining. Relative molecular weights are shown. The 
positions of MOB1A, NDR2, LATS1 and MST2 are indicated on the right. MOB1A(wt), 
MOB1A(D63V) and MOB1A(K104E/K105E) readily co-fractionated with NDR2 (a). 
Phosphorylated MOB1A(wt) and MOB1A(K104E/K105E) co-eluted with LATS1, while 
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MOB1A(D63V) did not (b). MOB1A(wt) and MOB1A(D63V) co-fractionated with MST2, 
but MOB1A(K104E/K105E) did not co-elute with MST2 (c). 
 
To this end, bacterially expressed and purified full-length MOB1A proteins 
were incubated with NDR2 (25-88), LATS1 (618-697), or MST2 (2-392) 
protein fragments, followed by the gel filtration chromatography to analyse 
complex formation of recombinant proteins (Figure 3.3). Significantly, our 
findings revealed that D63V and K104E/K105E mutations in MOB1A did 
not affect the interaction with NDR2 when compared to wild type MOB1A 
(Figure 3.3a). Furthermore, we found that the D63V mutant of MOB1A, 
but not the K104E/K105E mutant, bound to LATS1 (618-697) comparable 
to wild-type MOB1A (Figure 3.3b). In addition, we could show that the 
K104E/K105E mutant of MOB1A, but not the D63V mutant, displayed a 
disrupted interaction with MST2 (2-392) (Figure 3.3c). 
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3.1.4. Results - Characterization of MOB1A mutants with 
selective binding to MST/NDR/LATS kinases in mammalian cells 
To develop research tools that allow us to understand which protein-protein 
interaction(s) (PPIs) between MOB1A and MST/LATS/NDR are required 
for YAP-Hippo signalling, cell proliferation and suppression of cellular 
transformation, we designed and characterized a series of mutants with 
affected binding of MOB1A to MST/LATS/NDR based on our structural 
studies (Section 3.1.3). Specifically, we focused on characterising MOB1A 
variants carrying E51K, D63V, K104E/K105E, E51K/K104E/K105E, or 
D63V/ K104E/K105E point mutations. The nomenclature of these 
mutations used in this thesis has been simplified, respectively, as follows: 
EK (E51K), DV (D63V), KEKE (K104E/K105E), EKKEKE 
(E51K/K104E/K105E), DVKEKE (D63V/K104E/K105E).  
Stavridi et al. (2003) reported that MOB1A has a flat surface rich in 
acidic residues on one side, which is believed to provide the structural basis 
for the association with the NDR1/2 and LATS1/2 kinases through 
electrostatic forces. Stavridi et al. (2003) found that the E51 of MOB1A is 
conserved from yeast to humans and speculated that this residue is very 
likely of functional importance. Furthermore, Hergovich et al. (2009) 
demonstrated that the substitution of Glu51 with Lys (E51K) interferes with 
the interaction with NDR1/2, highlighting the importance of the E51 residue 
of MOB1A for the interaction with the NDR1/2 kinases. In addition, based 
on our structural and biochemical studies (see section 3.1.2 and 3.1.3 
above), we concluded that MOB1A(DV) displays an abolished interaction 
with LATS1 (Figure 3.3), while the interactions with NDR2 and MST2 
remain fully intact (Figure 3.3). Furthermore, we also discovered that 
MOB1A (KEKE) displayed an abolished interaction with the MST2, but not 
with NDR2 and LATS1 (Figure 3.3). Following the discovery of these 
mutations which appear to be important for the interaction of hMOB1A with 
MST/LATS/NDR, these mutations were then characterized in mammalian 
cells using co-immunoprecipitation assays. To this end, hemagglutinin A 
(HA)-tagged MST1/2, LATS1/2, NDR1/2 and myc-tagged MOB1A variants 
were co-expressed in HEK 293 cells, followed by immunoprecipitation with 
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anti-HA 12CA5 antibody, before analyses of protein complexes by Western 
blotting.  
Firstly, the characterization of our MOB1A variants with respect to 
MST1/2 binding was carried out. The results are presented in Figure 3.4 
below. 
   
 
Figure 3.4. Characterization of the interaction of MOB1A variants with MST1/2.  
(a-d) Lysates of HEK293 cells expressing full-length HA-MST1 or HA-MST2 wild-type 
(wt) together with indicated full-length MOB1A versions were subjected to 
immunoprecipitation (IP) using anti-HA. Complexes were studied by immunoblotting using 
anti-myc (top) and anti-HA (top middle). Input lysates were analysed with anti-myc 
(bottom middle) and anti-α-tubulin (bottom). Relative molecular weights are shown. The 
EK and KEKE mutations caused loss of binding to MST1/2, while the DV mutant bound 
normally. Complexes were studied by immunoblotting using anti-myc (top) and anti-HA 
(top middle). Input lysates were probed with anti-myc (bottom middle) and anti-α-tubulin 
(bottom). Relative molecular weights are shown. 
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We investigated complex formation of MOB1A(wt) and MOB1A mutants 
with the MST1/2 kinases in HEK293 (Figure 3.4). To this end, N-
terminally tagged versions of HA-MST1 and HA-MST2 were co-expressed 
with N-terminally tagged versions of myc-MOB1A(wt) and myc-MOB1A 
mutants, followed by co-immunoprecipitation using anti-HA. These 
experiments revealed that MOB1A(EK), MOB1(EKKEKE), and 
MOB1A(DVKEKE) cannot bind to MST1 and MST2 (Figures 3.4a and 
3.4c). In sharp contrast, MOB1A(DV) associated with MST1 and MST2 
like wild-type MOB1A (Figures 3.4a and 3.4c). Significantly, the 
MOB1A(KEKE) mutant could not form a complex with neither HA-MST1 
nor HA-MST2 (Figures 3.4b and 3.4d). Collectively, these findings 
suggest that the MOB1A(EK) and MOB1A(KEKE) variants are deficient in 
MST1/2 binding, while MOB1A(DV) binds normally to MST1/2. Thus, we 
established in Figure 3.4 MOB1A mutants that allow us to test the 
significance of the MST1/2-MOB1A interaction in Hippo signalling. 
Furthermore, these findings (Figure 3.4) also further support our 
biochemical data presented in section 3.1.3 above.  
Second, the PPIs of our panel of MOB1A mutants with LATS1/2 
were examined. The results are shown in Figure 3.5 below. 
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Figure 3.5. Characterization of the interaction of MOB1A variants with the LATS1/2 
kinases. 
(a-d) Lysates of HEK293 cells expressing full-length HA-tagged LATS1 or LATS2 wild-
type (wt) together with the indicated full-length MOB1A versions were subjected to 
immunoprecipitation (IP) using anti-HA 12CA5 antibody. Complexes were analysed by 
immunoblotting using anti-myc (top) and anti-HA antibody (top middle). Input lysates were 
analysed with anti-myc (bottom middle) and anti-a-tubulin antibody (bottom). Relative 
molecular weights are shown. The EK and DV mutations abolished MOB1 binding to 
LATS1/2, while the KEKE mutant bound normally. Complexes were analysed by 
immunoblotting using anti-myc (top) and anti-HA (top middle). Input lysates were analysed 
with anti-myc (bottom middle) and anti-a-tubulin (bottom). Relative molecular weights are 
shown.  
 
We investigated complex formation of MOB1A(wt) and MOB1A mutants 
with the LATS1 and LATS2 kinases in HEK293 cells (Figure 3.5). To this 
end, N-terminally tagged versions of HA-LATS1 and HA-LATS2 were co-
expressed with N-terminally tagged versions of myc-MOB1A wt and 
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mutants, followed by co-immunoprecipitation using anti-HA. These 
findings uncovered that only MOB1A(wt) and MOB1A(KEKE) can bind to 
LATS1 and LATS2, while the remainder mutants did not to interact with 
LATS1 and LATS2 (Figure 3.5). Collectively, these findings show that the 
MOB1A(DV) and MOB1A(EK) variants are deficient in LATS1/2-binding, 
while MOB1A(KEKE) can normally associate with LATS1 and LATS2. 
Therefore, we established here a foundation that allows us to study the 
significance of LATS1/2-MOB1A complex formation in Hippo core 
signalling. Furthermore, our data presented here (Figure 3.5) also support 
the biochemical findings presented in section 3.1.3.  
Third, the characterization of MOB1A mutants with respect to 
NDR1/2 binding was carried out. The corresponding results are presented in 
Figure 3.6 below.  
 
 
Figure 3.6. Characterization of the interaction of MOB1A variants with NDR1/2. 
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(a-d) Lysates of HEK293 cells expressing full-length HA-NDR1 or HA-NDR2 wild-type 
(wt) together with the indicated full-length MOB1A versions were subjected to 
immunoprecipitation (IP) using anti-HA 12CA5 antibody. Complexes were studied by 
immunoblotting using anti-myc (top) and anti-HA antibody (top middle). Input lysates were 
analyzed with anti-myc (bottom middle) and anti-a-tubulin antibody (bottom). Relative 
molecular weights are shown. Only versions carrying the EK mutation displayed a 
reduction of binding to NDR1/2. Complexes were examined by immunoblotting using anti-
myc (top) and anti-HA (top middle). Input lysates were investigated with anti-myc (bottom 
middle) and anti-a-tubulin (bottom). Relative molecular weights are shown. 
 
N-terminally tagged versions of HA-NDR1 and HA-NDR2 were co-
expressed with N-terminally tagged versions of myc-MOB1A(wt) and myc-
MOB1A mutants, followed by co-immunoprecipitation using anti-HA. 
These findings uncovered that the MOB1A(EK) and MOB1A(EKKEKE) 
mutants cannot bind to NDR1 and NDR2, while the MOB1A(DV) and 
MOB1A(DVKEKE) interacted normally with NDR1 and NDR2 when 
compared to wild-type MOB1A (Figures 3.6a and 3.6c). In addition, we 
studied the interaction of MOB1A(KEKE) with HA-NDR1 and HA-NDR2, 
and found that the MOB1A(KEKE) can bind normally to NDR1 and NDR2 
(Figures 3.6b and 3.6d). Collectively, our data shown in Figure 3.6 
suggests that only MOB1A(EK) and MOB1A(EKKEKE) are deficient in 
NDR1/2 binding, while all other mutants tested displayed normal 
interactions with NDR1/2. Thus, we establish here (Figure 3.6) a research 
tools allowing us to study the significance of the interaction of MOB1A 
with NDR1/2 in the context of Hippo core signalling. 
Taken together, in full agreement with published literature (Stavridi, 
Harris et al. 2003, Bichsel, Tamaskovic et al. 2004, Bothos, Tuttle et al. 
2005, Hergovich, Bichsel et al. 2005, Hergovich, Schmitz et al. 2006, 
Vichalkovski, Gresko et al. 2008, Hergovich, Kohler et al. 2009, Kohler, 
Schmitz et al. 2010, Chen, Zhang et al. 2015, Hoa, Kulaberoglu et al. 2016) 
and the structural/biochemical studies presented in section 3.1.2 and 3.1.3, 
we found that MOB1A(wt) can stably bind to MST1/2, NDR1/2, and 
LATS1/2 kinases (Figures 3.4, 3.5, and 3.6). More importantly, we 
characterized a series of selected MOB1A with regard to MST/NDR/LATS 
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binding. These experiments revealed that the MOB1A(EK) does not to 
interact with any of the NDR/LATS/MST kinases. In contrast, 
MOB1A(DV) selectively impaired the binding of MOB1A with LATS1/2, 
while the MOB1A(DV) normally bound to MST1/2 and NDR1/2 kinases. 
The MOB1A(KEKE) also interacted normally with LATS1/2 and NDR1/2 
kinases, while the KEKE mutations selectively interfered with the 
interaction of MOB1A with MST1/2 kinases. In addition, the combination 
of the EK and DV with KEKE were tested for their ability to interact with 
MST1/2, LATS1/2, and NDR1/2 kinases, respectively. This revealed that 
the MOB1A(EKKEKE) does not interact stably with any of the tested 
kinases. The MOB1A(DVKEKE) mutant interacted only with NDR1/2 
kinases, but did not bind to any of the other Hippo kinases tested. The 
binding properties of all mutants tested are summarized in Figure 3.7, 
including an illustration of the location of the key residues in the published 
structure of MOB1A.    
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Figure 3.7. Generation of MOB1A variants to dissect the importance of MOB1A 
interactions with mammalian Hippo core cassette kinases. 
(a) Model illustrating two key research questions regarding MOB1A as a hub of 
mammalian Hippo core signalling: (1) Does MOB1A interact differently with MST1/2, 
LATS1/2 and NDR1/2 in human? (2) Which interactions of MOB1A with MST1/2, 
LATS1/2, or NDR1/2 are biologically important in the context of YAP-Hippo signalling? 
(b) Schematic summary of the biochemical and molecular characterization of the indicated 
MOB1A variants presented in Figures 3.1 to 3.6. (c) Model of human MOB1A(33-216) 
depicting the possibly opposing binding sites on MOB1A of NDR/LATS and MST1/2 
kinases. Secondary structure elements of MOB1A are highlighted. The locations of Glu51, 
Asp63, and Lys104/Lys105 in MOB1 are indicated. (d) Schematic model of how the 
differential binding of MOB1A to MST1/2, LATS1/2 and NDR1/2 can be experimentally 
exploited using the DV and KEKE mutations in order to study the biological importance of 
these different interactions of MOB1A with Hippo core cassette kinases. 
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3.1.5. Discussion 
Taken together, our structural and biochemical data presented here provide 
novel insight into the complex formation of MOB1A with the Hippo core 
kinases, MST1/2, NDR1/2, and LATS1/2 kinases. In our structural studies, 
we report for the first time the crystal structure of MOB1A-NDR2 complex, 
encompassing the entire region of NDR2 which is required for binding to 
MOB1A (Figure 3.1). Our findings revealed that MOB1A utilises its 
negatively-charged surface to interact with positively charged residues 
(K25/R42/R79/K81/R82) of NDR2 (Figure 3.1b). Furthermore, we could 
divide the recognition interface between NDR2 and MOB1A into two 
sections (Figures 3.1e and 3.1f). At the first interaction interface, Y32 of 
NDR2 is at a central position with its side-chain hydroxyl group forming 
hydrogen bonds with Q67 and H185 MOB1A (Figure 3.1e). Moreover, we 
observed that K25 of NDR2 forms hydrogen bonds with the main-chains of 
L173 and Q174 of MOB1A, and L28, L35, and I36 of NDR2 associate with 
L36, G39, L41, A44, M70, and L71 of MOB1A by van der Waals contacts 
at first interaction interface. At the second interaction interface, we 
discovered that L78 of NDR2 forms hydrophobic interaction with W56 and 
V59 of MOB1A and a salt bridge with E55 of MOB1A (Figure 3.1f). 
Intriguingly, analyses of the sequence alignments of the NDR/LATS kinases 
revealed that although most of the MOB1-binding residues are conserved in 
NDR/LATS kinases from yeast to humans (Figure 3.2a), there is a peculiar 
subfamily-specific residue corresponding to Y32 of NDR2. In the NDR-
subfamily including human NDR1/2, Drosophila Tricornered, S. cerevisiae 
Dbf2/Dbf20/Cbk1, and S. pombe Sid2/Orb6, the residue at this key position 
is an invariant tyrosine (Figure 3.2a). In stark contrast, in the LATS-
subfamily including human LATS1/2 and Drosophila Wts, a valine or 
isoleucine occurs at this key position (Figure 3.2a).  
Structure based sequence alignment of the conserved N-terminal 
regulatory domain of NDR/LATS kinases revealed that the D63 residue of 
MOB1A is essential for binding to LATS1 (Figure 3.2b), but not for 
binding to NDR2 (Figure 3.2b). Sepecifically, we found that H646 of 
LATS1 makes a hydrogen bond with D63 of MOB1A (Figure 3.2b, bottom 
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model), whereas F31 of NDR2, the corresponding residue to H646 of 
LATS1, does not interact with D63 of MOB1A (Figure 3.2b, top model).  
In addition to the structural analyses of NDR/MOB1A and 
LATS/MOB1A complexes (Figures 3.1 and 3.2), we also sought to 
determine key residues mediating the interaction of MOB1A with the 
MST1/2 kinases. To do so, we tested by co-immunoprecipitation assays the 
interactions of a range of MOB1A mutants with wild-type MST1/2 kinases 
(Hergovich, A., unpublished data now shown). Considering that negatively 
charged surfaces of MOB1A are responsible for the interactions with 
positively charged surfaces of NDR/LATS kinases (see Figures 3.1 and 
3.2) and that MOB1A interacts with MST1/2 kinases differently than with 
NDR/LATS (Ni, Zheng et al. 2015, Kim, Tachioka et al. 2016), we 
hypothesized that potentially positively charged residues of MOB1A are 
central for complex formation with MST1/2. Significantly, we showed that 
MOB1(KEKE) mutant abolished the interaction with MST2 (Figure 3.3), 
but not with NDR2 and LATS1 (Figure 3.3) by gel filtration 
chromatography. 
Initially, to investigate the importance of the residues required for 
MOB1A binding to MST1/2, LATS1/2, and NDR1/2, we performed gel 
filtration chromatography using recombinant proteins. Our findings 
uncovered that the MOB1(DV) did not interact with LATS1, while binding 
normally to NDR2 and MST2 (Figure 3.3). The MOB1A(KEKE) also 
displayed a specific loss of interaction (LOI), since MOB1A(KEKE) did not 
interact with MST2, but associated normally with NDR2 and LATS1 
(Figure 3.3).  
To further characterize and confirm the importance of the residues 
important for MOB1A binding to MST1/2, LATS1/2, and NDR1/2, we 
tested selected mutant versions of MOB1A in HEK293 cells with regard to 
binding to full length wild-type versions of MST1/2, LATS1/2, and NDR1/2 
kinases (Figures 3.4, 3.5, and 3.6). Significantly, this approach confirmed 
that MOB1A(DV) only displayed a disruption of  the association with 
LATS1/2 kinases, while MOB1A(DV) bound normally to NDR1/2 and 
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MST1/2 kinases. In contrast, the MOB1A(KEKE) only displayed a 
disruption of the interaction with MST1/2 kinases, while MOB1A(KEKE) 
associated normally with NDR1/2 and LATS1/2 kinases. Noteworthy, 
MOB1A(DVKEKE) only associated with NDR1/2 kinases, while displaying 
a complete LOI with MST1/2 and LATS1/2 kinases. 
Stavridi et al. (2003) showed that E51 of MOB1A is conserved from 
yeast to humans and speculated that this residue is very likely of functional 
importance. Furthermore, Hergovich et al. (2009) demonstrated that the 
substitution of Glu51 with Lys (E51K) interferes with the interaction with 
NDR1/2, highlighting the importance of the E51 residue of MOB1A for the 
interaction with the NDR1/2 kinases. Therefore, we also tested 
MOB1A(EK) with regard to binding to MST1/2, LATS1/2, and NDR1/2 
kinases. This allowed us to confirm that MOB1A(EK) does not bind to 
NDR1/2 kinases. Moreover, we also discovered that MOB1A(EK) cannot 
associate with the LATS1/2 and MST1/2 kinases. 
Hippo signalling represents a MST/LATS/NDR kinase cascade that 
is tightly regulated by different protein-protein interactions (Hergovich 
2012). Very interestingly, MST/LATS/NDR signalling is regulated by 
members of the MOB protein family. Recent studies reported that MOB1 
knockout mice display much bigger tumour that LATS deficient mice, 
indicating that MOB1 has LATS independent tumour suppressive role 
possibly including MOB1/MST and/or MOB1/NDR complexes. Thus, it is 
crucial to understand the complex protein-protein interaction of MOB1A 
with the Hippo kinases, such as MST1/2, LATS1/2, and NDR1/2. In this 
context, we define here key residues of MOB1A that are required for 
binding to MST1/2, LATS1/2, and NDR1/2 by structural and biochemical 
studies. More specifically, we managed to generate MOB1A LOI versions 
that display selective LOI with the Hippo core kinases. Therefore, we are 
establishing here a foundation that allow us to understand the significance of 
MOB1A-MST1/2, MOB1A-LATS1/2, MOB1A-NDR1/2 complex 
formation in the context of Hippo core signalling. 
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3.2. Defining the importance of complex formation of MOB1A 
with the Hpo, Wts, and Trc kinases in fly cells 
3.2.1. Abstract 
The mammalian Hippo core cassette consists of MST/LATS/NDR kinases 
and MOB1, with recent studies suggesting that MOB1A functions as the 
central hub of Hippo signalling. In Drosophila, the Hpo, Warts, and Trc are 
the functional counterparts of the mammalian MST1/2, LATS1/2, and 
NDR1/2 kinases, hence, the Hpo, Wts, and Trc kinases function as key 
players in the fly Hippo pathway. It was established that functional loss of 
Hpo, Wts, or Trc can be compensated by expression of human MST, 
LATS1, or NDR1, respectively. Significantly, expression of human 
MOB1A can also compensate for the loss-of-function of Mats, the fly Mob1 
protein. Therefore, we hypothesized that the interaction patterns of MOB1A 
with Hpo, Warts, and Trc kinases are conserved from flies to human. 
Interestingly, we report here that the interaction patterns of MOB1A with 
the Hpo, Warts, and Trc kinases in Drosophila cells are highly similar with 
the patterns observed in human cells. 
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3.2.2. Introduction 
The Hippo pathway was discovered to control cell proliferation, apoptosis, 
and differentiation (Hergovich 2013); therefore, the Hippo pathway may 
play crucial role in coordinating these cellular processes. Importantly, 
Drosophila Hippo signalling is regulated by various protein-protein 
interactions (Hergovich 2012). Even more importantly, it was found that 
genetic disruption of the core component of the Drosophila Hippo pathway 
result in robust tissue overgrowth. Furthermore, it was found that these 
overgrowth phenotypes can be rescued by the counterparts of mammalian 
proteins (Hergovich 2011). 
It is not known how Drosophila Hippo signalling is tightly regulated 
by complex protein-protein interactions involving Mats. Therefore, we 
hypothesized that MOB1A can also interact with the Hpo, Wts, and Trc 
kinases (the counterparts of the mammalian MST1/2, LATS1/2, and 
NDR1/2 kinases) in a similar fashion as reported above for their human 
counterparts (see summary in Figure 3.7). Very interestingly, we show here 
that the interaction patterns of MOB1A with the Hpo, Warts, and Trc in 
Drosophila cells is highly similar with the patterns observed in human cells 
(see summary in Figure 3.7). Thus, our LOI versions of MOB1A will allow 
us to understand which protein-protein interactions of MOB1A are 
important for embryogenesis and tumour suppression in Drosophila, in 
addition to studying their importance in human cancer cells.    
  
128 | P a g e  
 
3.2.3. Results - Characterization of MOB1A mutants with 
selective binding to the Hpo/Wts/Trc kinases in fly cells 
To expand the characterization of our panel of MOB1A versions (see figure 
3.7), we characterized the PPIs between MOB1A variants and the Hpo, 
Warts, and Trc kinases (the Drosophila counterparts of the mammalian 
MST1/2, LATS1/2, NDR1/2 kinases). Through phylogenetic analysis, it has 
been shown that Drosophila Mats (dMOB1) and human MOB1A shares 87 
% identity, strongly suggesting that the functions of Mats proteins are 
conserved from Drosophila to humans (Hergovich 2011). Indeed, Lai et al. 
(2005) reported that loss of function of Mats can be rescued by expression 
of MOB1A, supporting the notion that the functions of MOB1A are 
conserved between flies and humans. In addition, it has been shown that the 
MST1/2 kinases can regulate MOB1A in a similar manner as reported for 
the regulation of Mats by Hpo in fly cells (Hergovich, 2011; Wei et al, 
2007). Furthermore, it has also been reported that MOB1 and Mats can 
associate with LATS1/2 and NDR1/2, Warts and Trc kinases, respectively. 
These findings collectively suggest that the functional importance of PPIs 
between MOB1A and Hippo core kinases are conserved from insects to 
humans. 
First, the PPIs of our selected MOB1A mutants with Hpo were 
examined. The results are presented in Figure 3.8 below. 
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Figure 3.8. Characterization of the interaction of MOB1A variants with the fly Hpo 
kinase. 
(a-b) Lysates of Drosophila S2R+ cells expressing full-length HA-Hippo(wt) together with 
indicated full-length MOB1A versions were subjected to immunoprecipitation (IP) using 
anti-HA. The KKEE mutations caused loss of binding to Hpo, while the DV mutant bound 
normally. Complexes were studied by immunoblotting using anti-myc (top) and anti-HA 
(top middle). Input lysates were probed with anti-myc (bottom middle) and anti-α-tubulin 
(bottom). Relative molecular weights are shown. 
 
To characterize the interactions of MOB1A(wt) and MOB1A mutants with 
Hpo, S2R+ cells were co-transfected with N-terminally tagged versions of 
myc-MOB1A(wt) and myc-MOB1A mutants and HA-Hpo, followed by co-
immunoprecipitation using anti-HA antibody. This revealed that Mats and 
MOB1A(wt) bound similarly to Hpo in S2R+ cells (Figure 3.8), confirming 
that Mats/Hpo and hMOB1A/Hpo interactions are conserved. As further 
indicated in Figure 3.8, MOB1A(wt) lane and MOB1A(DV), but not the 
other MOB1A variants, were able to bind to Hpo. Collectively, our data 
presented in Figure 3.8 suggest that the MOB1A(KEKE) mutant is deficient 
in Hpo binding, hence developing a research tool that allow us to understand 
the role of MOB1A-Hpo complex formation in complex multicellular 
organism such as Drosophila. Noteworthy, the observed interaction pattern 
in fly cells (Figure 3.8) is identical with the one observed in mammalian 
cells (Figure 3.7). 
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Second, the PPIs of our selected hMOB1A mutants with Warts were 
examined. The results are presented in Figure 3.9 below. 
 
 
Figure 3.9. Characterization of the interaction of MOB1A variants with the Wts 
kinase. 
(a-b) Lysates of Drosophila S2R+ cells expressing full-length HA-Wts(wt) together with 
indicated full-length MOB1A versions were subjected to immunoprecipitation (IP) using 
anti-HA. Complexes were analyzed by immunoblotting using anti-myc (top) and anti-HA 
(top middle). Input lysates were analyzed with anti-myc (bottom middle) and anti-α-tubulin 
(bottom). Relative molecular weights are shown. The DV mutant did not bind to Warts, 
while the KEKE mutant bound normally. 
 
To characterize the interactions of MOB1A(wt) and MOB1A mutants with 
Hpo, S2R+ cells were transfected with N-terminally tagged versions of 
myc-MOB1A(wt) and myc-MOB1A mutants and HA-Hpo, followed by co-
immunoprecipitation using anti-HA antibody. As indicated in Figure 3.9a, 
MOB1A(wt) and Mats  were able to bind strongly to Wts. Following that, 
we characterized the binding of our MOB1A mutants to Wts. This revealed 
that MOB1A(KEKE) associated with Wts like wild-type MOB1A, while the 
remaining MOB1A variants did not interact stably with Wts (Figure 3.9b). 
Collectively, these data suggest that the MOB1A(DV) mutant is deficient in 
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Wts binding, hence establishing a foundation that allow us to study the 
significance of MOB1A-Wts complex formation in Drosophila. 
Noteworthy, this interaction pattern is identical with the one observed in 
mammalian cells (Figure 3.7).  
Last, the PPIs of our selected hMOB1A mutants with Trc were 
examined. The results are illustrated in Figure 3.10 below. 
 
 
Figure 3.10. Characterization of the interaction of MOB1A variants with the Trc 
kinase 
(a-b) Lysates of Drosophila S2R+ cells expressing full-length HA-Trc(wt) together with 
indicated full-length MOB1A versions were subjected to immunoprecipitation (IP) using 
anti-HA. Complexes were examined by immunoblotting using anti-myc (top) and anti-HA 
(top middle). Input lysates were investigated with anti-myc (bottom middle) and anti-α-
tubulin (bottom). Relative molecular weights are shown. 
 
To characterize the interactions of MOB1A(wt) and MOB1A mutants and 
Mats with Trc, S2R+ cells were co-transfected with N-terminally tagged 
versions of myc-hMOB1A(wt) and myc-MOB1A mutants and HA-Trc, 
followed by co-immunoprecipitation using anti-HA antibody. As indicated 
in Figure 3.10a, both Mats and MOB1A(wt) were able to associate with 
Trc. Following that, we characterized the binding of our MOB1A mutants to 
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Trc. This revealed that all mutants of MOB1A  normally bound to Trc like 
wild-type MOB1A. 
Taken together, we show here that MOB1A interacts with the Hpo, Warts, 
and Hpo kinases in fly cells. In addition, we present the characterization of 
the interaction patterns of our selected MOB1A versions with the fly Hippo 
core kinases. This revealed that the MOB1A(DV) can interact with Trc and 
Hpo, while being unable to associate with Wts. In contrast, MOB1A(KEKE) 
can interact with Wts and Trc, but does not associate with Hpo. Therefore, 
we are describing here development of research tools that are suitable to 
investigate the significance of MOB1A-Hpo, MOB1A-Wts, and MOB1A-
Trc complex formation in the context of Mats loss-of-function. Furthermore, 
our results presented here suggest that the interaction patterns of MOB1A 
variants in fly cells are nearly identical with the patterns observed in 
mammalian cells (Figure 3.11).  
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Figure 3.11. Generation of MOB1 variants to dissect the importance of MOB1 
interactions with Drosophila Hippo core cassette kinases.  
(a) Model illustrating two key research questions regarding MOB1 as a hub of Drosophila 
Hippo core signalling: (1) Does MOB1 interact differently with Hippo, Warts and Trc in fly 
cells? (2) Which interactions of MOB1 with Hippo, Warts, or Trc are biologically 
important in the context of Yki-Hippo signalling? (b) Schematic summary of the 
biochemical and molecular characterization of the indicated MOB1A variants presented in 
Figures 3.8 to 3.10. (c) Model of human MOB1A(33-216) depicting the possibly opposing 
binding sites on MOB1 of Trc/Warts and Hpo kinases. Secondary structure elements of 
MOB1 are highlighted. The locations of Asp63, and Lys104/Lys105 in MOB1 are 
indicated. (d) Schematic model of how the differential binding of MOB1 to Hippo, Warts 
and Trc can be experimentally exploited using the D63V and K104E/K105E mutations in 
order to study the biological importance of these different interactions of MOB1 with 
Drosophila Hippo core cassette kinases 
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3.2.4. Discussion 
Our structural and biochemical studies of human Hippo core components 
revealed the identity of key residues in MOB1A that are required for the 
binding of MOB1A to the MST1/2, LATS1/2, and NDR1/2 kinases (see 
section 3.1 above). Importantly, our structural and biochemical studies 
presented above revealed that D63 residue of MOB1A is required for 
LATS1/2-binding but not NDR1/2-binding, while K104E/K105E residues 
of MOB1A is key binding residues essential of binding to MST1/2, not 
LATS1/2 and NDR1/2 kinases. Collectively, these results develop an 
important tool to study the importance of MOB1A-MST1/2, MOB1A-
LATS1/2, and MOB1A-NDR1/2 complex formation in the context of the 
regulation of Hippo signalling in mammalian cells.  
After having revealed the key residues that plays crucial roles in the 
binding of MOB1A to MST1/2, LATS1/2, and NDR1/2, we asked next 
whether these residues of MOB1A are also critically important for MOB1A 
binding to the fly Hpo, Warts, and Trc kinases. To do so, we established 
first that MOB1A(wt) can interact with the Hpo, Wts, and Trc kinases. We 
next tested whether the important residues that disrupted binding of 
MOB1A to the MST1/2, LATS1/2, NDR1/2, respectively, are also 
important for the interactions of MOB1A with the fly Hippo core kinases 
Hpo, Wts, and Trc. Significantly, these analyses of PPIs in the fly cell 
extracts revealed that the interaction patterns in Drosophila cells are highly 
similar with of the patterns observed in mammalian cells. This strongly 
suggests that the regulation of Hippo core signalling by MOB1A is highly 
conserved from Drosophila to humans. Thus, our selected mutants of 
MOB1A will allow us to understand which protein-protein interactions are 
required for embryogenesis, and tissue growth control in Drosophila, in 
addition to performing experiments in human cancer cells.          
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3.3. Defining phosphorylation patterns of our MOB1A variants by 
human MST1/2 and fly Hpo kinases 
 
3.3.1. Abstract 
The Hippo core pathway is regulated through phosphorylation by MST1 and 
MST2 kinases. Importantly, recent studies revealed that MST1/2 (Hpo) 
phosphorylate MOB1A (Mats) at Thr12 and Thr35 in human and 
Drosophila. Our data presented here confirm that MOB1A is 
phosphorylated at Thr12 and Thr35 by MST1 and MST2 kinases. Thus, we 
determined next the phosphorylation status of our MOB1A variants by the 
MST1, MST2, and Hpo kinases, respectively. This revealed that our 
selected MOB1A variants are normally phosphorylated on Thr12 and Thr35 
by MST1, MST2, and Hpo. First, these observations further strengthen the 
notion that the Hippo pathway is highly conserved from Drosophila to 
humans. Second, our data presented here suggest that any changes in 
binding patterns of MOB1A versions are very unlikely a consequence of 
alterations of the phosphorylation status of our selected MOB1A variants.    
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3.3.2. Introduction 
The core of the Hippo pathway consist of MST1/2(Hpo), LATS1/2 (Wts), 
NDR1/2 (Trc) and MOB1A (Mats) in human (Drosophila) cells. In 
Drosophila, Hpo can phosphorylate Mats, thereby enhancing Mats binding 
to the Wts kinases (Wei, Shimizu et al. 2007). Recent studies revealed that 
Mats interacts with and regulate Wts allosterically (Lai, Wei et al. 2005, 
Vrabioiu and Struhl 2015). Moreover, it was also shown that Mats can also 
interact with Trc and is required for Trc functions in flies (He, Emoto et al. 
2005). In mammals, the regulation of Hippo signalling functions in a similar 
way, though it is more complicated. Praskova et al. (2008) identified 
MOB1A proteins as a substrate of MST1/2. They showed that MST1/2 can 
phosphorylate MOB1A at Thr12 and Thr35, thereby significantly enhancing 
the efficiency of MOB1A binding to NTR domains of human NDR1/2 and 
LATS1/2 kinases (Hergovich, Schmitz et al. 2006, Hergovich, Stegert et al. 
2006, Hergovich 2013). On the one hand, the association of MOB1A with 
NDR/LATS kinases initiates their autophosphorylation in the regulatory T-
loop (Bichsel, Tamaskovic et al. 2004, Hergovich, Bichsel et al. 2005, 
Hergovich, Schmitz et al. 2006, Praskova, Xia et al. 2008, Cook, Hoa et al. 
2014, Hoa, Kulaberoglu et al. 2016). On the other hand, binding of MOB1A 
to NDR/LATS kinases is required for their phosphorylation in the 
hydrophobic motif by MST1/2 (Praskova, Xia et al. 2008, Hergovich, 
Kohler et al. 2009, Cook, Hoa et al. 2014, Hoa, Kulaberoglu et al. 2016). 
Consequently, current evidence suggests that the association of MOB1A 
with the NDR/LATS kinases is essential for the activation of NDR/LATS 
kinases. In summary, the binding of MOB1A to NDR/LATS is influenced 
by MST1/2-mediated phosphorylation of MOB1A (Praskova, Xia et al. 
2008, Hergovich 2011), hence one can conclude that MOB1A 
phosphorylation by MST1/2 plays an important role in the regulation of the 
Hippo pathway. We therefore examined whether our MOB1A mutants serve 
as substrates of MST1, MST2, and Hpo, respectively, which revealed that 
the phosphorylation of our selected MOB1A variants on Thr12 and Thr35 is 
not significantly changed.    
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3.3.3. Results - Testing selective MOB1A mutants as MST1/2 
substrates 
Considering that MST1 and MST2 can function as upstream kinase of 
MOB1A (Praskova, Xia et al. 2008), we tested whether our MOB1A 
mutants are phosphorylated by MST1 and MST2 similarly to wild-type 
MOB1A. To do so, we pursued two lines of in vitro kinase assays. First, 
radioactive in vitro kinase assays were performed to measure the total 
phosphorylation of MOB1A. Second, we utilized specific anti-phospho-
antibodies raised against phospho-Thr12 (T12-P) and phosphor-Thr35 (T35-
P) to measure MST1/2-mediated MOB1A phosphorylation in our in vitro 
kinase assays. 
Prior to the characterization of our MOB1A variants as MST1/2 
substrates, recombinant MAL-tagged MOB1A variants were bacterially 
expressed and then purified as outlined in section 2.2.2.6 above. Equal 
amounts of our MAL-MOB1A proteins were analysed by SDS-PAGE 
followed by Coomassie staining to validate the quality and purity of our 
protein preparations (Figure 3.12).  
 
Figure 3.12. Bacterially expressed and purified MAL-MOB1A variants. 
All MAL-MOB1A recombinant proteins were bacterially expressed and purified as 
described in section 2.2.2.7. The purified proteins were run on 8 % gel and the gels were 
stained with Coomassie staining as defined in section 2.2.2.7. The location of the 
recombinant MAL-MOB1A versions are pointed out by an arrow. 
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 After confirming equal quality and purity of our recombinant MAL-
MOB1A proteins, equal amounts of recombinant proteins were used as 
substrates in in vitro kinase assays as outlined below.   
First, in vitro kinase assays using radiolabelled ATP were performed 
as outlined in section 2.2.2.6. The results are presented in Figure 3.13 
below. 
 
Figure 3.13. Phosphorylation of MOB1A mutants by MST1/2. 
GST-tagged full-length MST1 (a) and MST2 (b) kinases were incubated with purified 
bacterially expressed MAL-MOB1A proteins as described in section 2.2.2.6. As control, 
GST-MST1 and MST2 were incubated without MAL-MOB1A proteins (Top panel, lane 
1). After the kinase reaction, proteins were separated by SDS-PAGE and detected by 
autoradiography (top panel) or coommassie stain (bottom panel). All MAL-MOB1A 
variants, except for MOB1A(DVKEKE), displayed the same phosphorylation status. The 
autophosphorylation of MST1/2 are also visible.   
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Recombinant GST-tagged MST1 and GST-MST2 kinases were 
incubated with recombinant MAL-MOB1A variants as substrates using 
[P32]γATP as a source of ATP, followed by SDS-PAGE and 
autoradiography. As shown in Figure 3.13, all MOB1A mutants tested, 
except for MOB1A(DVKEKE), were normally phosphorylated by MST1/2 
when compared to wild type MOB1A. These results suggest that all 
MOB1A mutants, with the exception of MOB1A(DVKEKE), serve as 
MST1/2 substrates like wild-type MOB1A. Considering that MOB1A(EK) 
and MOB1A(KEKE) were phosphorylated like wild-type MOB1A by 
MST1/2 (Figure 3.13), although they cannot form a stable complex with 
MST1/2 (see section 3.1.4 above), these findings further suggested that 
MOB1A and MST1/2 do not need to stably interact for efficient 
phosphorylation of hMOB1A by MST1/2. Second, we utilized specific anti-
phospho-antibodies raised against phospho-Thr12 (T12-P) and phosphor-
Thr35 (T35-P) to measure MST1/2-mediated MOB1A phosphorylation in 
our in vitro kinase assays. However, before testing the phosphorylation 
status of our MOB1A variants on Thr12 and Thr35, we aimed to validate 
the specificities of the available anti-T12-P and anti-T35-P antibodies were 
tested. The results of these specificity tests are presented in Figure 3.14. 
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Figure 3.14. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in the 
context of MST1/2-mediated phosphorylation of MOB1A.  
(a,b) Recombinant full-length GST-MST1 or GST-MST2 wild-type (wt) were incubated 
with full-length recombinant Mal-MOB1A(wt) or the T12A and T35A phospho-acceptor 
mutants. Following kinase reactions, the samples were analysed by Western blotting using 
indicated antibodies. Relative molecular weights are shown. Noteworthy, the anti-T12-P 
antibody only detected wild-type MOB1A when the kinase assays contained GST-MST1/2, 
while MOB1A (T12A) was not detected (a). The anti-T35-P antibody also specifically 
detected the phosphorylation of MOB1A on Thr35 (b).  
 
Praskova et al. showed that MOB1A is phosphorylated at Thr12 and 
Thr35 by MST1/2. To develop research tools that allow the study of 
phosphorylation of MOB1A by MST1 and MST2 on Thr12 and Thr35, we 
characterised antibodies that specifically recognise MOB1A phosphorylated 
on Thr12 (anti-Thr12-P) and Thr35 (anti-Thr35-P). To test the specificity of 
these anti-phospho antibodies, we generated phosphor-acceptor mutants 
carrying Thr12 to Ala (T12A) or Thr35 to Ala (T35A) substitutions, and 
subsequently compared phosphorylation of recombinant MAL-
MOB1A(T12A) and MAL-MOB1A(T35A) with the wild-type MAL-
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MOB1A (Figure 3.14). In vitro kinase assays. in vitro kinase assays were 
performed by incubating recombinant GST-tagged MST1/2 kinases with 
recombinant MAL-MOB1A variants in the presence of unlabelled ATP, 
followed by SDS-PAGE and Western blotting using the anti-T12-P and 
anti-T35-P antibodies. These experiments revealed that MOB1A(wt) display 
clearly detectable Thr12 and Thr35 phosphorylation (Figure 3.14, lanes 2). 
Demonstrating the specificity of the anti-phospho antibodies, 
MOB1A(T12A) and MOB1A(T35A) were not recognized by the anti-T12-P 
and anti-T35-P antibodies, respectively (Figure 3.14, compare lanes 2 and 
3). This confirmed that the anti-T12-P and anti-T35-P antibodies can 
specifically detect the phosphorylation of MOB1A at Thr12 and Thr35 by 
MST1 and MST2. Kinase assays that only contained GST-MST1, GST-
MST2, or MAL-hMOB1A recombinant proteins were used as additional 
negative controls (Figure 3.14), further confirming the specificity of the 
anti-phospho antibodies.      
Next, the phosphorylation status of our MOB1A variants by MST1 
and MST2 was tested. The results are shown below in Figure 3.15.  
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Figure 3.15. Characterization of the MST1/2-mediated phosphorylation of MOB1A 
variants. 
(a,b) Recombinant full-length GST-MST1 or GST-MST2 wild-type (wt) were incubated 
with indicated full-length recombinant Mal-MOB1A variants. The reactions which only 
contained MST1 or MST2 were used as control. Following kinase reactions, the samples 
were analysed by immunoblotting using the specified antibodies. Relative molecular 
weights are indicated. 
 
More specifically, given the specificity of these phosphor-specific 
antibodies (Figure 3.14), we sought to determine whether our MOB1A 
versions are affected with respect to phosphorylation by MST1 and MST2 
on Thr12 and Thr35. In vitro kinase assays were performed by incubating 
recombinant GST-MST1 or GST-MST2 kinases with recombinant MAL-
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MOB1A variants in the presence of unlabelled ATP, before samples were 
analysed by SDS-PAGE and Western blotting (Figure 3.15). These 
experiments showed that our MOB1A versions are phosphorylated on Thr12 
and Thr35 by MST1 and MST2 like wild-type MOB1A (Figure 3.15). 
Collectively, our findings presented in this section suggest that MOB1A and 
MST1/2 do not need to stably interact for phosphorylation (Figure 3.7). 
Even more importantly, these findings propose that changes in MST1/2-
mediated phosphorylation of MOB1A are very unlikely the cause of the 
observed alterations of binding patterns of our MOB1A variants. 
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3.3.4. Results - Testing selective MOB1A mutants as Hpo 
substrates 
Considering that the Thr12 and Thr35 residues of human MOB1A are 
conserved as Thr12 and Thr35 residues in Drosophila Mats protein (the 
counterpart of human MOB1A) (Lai, Wei et al. 2005), we hypothesized that 
MOB1A can also be phosphorylated by fly Hpo (the counterpart of human 
MST1/2). To determine whether MOB1A is also potentially regulated by 
Hpo in fly cells, the phosphorylation of MOB1A by Hpo at Thr12 and 
Thr35 was tested by using the anti-T12-P and anti-T35-P antibodies. In 
order to confirm that these anti-phospho-antibodies are also specific in this 
setting, we compared the phosphorylation of recombinant wild-type MAL-
MOB1A with the corresponding phospho-acceptor mutants, 
MOB1A(T12A) and MOB1A(T35A), respectively (Figure 3.16). 
Drosophila S2R+ cells transfected with N-terminally tagged 
versions of HA-Hpo wild-type were lysed and subjected to overnight IP 
with anti-HA 12CA5 antibody. Subsequently, in vitro kinase assays were 
performed by incubating immune-purified HA-Hpo with recombinant 
MAL-MOB1A proteins in the presence of unlabelled ATP. The in vitro 
kinase assay samples were then separated by SDS-PAGE, , followed by 
Western blotting with anti-T12-P(MOB1) an anti-T35-P(MOB1) antibodies. 
The results are presented below in Figure 3.16.   
 
 
Figure 3.16. Characterization of the anti-Thr12-P and anti-Thr35-P antibodies in the 
context of Hippo-mediated phosphorylation of MOB1A.  
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(a-b) Lysates of Drosophila S2R+ cells transiently expressing full-length HA-Hpo(wt) 
were subjected to immunoprecipitation with anti-HA 12CA5 antibody. Immunopurified 
proteins were then processed for kinase assays without or with the indicated full-length 
recombinant MOB1A versions. Following kinase reactions, the samples were examined by 
immunoblotting using the specified antibodies. Relative molecular weights are shown. 
Importantly, the anti-T12-P and anti-T35-P antibodies specifically detected Hippo-
mediated phosphorylation of MOB1A on Thr12 (c) and Thr35 (d). 
 
Significantly, these experiments revealed that Hpo can 
phosphorylate MOB1A on Thr12 and Thr35 (Figure 3.16). The 
recombinant MAL-MOB1A(T12A) and MAL-MOB1A(T35A) proteins 
served as negative controls, showing that the anti-phospho antibodies are 
specific also when the fly Hpo kinase is used. 
Considering that MOB1A is specifically phosphorylated by Hpo (see 
Figure 3.16 above), we sought next to determine the phosphorylation status 
of our MOB1A variants is affected by the fly Hpo kinase. The results are 
presented below in Figure 3.17.  
 
 
Figure 3.17. Characterization of the MST1/2(Hippo)-mediated phosphorylation of 
MOB1A variants.  
(a-b) Lysates of Drosophila S2R+ cells transiently expressing full-length HA-Hpo(wt) 
were subjected to immunoprecipitation with anti-HA. Immunopurified Hpo was then 
processed for kinase assays with the indicated full-length recombinant MOB1A versions. 
Following kinase reactions, the samples were examined by immunoblotting using indicated 
antibodies. Relative molecular weights are shown. 
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To test the phosphorylation status of our selected MOB1A variants, 
HA-Hpo was immune-purified from Drosophila S2R+ cells using anti-HA 
12CA5 antibody. Immunoprecipitated HA-Hpo was then incubated with 
recombinant MAL-MOB1A variants in the presence of unlabelled ATP, 
before processing for SDS-PAGE and immunoblotting with anti-phospho 
antibodies. As shown in Figure 3.17, these experiments revealed that our 
MOB1A variants are phosphorylated at Thr12 and Thr35 by Hpo very 
comparable to wild-type MOB1A. Therefore, we can draw the conclusion 
that the phosphorylation of our MOB1A mutants by Hpo is not significantly 
affected, as already observed when human MST1 and MST2 were tested 
(see section 3.3.3 above) (Figure 3.15). 
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3.3.5. Discussion 
Taken together, our study presented here provides novel insights into the 
phosphorylation of MOB1A by MST1, MST2, and Hpo. Our data presented 
here confirm that MOB1A is phosphorylated at Thr12 and Thr35 sites by 
MST1 and MST2 (Figure 3.14). Since MOB1A phosphor-acceptor mutants 
carrying Thr12 to Ala (T12A) and Thr35 to Ala (T35A) substitutions failed 
to be phosphorylated by MST1 and MST2 (Figure 3.14), we can be sure 
that these phosphorylation events are specific. We characterized and defined 
the important residues that selectively impair the binding of MOB1A to the 
Hippo core kinases MST1/2(Hpo), LATS1/2(Wts), and NDR1/2(Trc) in 
mammalian (fly) cells in section 3.2 and 3.3. In this section, we tested the 
phosphorylation of our selected MOB1A variants by MST1, MST2, and 
Hpo. Significantly, our data presented here uncover that our MOB1A 
variants are normally phosphorylated on Thr12 and Thr35 by MST1, MST2, 
and Hpo like wild-type MOB1A (Figure 3.15 and 3.17). Collectively, we 
can draw the conclusion that MOB1A-MST1/2(Hpo) complex formation is 
not required for phosphorylation (Figure 3.7). Even more importantly, these 
findings suggest that changes in MST1/2(Hpo)-mediated phosphorylation of 
MOB1A are very unlikely the cause of the observed alterations of binding 
patterns of our MOB1A variants.     
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3.4. Defining the tumour suppressive roles for MOB1A 
interactions with Hippo core kinases in human cancer cells 
3.4.1. Abstract 
The central mammalian Hippo core cassette consists of MST1/2, LATS1/2, 
NDR1/2 and MOB1, with recent studies of MOB1 knockout mice indicating 
that MOB1 functions as the central hub of Hippo signalling. More 
specifically, current evidence suggests that the Hippo core kinases are 
regulated by various protein-protein interactions with MOB1A as a kind of 
master regulator of Hippo tumour suppressor signalling. However, it has yet 
to experimentally shown that the tumour suppressive roles of the Hippo 
pathway are indeed regulated by interactions of MOB1A with Hippo core 
kinases. Therefore, we focused on deciphering the complex protein-protein 
interactions of MOB1 with MST1/2, LATS1/2 and NDR1/2 required for 
tumour suppression in human cancer cells. Using our MOB1A mutants, we 
studied the effects of MOB1A expression on the proliferation and 
anchorage-independent growth of human cancer cells, aiming to establish 
which MOB1 interactions are required for the tumour suppressive role of 
MOB1A. Interestingly, we found that wild-type MOB1A functions as 
tumour suppressor by inhibiting cell proliferation and anchorage-
independent growth of human cancer cells. More importantly, we further 
found that the interaction of MOB1A with MST1/2 or LATS1/2 is not 
required to suppress proliferation. We also discovered that complex 
formation of MOB1A with MST1/2 is dispensable for the suppression of 
anchorage-independent growth of human cancer cells, while the interactions 
with LATS1/2 and NDR1/2 appear to be essential for the tumour 
suppressive function of MOB1A.     
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3.4.2. Introduction 
The mammalian Hippo pathway has emerged as an essential tumour 
suppressor signalling network that controls cellular processes such as cell 
proliferation, cell death, and cell differentiation to ensure normal tissue 
development (Halder and Johnson 2011, Hergovich 2013, Yu and Guan 
2013). Dysregulation of the Hippo pathway is linked to different types of 
human cancers (Harvey, Zhang et al. 2013), clearly indicating that 
mammalian Hippo signalling function as a tumour suppressor pathway. 
Various genetic and biochemical studies have shown that the Hippo 
pathway is tightly regulated by various protein-protein interactions. 
Traditionally, activation of MST1/2 kinases triggers the phosphorylation 
and subsequently activation of the LATS1/2 kinases and MOB1A. In this 
regard, the interaction of MOB1A with LATS1/2 is an important step for 
LATS1/2-mediated phosphorylation and inactivation of YAP/TAZ 
(Hergovich 2012, Hoa, Kulaberoglu et al. 2016). In its on-state, mammalian 
Hippo signalling inactivates YAP/TAZ by LATS1/2-stimulated 
phosphorylation of YAP/TAZ through MST-MOB1A-LATS signalling. 
However, recent studies identified the NDR1/2 kinases as novel members of 
the core cassette of the Hippo pathway. More specifically, it was shown that 
NDR1/2 kinases can phosphorylate YAP on different residues, thereby 
resulting in the inactivation of YAP by cytoplasmic retention (Zhang, Tang 
et al. 2015). Furthermore, it was reported that NDR1/2 function as 
downstream of MST1, MST2, and MST3, and regulated by MOB1A 
binding (Hergovich, Stegert et al. 2006, Hergovich 2011, Hergovich 2013). 
Therefore, like LATS1/2, the NDR1/2 kinases can also function in Hippo 
core signalling as upstream kinases of YAP. 
Taken together, mammalian Hippo signalling is regulated by 
complex protein-protein interactions and phosphorylation events. However, 
it is currently unknown how Hippo signalling is controlled by the various 
protein-protein interactions of MOB1 with Hippo core kinases. In this 
context, studies of MOB1 knockout mice already indicate that MOB1 
functions as a central hub of Hippo signalling in tumour suppression, since   
(Nishio, Hamada et al. 2012, Nishio, Sugimachi et al. 2016) (Harvey, Zhang 
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et al. 2013). These studies further suggest that MOB1A has LATS1/2 and 
MST1/2 independent tumour suppressive functions possibly including the 
interaction of MOB1 with NDR1/2. Therefore, it is crucial to understand 
how MOB1A, as a central hub of Hippo signalling, differentially associate 
with the Hippo core kinases MST1/2, LATS1/2, and NDR1/2, thereby play 
important roles in tumour suppression. Therefore, we used our MOB1A 
variants as defined in Sections 3.1, 3.2, 3.3 to test which protein-protein 
interactions of MOB1 with Hippo core kinases are required for the 
suppression of cell proliferation and cellular transformation. Interestingly, 
our findings revealed that the association of MOB1A with MST1/2 or 
LATS1/2 is not essential for the suppression of cell proliferation. Moreover, 
we uncovered that the interaction of MOB1A with MST1/2 is dispensable 
for the suppression of anchorage-independent growth of human cancer cells, 
while the interactions with LATS1/2 and NDR1/2 appear to be essential for 
the tumour suppressive function of MOB1A 
 
 
 
  
151 | P a g e  
 
3.4.3. Results 
Mammalian Hippo signalling can be regulated through complex protein-
protein interactions of MOB1 with the Hippo core kinases MST1/2, 
LATS1/2, and NDR1/2 kinases. Considering that MOB1 deficient mice 
develop larger tumours with a broader range of tumour types than that of 
mice deficient for LATS1/2 or MST1/2, one can draw the conclusion that 
MOB1 functions as central hub of core Hippo signalling and has LATS1/2 
and MST1/2 independent tumour suppressive functions possibly including 
the interaction of MOB1 with NDR1/2. Thus, we exploited our MOB1A 
variants as defined in Sections 3.1, 3.2, 3.3 to understand which protein-
protein interactions of MOB1 with Hippo core kinases are essential for the 
suppression of cell proliferation and cellular transformation. To do so, we 
investigated two cell biological processes of human cancer cells. First, we 
examined whether MOB1 can function as a tumour suppressor by regulating 
cell proliferation. Second, we sought to study whether MOB1 can suppress 
anchorage-independent growth. 
To address our first aim, we generated human breast cancer MCF-7 
cells stably expressing our MOB1A mutants forms as outlined in section 
2.2.3.5. Lysates of transgenic MCF-7 cells were analysed by Western 
blotting to confirm the expression of our MOB1 versions (Figure 3.18a). 
Subsequently, cell proliferation rates of these cell pools were determined. 
The results are presented in Figure 3.18 below. 
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Figure 3.18. MOB1A functions as tumour suppressor by decreasing cell proliferation. 
(a) Lysates of MCF-7 cells stably expressing indicated cDNAs were processed for 
immunoblotting using indicated antibodies. Noteworthy, in spite of empty vector (lane 1), 
overexpression of the indicated hMOB1As (lanes 2, 3, 4, and 5) resulted in the decreased 
levels of total YAP1 comparable to empty vector (lane 1). Relative molecular weights are 
shown. (b) In parallel, the proliferation of MCF-7 cells stably expressing indicated cDNAs 
was monitored using IncuCyte live cell imaging for the indicated time periods. Data 
represent the average of three experiments performed in triplicates using cell pools that 
were generated independently three times (n=3, *p<0.05; **p<0.01; ***p<0.001; ns, not 
significant, compared to EV). Of note, all cell pools expressing indicated MOB1A variants 
displayed decreased cell proliferation compared to empty vector expressing cells.  
 
To test whether MOB1A can function as a tumour suppressor by 
suppressing human cancer cell proliferation, we stably expressed our 
MOB1A mutants in MCF-7 cells (Figure 3.18a), and then monitored the 
proliferation of these cell pools stably expressing our MOB1A mutants 
(Figure 3.18b). Importantly, this revealed that MOB1A(wt) can function as 
a tumour suppressor by decreasing cell proliferation of human cancer cells 
(Figure 3.18b, violet line). We further observed that the levels of total and 
phosphorylated YAP1 were decreased upon expression of MOB1A(wt) 
(Figure 3.18a, compare lanes 1 and 2). Surprisingly, expression of 
MOB1A(DV) or MOB1A(KEKE) resulted in decreased YAP1 levels and 
suppression of cell proliferation (Figure 3.18), suggesting that the 
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interaction of MOB1A with LATS1/2 or MST1/2, respectively, is 
dispensable for this tumour suppressive function of MOB1A. In contrast, 
cells expressing MOB1A(DVKEKE) did not suppress cell proliferation like 
wild-type MOB1A (Figure 3.18b, compare black and violet lines), 
although YAP1 protein levels were decreased like in cells expressing wild-
type MOB1A (Figure 3.18a, compare lanes 2 and 5). This finding 
indicates that the combined loss of binding to LATS1/2 and MST1/2 by 
MOB1A is impairing the tumour suppressive function of MOB1A without 
affecting the suppression of YAP1. Nevertheless, since MOB1A(DVKEKE) 
expressing cells still decrease proliferation and YAP1 levels when compared 
to empty vector (EV) expressing controls (Figure 3.18b, compare red and 
black lines), this finding further suggests that in addition to MST1/2 and 
LATS1/2 other YAP1 regulators are likely to be supported by MOB1A. 
Considering that MOB1A(DVKEKE) still binds normally to the NDR1/2 
kinases (see sections 3.1, 3.2, 3.3), it is quite likely that in our proliferation 
setting NDR1/2 remain their function as YAP regulators. 
Taken together, we report here that MOB1A can function as a 
tumour suppressor by controlling the YAP1 onco-protein. Furthermore, by 
using our hMOB1A mutants we could address which protein-protein 
interactions of MOB1 with Hippo core kinases are required for cell 
proliferation, which revealed that the association of MOB1A with MST1/2 
or LATS1/2 is not essential for the suppression of cell proliferation. 
Furthermore, our data revealed that NDR1/2 function as YAP regulator in 
cell proliferation setting (Figure 3.18).  
Next, to address our second aim, we generated MCF-7 cells stably 
expressing our MOB1A variants. Lysates of infected MCF-7 cells were 
analysed by Western Blotting to confirm expression of our MOB1A 
versions (Figure 3.19a). Subsequently, anchorage-independent growth 
assays were performed as described in (section 2.2.3.7). The results are 
presented in Figure 3.19 below. 
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Figure 3. 19.  MOB1A can suppress proliferation and anchorage-independent growth 
of human cancer cells through different interactions with Hippo core cassette kinases. 
(a) Immunoblotting with indicated antibodies of cell lysates derived from MCF-7 human 
breast cancer cells stably expressing the indicated HA-MOB1 variants or empty vector 
(EV). Relative molecular weights are indicated. (b) Quantifications of the soft agar growth 
assays shown in c. The average of three experiments performed in duplicates is shown 
(n=3, *p<0.05; **p<0.01; ***p<0.001; ns, not significant, compared to EV). P values are 
as follows: EV vs WT is 0.0014, EV vs DV is 0.7526, EV vs KEKE is 0.0245, EV vs 
DVKEKE is 0.1143 (d) Representative images are displayed. 
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To test whether MOB1A expression can play a role in suppressing 
anchorage-independent growth of human cancer cells, we infected MCF-7 
cells with retrovirus expressing MOB1A(wt) or EV and subsequently set up 
anchorage independent assay as described in section 2.2.3.7. Importantly, 
we discovered that MOB1A expression can significantly inhibit anchorage 
independent growth of MCF-7 cells (Figure 3.19). It has been shown that 
YAP1 overexpression can effectively induce anchorage independent growth 
of non-tumour breast cancer MCF10A cells (Overholtzer, Zhang et al. 
2006). Thus, we examined the levels of total YAP expression in our cell 
pools, revealing that total YAP1 expression is dramatically decreased in 
MOB1A(wt) expressing cells compared to empty vector controls (Figure 
3.19a, compare lanes 1 and 2).  
Next, we asked which protein-protein interactions of MOB1A with 
Hippo core kinases are required for suppressing anchorage-independent 
growth of MCF-7 cells. To do so, we tested cell pools expressing our 
MOB1A mutants in anchorage independent growth assays (Figure 3.19). 
We found that MOB1A(KEKE) expression can effectively inhibit 
anchorage independent growth as observed in MOB1A(wt) expressing cells 
(Figure 3.19). In stark contrast, expression of MOB1A(DV) or 
MOB1A(DVKEKE) failed to inhibit anchorage-independent growth 
(Figure 3.19), suggesting that the interaction of MOB1A with the LATS1/2 
kinases is essential for this tumour suppressive function of MOB1A. 
Taken together, in full support of our cell proliferation experiments 
(Figure 3.18), we show here that MOB1A(wt) can function as a tumour 
suppressor by inhibiting anchorage independent growth of MCF-7 cancer 
cells. Furthermore, our data revealed that complex formation of MOB1A 
with MST1/2 is dispensable for these tumour suppressive functions of 
MOB1A, while the interactions of MOB1A with the LATS1/2 and NDR1/2 
kinases are required for the suppression of cellular transformation 
phenotypes of MCF-7 cells.  
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3.4.4. Discussion 
The Hippo pathway is known as a master regulator of organ size control 
regulating cell, proliferation, death and cellular transformation (Harvey, 
Zhang et al. 2013, Hergovich 2013, Yu and Guan 2013, Johnson and Halder 
2014). Uncontrolled cell proliferation, death, cellular transformation are 
regarded as main hallmarks of cancer development (Hanahan and Weinberg 
2011). Mammalian Hippo signalling is tightly regulated by complex 
protein-protein interactions of MOB1 with the Hippo core kinases MST1/2, 
LATS1/2, and NDR1/2 kinases. However, very little is known about how 
MOB1, as central hub of the Hippo pathway, differentially associates with 
MST1/2, LATS1/2, and NDR1/2 and thereby potentially plays diverse 
tumour suppressive roles. In this regard, we molecularly characterized the 
interactions of MOB1A with MST1/2, LATS1/2, and NDR1/2 as outlined in 
sections 3.1, 3.2, and 3.3. Here, to cell biologically investigate the roles of 
MOB1A in tumour suppression, we generated MCF-7 cells stably 
expressing MOB1A(wt) and subsequently analysed cell proliferation rates 
and anchorage independent growth. Interestingly, our results revealed that 
MOB1A can function as a tumour suppressor by dramatically decreasing 
cell proliferation and anchorage independent growth (Figures 3.18 and 
3.19). Considering that the total protein levels of the proto-oncoprotein 
YAP1 also decreased upon MOB1A(wt) expression (Figures 3.18a and 
3.19a), it is tempting to draw the conclusion that the diminished 
proliferation and anchorage-independent growth of MCF-7 cells expressing 
MOB1A(wt) was caused by the decrease in YAP1 levels. 
Even more importantly, we used our MOB1A mutants to address 
which protein-protein interactions of MOB1A with Hippo core kinases are 
required for the suppression of cell proliferation and anchorage-independent 
growth of human cancer cells (Figures 3.18 and 3.19). Furthermore, on the 
one hand, our cell proliferation experiments uncovered that the interaction 
of MOB1A with MST1/2 or LATS1/2 is not essential for suppressing 
proliferation. On the other hand, our anchorage independent growth assay 
revealed that complex formation of MOB1A with MST1/2 is dispensable 
for the suppression of anchorage-independent growth of human cancer cells, 
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while the interactions with LATS1/2 and NDR1/2 appear to be required for 
the tumour suppressive function of MOB1A.  
 
 
 
 
 
 
 
 
 
 
 
  
158 | P a g e  
 
3.5. Defining the tumour suppressive roles of MOB1A interactions 
with the Hippo core kinases in Drosophila melanogaster 
 
3.5.1. Abstract 
In Drosophila, the Hippo pathway is an essential signalling cascade which 
is required for normal development and tissue growth control. The central 
Hippo core cassette in Drosophila consists of the Hippo core kinases Hpo, 
Wts, and Trc (the counterparts of human MST1/2, LATS1/2, and NDR1/2), 
as well as Mats (the counterpart of human MOB1A/B). A recent study 
showed that loss-of-function of Mats results in embryonic homozygous 
lethality and severe tissue overgrowth phenotype in mosaic eyes, suggesting 
that Mats functions as a central hub of fly Hippo signalling. Very 
interestingly, the same study also showed that the tissue overgrowth 
phenotype caused by Mats loss-of-function can be rescued by expression of 
human MOB1A, suggesting that the regulation of Hippo signalling by 
MOB1A/Mats is highly conserved from Drosophila to humans. Therefore, 
we sought to determine whether MOB1A expression can also rescue the 
homozygous lethality driven by Mats loss-of-function. Indeed, we 
discovered that the homozygous lethality caused by mats loss-of-function 
can be rescued by MOB1A expression. We therefore used the MOB1A 
rescue of the mats mutation in flies as a paradigm to test the importance of 
MOB1A interaction with its partners by introducing into flies MOB1A 
transgenes bearing various mutations. Intriguingly, the study of these flies 
revealed that the Hippo/MOB1A interaction is neither required for life nor 
for tumour suppression (suppression of tissue overgrowth), while the other 
interactions of MOB1A with Hippo core cassette kinases are essential in a 
context-dependent manner. 
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3.5.2. Introduction 
The coordination of cell growth, proliferation, and death determines the 
appropriate number of cell in tissue and thereby organ size (Harvey, Zhang 
et al. 2013). Dysregulation of these processes can result in cancer 
development (Harvey, Zhang et al. 2013). Recent studies discovered Hippo 
signalling as a master regulator of these processes in Drosophila 
melanogaster. Drosophila Hippo core signalling consists of the Hippo core 
kinases Hpo, Wts, Trc, as well as the signal transducer Mats (Hergovich 
2016). Mechanistically, Hpo phosphorylates and thereby activates Wts and 
Mats (Yang, Cron et al. 2002). The complex composed of Mats/Warts then 
phosphorylates and thereby inhibits Yorkie (the counterpart of human 
YAP/TAZ) (Hergovich 2013). The phosphorylation of Mats by Hpo seems 
to play a crucial role in promoting the association of Mats with Wts and 
ultimately the activation of Warts (Wei, Shimizu et al. 2007, Zheng, Wang 
et al. 2015), although this activation model has been challenged recently 
(Vrabioiu and Struhl 2015). Moreover, it was also shown that Mats also can 
associate with Trc and that complex formation of Trc with Mats can play an 
important role in the regulation of fly wing development (He, Emoto et al. 
2005, Hergovich 2012, Hergovich 2016). Indeed, Mats mutant cells in fly 
wing display phenotypes that are typical of Trc and Wts deficiency (He, 
Emoto et al. 2005), strongly suggesting that Mats can be essential for Trc 
and Warts signalling.  
Taken together, Drosophila Hippo signalling is regulated by various 
protein-protein interactions involving the Mats (aka dMOB1) as a central 
signal transducer. Recent findings actually show that the core components 
of the Hippo pathway are evolutionally conserved from Drosophila to 
humans (Geng, He et al. 2000, Wu, Huang et al. 2003, Lai, Wei et al. 2005, 
Hergovich 2011). However, it is currently unknown how the Drosophila 
Hippo pathway is regulated by the protein-protein interactions of 
Mats/dMOB1 with the Hippo core kinases. Specifically, it is vital to 
understand how Hpo/Wts/Trc kinase signalling is regulated by Mats. A 
recent report using conformation sensors proposed that the Wts/Mats 
complex formation is required for allosteric Wts activation, while the 
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Hpo/Mats interaction seem to be dispensable (Vrabioiu and Struhl 2015). 
However, these findings are solely based on FRET conformation sensors 
and the actual molecular basis of Wts activation by Mats remains unknown. 
Hence, experimental evidence using full-length proteins carrying selective 
manipulations is yet outstanding. We report here that the expression of 
MOB1A(wt) can rescue the homozygous lethality driven by Mats loss-of-
function. Moreover, our study of MOB1A variants in transgenic flies 
revealed that the Hippo/MOB1A interaction is neither required for viability 
nor for tumour suppression. In contrast, the interactions of MOB1A with the 
other Hippo core cassette kinases Wts and Trc are essential in a context-
dependent manner. 
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3.5.3. Results – The characterisation of mats loss-of-function and 
transgenic flies expressing MOB1A variants  
Lai et al (2005) observed that mats loss-of-function causes embryonic 
lethality, with increased cell proliferation and tissue overgrowth in mosaic 
clones. More importantly, they showed that expression of human 
MOB1A(wt) in Mats mutant clones compensated for the mats loss-of-
function in larval eye discs (Lai, Wei et al. 2005). Since MOB1A expression 
can rescue mats loss-of-function phenotype in mosaic clones, we speculated 
that MOB1A expression may compensate for the embryonic lethality caused 
by mats loss-of-function. To test this hypothesis, we generated transgenic 
flies expressing myc-tagged MOB1A(wt) under the control of the ubiquitin 
63E promoter (ubi>myc-hMOB1A(wt). Furthermore, to understand which 
PPIs between MOB1A and Wts, Trc, Hpo are required to prevent embryonic 
lethality, we also generated transgenic flies expressing our MOB1A variants 
in the same locus using the ΦC31 integrase system. However, before we 
could test whether the embryonic lethality caused by mats loss of function 
can be rescued by MOB1A(wt) expression, we confirmed that mats trans-
heteroallelic combinations result in the homozygous embryonic lethality in 
our setting. The crosses outlined in Figure 3.20. 
     
 
Figure 3.20. Confirmation of the homozygous lethality caused by mats loss-of-
function.  
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The aim of this cross was to confirm that the lethality is caused by mats loss-of-function, 
independently of additional mutations in in the available mats mutants stocks.  Female 
virgin w;; FRT82B, mats
roo
/ TM6B flies were crossed with male w;; FRT82B, mats
e235
/ 
TM6B flies as outlined. After this crossing, only heterozygous flies developed to 
adulthood, while homozygous flies failed to develop 
 
To confirm that the homozygous lethality driven by mats results from mats 
loss-of-function, flies carrying two independent mats mutant alleles (mats
roo
 
and mats
e235
) were crossed (Figure 3.20). The mats
e235
 mutant allele was 
generated by P-element mobilisation (Lai, Wei et al. 2005), which is the 
process of imprecise transposon excision leading to deletion of surrounding 
genomic sequences. mats
235
 results in deletion of most of the mats coding 
sequence. The mats
roo
 mutant allele is an insertion of a 428 base pair Roo 
transposon at the beginning of the mats third exon (Lai, Wei et al. 2005), 
leading to premature termination of the Mats protein. Both alleles are 
though to be null for the mats locus. As expected, these alleles failed to 
complement each other, confirming the lethality of the mats mutations 
(Figure 3.20). 
After confirming that mats loss-of-function results in homozygous 
embryonic lethality (see section 3.5.3 above), we sought to test whether 
MOB1A(wt) can compensate for the embryonic lethality driven by mats 
loss-of-function. To do so, the mats
roo
 transgene was recombined into the 
proximity of the chromosomal arm where our MOB1A(wt) transgene was 
integrated (see section 2.2.5.3). MOB1A(wt) and MOB1A variants were 
inserted on third chromosome at cytological location 89E11 using the ΦC31 
integrase-mediated transgenesis system, which utilises the recombination 
between an attP docking site and the bacterial attachment attB site (Figure 
3.21a). For the recombination of the Mats
Roo
 transgene, Virgin w;; 
ubi>myc-hMOB1A, endogenous Mats/ FRT82B, Mats
roo 
flies were crossed 
with male +/TM6B flies (see section 2.2.5 for further details). 
Importantly, to ensure that MOB1A(wt) and MOB1A mutants are expressed 
equally, we performed Western blot analysis of transgenic flies (see Figure 
3.21b). Our results presented in Figure 3.21b show that MOB1A(wt) and 
MOB1A variants are expressed equally. After the required recombination 
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and confirmation of equal expression of our MOB1A variants in the 
different fly lines, we performed the crosses presented in Figure 3.21c.  
 
 
Figure 3.21. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) 
rescues larval lethality of mats deficient flies. 
(a) Schematic representation of the generation of MOB1A transgenic flies. Plasmids which 
can ubiquitously express N-terminally myc-tagged wild-type (wt) or mutant human MOB1 
(ubi>-myc-hMOB1A) were inserted into an identical genome location (attP site at 89E11 on 
chromosome 3) using ΦC31-mediated recombination. (b) Whole flies of indicated 
genotypes were analysed by Western blotting. Equal expression of the myc-tagged MOB1A 
transgenes was observed. DV/KE/KE, D63V/K104E/K105E. (c) Genetic schemes 
illustrating how we tested which MOB1A transgenes can rescue the larval lethality of Mats 
deficient flies. wt, wild-type; DV, D63V; KE/KE, K104E/K105E; DV/KE/KE, 
D63V/K104E/K105E. Adult flies expressing myc-MOB1A(wt) or myc-
MOB1A(K104E/K105E) in a mats null (mats
roo
/mats
e235
) genetic background are viable 
and fertile, indicating that the interaction of MOB1 with Hippo is dispensable for normal 
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fly development. In contrast, adult flies expressing myc-MOB1A(D63V) or myc-
MOB1A(D63V/K104E/K105E) in a mats null background were not observed, indicating 
that the interaction of MOB1 with Wts is essential for normal fly development.  
 
To determine whether MOB1A can rescue the embryonic lethality caused 
by mats loss-of-function, w;; ubi>myc-MOB1A(wt), mats
roo
/ TM6B flies 
were mated with w;; FRT82B, mats
e235
/ TM6B flies as outlined in Figure 
3.20. This cross revealed that homozygous embryonic lethality caused by 
Mats loss-of-function can be rescued by transgenic ubiquitous expression of 
human MOB1A (wt) (Figure 3.21c, first cross). 
We identified and characterized MOB1A variants with respect to 
binding to Hpo, Wts, and Trc (defined in sections 3.2 and 3.3 above). 
Therefore, considering further that MOB1A(wt) can rescue the homozygous 
lethality caused by homozygous mats loss-of-function (Figure 3.21c, first 
cross), we sought to test which PPIs of MOB1A with the Hippo core 
kinases are required to prevent embryonic lethality of Mats null flies. To do 
so, we generated transgenic flies expressing our MOB1A mutants from one 
fixed chromosomal location (Figure 3.21a) and performed compensation 
crossings, as shown in Figure 3.21 c. As expected, transgenic flies 
expressing MOB1A(DV) or MOB1A(DVKEKE) failed to compensate for 
the lethality driven by mats loss-of-function (Figure 3.21c). In stark 
contrast, transgenic flies expressing MOB1A(KEKE) were viable and fertile 
in a mats null background, hence indicating that expression of 
MOB1A(KEKE) fully compensates for mats loss-of-function like flies 
expressing wild-type MOB1A (Figure 3.21c). Considering that 
MOB1A(DV) is deficient in binding to Wts, while MOB1A(KEKE) does 
not associate with Hpo (see section 3.2 above), these results collectively 
indicate that the binding of MOB1A to Wts is necessary for normal fly 
development, while complex formation between MOB1A and Hpo is 
dispensable. 
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 3.5.4. Results – The characterisation of transgenic flies expressing 
MOB1A variants in mosaic fly tissues 
We showed above that two independent mutant mats alleles result in 
homozygous lethality in Drosophila. Furthermore, we found that expression 
of MOB1A(wt) or MOB1A(KEKE) can rescue for homozygous lethality 
caused by mats loss-of-function, while expression of MOB1A (DV) or 
MOB1A(DVKEKE) cannot compensate for mats loss-of-function (see 
sections 3.5.3). To further characterise our lines of transgenic mutant flies, 
clonal analysis was performed. These genetic mosaic analyses allowed us to 
analyse mutant phenotypes of an essential genes at different tissue levels. 
Specifically, using genetic mosaic approaches, patches of homozygous 
mutant tissues can be generated in a heterozygous background. To achieve 
this in our settings, FRT sites were recombined into the long arm of the third 
chromosome of our transgenic flies (see section 2.2.5.4). Consequently, 
upon expression of the FLP recombinase somatic crossovers can be 
achieved (see section 2.2.5.8). We recombined the FRT sites as described in 
section 2.2.5.4. After the FRT recombination, the mosaic flies were 
generated as described in section 2.2.5.8 to test three different FLP 
approaches: adult eye, the imaginal discs eye, the imaginal discs wing. 
First, we examined the functions of our MOB1A variants in 
Drosophila adult eye development.  The results of adult eye are presented in 
Figure 3.22 below.  
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Figure 3.22. Ubiquitous expression of human MOB1(wt) or MOB1(K104E/K105E) 
rescues tissue overgrowth phenotype driven by Mats loss-of-function 
Briefly, virgin ey-FLP;;FRT82B GFP/TM6B were crossed with ey-FLP;;FRT82B 
GFP/TM6B (a) w;; FRT82B,ubi>MOB1A(WT), Mats
roo
/TMB6 (b), w;; 
FRT82B,ubi>MOB1A(DV), mats
roo
/TMB6 (c), w;; FRT82B,ubi>MOB1A (KEKE), 
Mats
roo
/TMB6 (d), w;; FRT82B,ubi>MOB1A (DVKEKE), mats
roo
/TMB6 (e), and w;; 
FRT82B, mats
roo
/TMB6. mats loss-of-function caused by mats
roo 
result in severe 
overgrowth phenotype (f). This severe overgrowth phenotype can be rescued by expression 
of MOB1A(wt) (b) or MOB1A(KEKE) (d), while MOB1A(DV) (c) and 
MOB1A(DVKEKE) (e) display overgrowth phenotype compared to control (a).   
 
In the first instance, we targeted the formation of mats clones to the eye 
imaginal disc (the larval epithelial structure giving rise to the adult eye) by 
expressing FLPase under the control of the eye-specific eyeless promoter 
(eyFLP, Newsome, TP et al Development 2000). 
167 | P a g e  
 
Our findings further confirmed that Mats loss-of-function caused by the 
transgene mats
roo
 developed severe overgrowth eye phenotype (Lai, Wei et 
al. 2005) (Figure 3.22f) and this severe overgrowth eye phenotype can be 
rescued by the expression of MOB1A(wt) (Lai, Wei et al. 2005) (Figure 
3.22b). Furthermore, our findings revealed that the expression of 
MOB1A(KEKE) fully rescued the severe overgrowth eye phenotype like 
flies expressing MOB1A(wt) (Figure 3.22b and 3.22d), while the 
expression of MOB1A(DV) or MOB1A(DVKEKE) failed to completely 
compensate for the severe overgrowth phenotype (Figure 3,22c and 3.22e). 
Taken together, in full agreement with our compensation crossing regarding 
normal fly development (Figure 3.21c), MOB1A(wt) or MOB1A(KEKE) 
can functionally replace Mats in both Drosophila embryogenesis and eye 
development, while MOB1A(DV) or MOB1(DVKEKE) cannot rescue for 
mats loss-of-function. These findings reveal that the Hippo/MOB1A 
interaction is neither required for fly development nor for tumour 
suppression. In contrast, the interactions of MOB1A with the other Hippo 
core cassette kinases Wts and Trc are essential in a context-dependent 
manner. Interestingly, flies expressing MOB1A(DV) or 
MOB1A(DVKEKE) with eye specific Mats loss-of-function did not display 
as severe tissue overgrowth phenotypes as observed upon Mats loss-of-
function alone (Figure 3.21). Considering that MOB1A(DV) or 
MOB1A(DVKEKE) can still bind to Trc, these observations imply that 
complex formation of MOB1A with Trc possibly can help to regulate tissue 
growth to some extent. 
Traditionally, the final output of Drosophila Hippo signalling is to 
restrict cell proliferation by inhibiting the transcriptional co-activator Yki. 
To monitor Yki activity, two well-characterised Yki targets Expanded (Ex) 
and Diap are commonly used as readout (Huang, Wu et al. 2005, 
Hamaratoglu, Willecke et al. 2006). Therefore, we used the Yki target genes 
Ex as a readout for Yki activity. Specifically, we examined the functions of 
our MOB1A variants in imaginal discs wing and eye by monitoring Yki 
activity using the target gene Ex. we dissected wing and eye imaginal discs, 
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after generating mosaic flies, and immunostained with Ex antibodies 
(summarized in section 2.2.5.8 and 2.2.5.9). 
We generated clones in the wing and eye imaginal discs by 
expressing FLPase under the control of the heat shock protein 70 (hsp70 – 
hsFLP) and eye-specific eyeless (eyFLP) promoters, respectively. The 
results of wing and eye imaginal discs are presented in Figure 3.23 and 3.24 
below. 
  
 
Figure 3.23. Ubiquitous expression of the MOB1A(wt) transgene restores ex 
upregulation in mats
roo
 mutant clones in wing imaginal discs.  
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(A, A’, C, C’) Maximum intensity projections of the apical region of wing imaginal discs 
containing mats
roo
 clones (negatively marked by GFP), immunostained for Ex protein in 
red. (B, B’, B’’, D, D’, D’’). X-Z confocal sections through the same wing discs shown in 
A and C.  Nuclei are stained with DAPI (blue). Ex protein levels increase markedly in 
Mats
roo
 clones (A, B), but this increase is rescued by expressing of MOBA(wt) transgene 
(C, D).  Larvae were heat-shocked at 3 days after egg laying, and dissected as wandering 
L3s (approximately day 7). All scale bars are 20 µm. These studies were performed in 
collaboration with the Tapon Labaratory. Pictures were kindly provided by Dr. Maxine 
Holder. 
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Figure 3.24. Ubiquitous expression of MOB1A(wt) transgene rescues Ex upregulation 
in mats
roo
 mutant clones in the eye imaginal discs. 
(A, A’, C, C’) Maximum intensity projections of the apical region of eye imaginal discs 
containing mats
roo
 clones (negatively marked by GFP), immunostained for Ex protein. (B, 
B’, D, D’). X-Z confocal sections through the same eye discs shown in A and C.  Nuclei are 
stained with DAPI. Ex protein levels increase markedly in Mats
roo
 clones (A, B), but this 
increase is rescued by expressing the MOB1A(wt) transgene (C, D).  Larvae were heat-
shocked at 3 days after egg laying, and dissected as wandering L3s (approximately day 7).  
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All scale bars are 20 µm. These studies were performed in collaboration with the Tapon 
Labaratory. Pictures were kindly provided by Dr. Maxine Holder. 
 
Our findings reported in section 3.5.5.1 revealed that Mats loss-of-function 
drives tissue overgrowth phenotype in the eye (Figure 3.22f). Furthermore, 
we also confirmed that tissue overgrowth phenotype caused by Mats loss-
of-function can be rescued by the expression of MOB1A(wt) (Figure 
3.22b). The final output of Drosophila Hippo signalling is to negatively 
regulate Yki. Therefore, we used the Yki target gene Ex as a readout, which 
is a well-established readout for monitoring Yki activity (Hamaratoglu, 
Willecke et al. 2006). Our findings revealed that Mats loss-of-function 
result in strong upregulation of Ex protein in the wing and eye imaginal 
discs (Figure 3.23 and 3.24). Moreover, we confirmed that Ex upregulation 
driven by Mats loss-of-function can be rescued by the expression of 
MOB1A(wt) (Figure 3.23 and 3.24). We next used our MOB1A variants to 
address which PPIs of MOB1A with Hippo core kinases is required for the 
regulation of Yki activity. The results are presented in Figure 3.25 and 3.26 
below.    
172 | P a g e  
 
 
Figure 3.25.  Expression of MOB1A(KEKE) restores normal Ex levels in mats
roo
 
mutant clones in the wing imaginal disc, while expression of MOB1A(DV) or 
MOB1A(DVKEKE) does not. 
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(A, A’, C, C’, E, E’) Maximum intensity projections of the apical region of wing imaginal 
discs containing mats
roo
 clones (negatively marked by GFP in green), immunostained for 
Ex protein in red. (B, B’, B’’, D, D’, D’’, F, F’, F’’) X-Z confocal sections through the 
same wing discs shown in A, C and E.  Nuclei are stained with DAPI in blue. Ex protein 
levels still increase in mats
roo
 clones in the presence of the MOBA(DV) and 
MOB1A(DVKEKE) transgenes (A, B, E, F), but not in the presence of the 
MOB1A(KEKE) transgene (C, D). Larvae were heatshocked at 3 days after egg laying, and 
dissected as wandering L3s (approximately day 7).  All scale bars are 20 µm. These studies 
were performed in collaboration with the Tapon Labaratory. Pictures were kindly provided 
by Dr. Maxine Holder. 
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Figure 3.26. Expression of MOB1A(KEKE) restores normal Ex levels in mats
roo
 
mutant clones in the eye imaginal disc, while expression of MOB1A(DV) or 
MOB1A(DVKEKE) does not. 
(A, A’, C, C’, E, E’) Maximum intensity projections of the apical region of eye imaginal 
discs containing Mats
roo
 clones (negatively marked by GFP), immunostained for Ex protein. 
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(B, B’, D, D’, F, F’) X-Z confocal sections through the same wing discs shown in A, C and 
E.  Nuclei are stained with DAPI. Ex protein levels still increase in mats
roo
 clones in the 
presence of the MOB1A(DV) and MOB1A(DVKEKE) transgenes (A, B, E, F), but not in 
the presence of the MOB1A(KEK1) transgene (C, D).  Larvae were heat-shocked at 3 days 
after egg laying, and dissected as wandering L3s (approximately day 7).  All scale bars are 
20 µm. These studies were performed in collaboration with the Tapon Labaratory. Pictures 
were kindly provided by Dr. Maxine Holder. 
 
We previously identified and characterized MOB1A variants with 
respect to binding to Hpo, Wts, and Trc (see sections 3.2 and 3.3). 
Considering further that expression of MOB1A(wt) can rescue the tissue 
overgrowth phenotype caused by Mats loss-of-function (Figure 3.22), we 
sought to test which PPIs of MOB1A with the Hippo core kinases are 
required for the regulation of Yki activity. To do so, we generated mosaic 
clones in the wing and eye imaginal discs and monitored Yki activity 
through Ex expression levels (Figure 3.24). Importantly, our findings 
revealed that mats null mutant clones with MOB1A(DV) or 
MOB1A(DVKEKE) expression displayed the elevated Ex expression 
(Figures 3.25 and 3.26) as observed in Mats null clones (Figures 3.23 and 
3.24). In contrast, upon expression of MOB1A(KEKE) in Mats deficient 
clones, we could not detect any significant increase of Ex expression 
(Figures 3.25 and 3.26). Therefore, the data shown in Figures 3.25 and 
3.26 suggest collectively that only MOB1A(KEKE) or MOB1A(wt) 
expression is sufficient to suppress Yki activity in Mats mutant clones. 
Taken together, these findings further indicate that Hpo/MOB1A complex 
formation is not important for the regulation of Yki activity, while 
Wts/MOB1A and possibly also Trc/MOB1A complex formations are 
required for tissue growth by regulating Yki activity in our experimental 
settings. 
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3.5.3. Discussion 
Hippo signalling in Drosophila regulates tissue growth by the coordination 
of cell proliferation, and apoptosis (Zhao, Li et al. 2010). Current evidence 
proposes that Drosophila Hippo signalling is tightly regulated by complex 
protein-protein interactions of Mats with the Hpo, Wts, and Trc kinases 
(Hergovich 2011, Hergovich 2016). Recent studies showed that the 
functions of Mats are highly conserved from Drosophila to humans, since 
Mats loss-of-function can be compensated by the expression of human 
MOB1A (Lai, Wei et al. 2005).  However, it has remained unknown how 
Mats, as a central hub of the Hippo pathway, differentially interacts with the 
Hippo core kinases Hpo, Wts, and Trc and thereby potentially regulate 
tissue growth through different signalling branches. In a recent study, 
Vrabioiu et al. (2015) proposed that Mats/Wts complex formation is 
essential for Wts activation, while Mats/Hpo complex formation is 
dispensable for Wts activation. However, these findings (Vrabioiu and 
Struhl 2015) are solely based on conformational sensors. In contrast, Ni et 
al. (2015) reported that complex formation of MST1/2(Hpo) with MOB1A 
is crucial for LATS1/2(Wts) activation. 
Therefore, we decided to investigate the regulatory interactions of 
Mats/MOB1 with the central Hippo core kinase cassette. First, we defined 
the molecular characteristic of the MOB1A interactions with Hpo(MST1/2), 
Wts(LATS1/2), and Trc(NDR1/2) as described in section 3.2, 3.2, and 3.3. 
Second, we studied MOB1A interactions in human cancer cell lines as 
outlined in section 3.4. Third, to develop research tools that allow us to 
investigate the roles for MOB1A interactions with Hippo core kinases in 
tissue growth, we generated transgenic flies expressing full-length versions 
of our MOB1A variants and subsequently profiled the viability, tissue 
overgrowth phenotype, and Yki target gene expression in these fly lines. 
Importantly, we found that the expression of human MOB1A(wt) can rescue 
the homozygous lethality caused by mats loss-of-function. Our findings 
further revealed that Hpo/MOB1A complex formation is not required for 
normal fly development, while the other interactions of MOB1A with the 
Wts and Trc kinases appear to be required for fly development. To further 
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consolidate our findings, we generated mosaic fly tissues expressing our 
MOB1A transgenes in mats null clones. This revealed that expression of 
MOB1A(wt) can prevent the tissue overgrowth phenotype driven by Mats 
loss-of-function. In addition, we also tested our MOB1A variants and found 
that Hpo/MOB1A complex formation is dispensable, while the other 
interactions of MOB1A with Hippo core cassette kinases are essential to 
prevent tissue overgrowth in adult fly eyes. Lastly, we studied Ex expression 
as a readout to monitor Yki activity in mats deficient tissues expressing our 
MOB1A transgenes. As expected, our findings revealed that Mats loss-of-
function results in upregulation of Ex proteins, while human MOB1A(wt) 
can decrease the upregulation of Ex to normal level in mats mutant clones, 
thereby showing that MOB1A(wt) expression can also rescue for mats loss-
of-function in these settings. Significantly we also showed that 
Hpo/MOB1A complex formation is dispensable for the regulation of Ex 
levels in a Mats loss-of-function background. In contrast, the other 
interactions of MOB1A with the Hippo core kinases seem to be essential for 
the regulation of Ex upon the Mats loss-of-function. Taken together, our 
study of MOB1A variants in transgenic flies revealed that the Hpo/MOB1A 
interaction is neither required for life nor for tumour suppression (the 
regulation of tissue overgrowth), while the interactions of MOB1A with the 
other Hippo core cassette kinases Wts and Trc are essential. 
Moreover, we noted two interesting aspects of our in vivo data. Firstly, 
while MOB1A/Hpo PPI disruption did not have a detectable effect on 
MOB1A function in the context of an otherwise wild type MOB1A 
(MOB1A(KEKE) mutant), we observed that, in the context of disrupted 
MOB1A/Wts interaction (MOB1A(DVKEKE) mutant), the Hpo/MOB1A 
interaction did affect MOB1A function. This is illustrated by the fact that, in 
the eye overgrowth assay, the MOB1A(DVKEKE) flies were noticeably 
more overgrown than MOB1A(DV) flies (compare the more wrinkled 
appearance of the head in Figure 3.22e with Figure 3.22c). Furthermore, in 
the wing clone experiments, we noticed that, while Ex levels were elevated 
in both the MOB1A(DVKEKE) and MOB1A(DV) situations, the 
MOB1A(DVKEKE) clones showed a high frequency of clone delamination 
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and loss in the wing pouch, indicative of a strong overgrowth phenotype and 
similar to the full mats mutant phenotype (Maxine Holder, personal 
communication). Thus, in the context of a weakened MOB1A function, loss 
of the MOB1A/Hpo interaction does reduce MOB1A in vivo function. 
 
The second interesting aspect of our in vivo work is that, while the 
MOB1A(DVKEKE) rescued flies showed a strong eye overgrowth 
phenotype and Ex upregulation (Figures 3.22e, 3.25e, 3.26e), these 
phenotypes were markedly weaker than the full mats loss-of-function 
phenotypes (compare Figure 3.22f with 3.22e), suggesting 
MOB1A(DVKEKE) can partially rescue the mats mutant phenotype. This 
could be due to several reasons. Firstly, as the MOB1A/Trc is not disrupted 
in the MOB1A(DVKEKE) mutant, the ability of this construct to partially 
rescue the mats mutant phenotype could be mediated by the MOB1A/Trc 
weakly repressing Yki activity. Indeed, Trc has been proposed to function 
partially redundantly with Wts, at least in some contexts (He, Emoto et al. 
2005). Secondly, despite the fact that the MOB1A(DVKEKE) mutant is 
severely impaired in its ability to bind Wts, it is nevertheless possible that 
some low-affinity Wts binding activity remains, which could be sufficient to 
partially rescue the mats mutant when MOB1A(DVKEKE) is overexpressed 
in vivo. To distinguish between these possibilities, we could deplete Trc in 
the context of the MOB1A(DVKEKE) rescue experiments to test for 
phenotypic enhancement. In addition, we could generate and introduce into 
flies mutations that either selectively disrupt the MOB1A/Trc or both the 
MOB1A/Trc and MOB1A/Wts interactions to test their ability to fully or 
partially rescue the mats phenotype. 
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4. Final discussion 
Hippo signalling has emerged as a tumour suppressor pathway regulating 
cellular processes such as cell proliferation, apoptosis, and differentiation 
(Hergovich 2016). Importantly, Hippo signalling is highly conserved from 
Drosophila to humans and is tightly regulated by complex protein-protein 
interactions involving complex formations of the MOB1A/B 
(Mats/dMOB1) signal transducer with the Hippo core kinases 
MST1/2(Hpo), LATS1/2(Wts), and NDR1/2(Trc) (Hergovich 2012). 
Recent studies of Mats (aka dMOB1).  revealed that Mats loss-of-
function results in more severe overgrowth phenotypes than Wts loss-of-
function in Drosophila (Tao, Zhang et al. 1999, Lai, Wei et al. 2005). In 
fully support of this, studies of MOB1 knockout mice reported that MOB 
loss-of-function results in the most dramatic tumour formation comparing to 
that of other Hippo components (Nishio, Sugimachi et al. 2016). Altogether, 
these findings suggest that MOB1(Mats/dMOB1) is the most important 
element of Hippo core signalling and functions as a master tumour 
suppressor. However, the molecular mechanism how MOB1(Mats) 
functions as a master tumour suppressor in Hippo signalling is not 
completely understood. These findings collectively suggest that 
MOB1(Mats) has LATS(Wts) independent tumour suppressor functions 
possibly including MOB1(Mats)/MST1/2(Hpo) or/and 
MOB1(Mats)/NDR1/2(Trc) complexes.  
   
4.1. Final discussion - from structural biology to cell culture 
Our data presented in section 3.1 provide, for the first time, crystal 
structures of the MOB1A-NDR2 complex, revealing key residues that are 
required for binding of MOB1A to NDR kinases. Specifically, our findings 
uncovered that MOB1A employs its negatively-charged surface to associate 
with positively charged residues of NDR2. Significantly, our structure based 
sequence alignment of different members of the NDR/LATS kinase family 
also revealed a single key residue of MOB1A that is required for binding of 
MOB1A to LATS1 kinase, but not to the NDR2 kinase. 
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In addition to our structural analysis of NDR/LATS kinases, 
considering further that (i) negatively charged surfaces of MOB1A are 
responsible for the interactions with positively charged surfaces of 
NDR/LATS kinases and (ii) that MOB1 interacts with MST1/2 differently 
than with NDR/LATS (Praskova, Xia et al. 2008, Kohler, Schmitz et al. 
2010, Ni, Zheng et al. 2015, Tang, Gill et al. 2015), we selectively mutated 
positively charged residues of MOB1A and tested their binding properties. 
This resulted in the discovery of two key residues of MOB1A that are 
essential for binding of MOB1A to the MST1/2 kinases. 
To further profile the importance of the key residues that are 
selectively required for binding to the MST1/2, LATS1/2, and NDR1/2 
kinases, we generated mutant forms of MOB1A carrying substitutions of 
selected residues and tested their binding properties to full-length MST1/2, 
LATS1/2, and NDR1/2 kinases in mammalian cells (see section 3.1). 
Significantly, these experiments established the importance of selected 
residues of MOB1A that are selectively essential for binding of MOB1A to 
the MST1/2, LATS1/2, and NDR1/2 kinases. Specifically, we discovered 
that D63 of MOB1A forms a hydrogen bonds with H646 of LATS1, while 
D63 of MOB1A is not important for binding to the corresponding residue 
F31 of NDR2. Supportively, our biochemical experiments show that mutant 
forms of MOB1A carrying D63 to V (D63V) substitutions completely 
abolish the binding of MOB1A to LATS1/2, but not to NDR1/2, suggesting 
that the binding of MOB1A to the LATS1/2 and NDR1/2 kinases is 
selectively supported by different key residues. In addition, our biochemical 
experiments revealed that mutant versions of MOB1A carrying K104/K105 
to E (K104E/K105E) substitution abrogate the binding of MOB1A to the 
MST1/2 kinase, but not to the LATS1/2 and NDR1/2 kinases. However, it is 
currently unknown how MOB1A interacts through these two residues with 
MST1/2 on the structural level. Therefore, the definition of crystal 
structures of the MOB1/MST complex are now warranted in order to help 
us understand the detailed molecular mechanism of the MOB1/MST 
complex formation.  
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The core components of the Hippo pathway are highly conserved 
from Drosophila to humans (Hergovich, Stegert et al. 2006, Hergovich 
2016). Considering that expression of wild-type human MOB1A can 
compensate for the tissue overgrowth phenotype caused by Mats/dMOB1 in 
Drosophila (Lai, Wei et al. 2005), we hypothesized that the regulation of the 
Hippo core kinases by Mats/dMOB1 is also conserved from Drosophila to 
humans. Significantly, in support of this hypothesis, our findings presented 
in section 3.2 revealed that the interaction patterns of MOB1A with the fly 
Hippo core kinases Hpo, Wts, and Trc in Drosophila cells are highly similar 
with the patterns observed in mammalian cells. Specifically, using human 
cells and proteins, we showed that D63 of MOB1A is required for 
associating with LATS1/2, but not with NDR1/2 and MST1/2, while 
K104E/K105E of MOB1A is essential for binding to MST1/2, but not to 
NDR1/2 and LATS1/2. Thus, we also tested MOB1A variants carrying 
substitutions of selected residues with regard to binding to full-length Hpo, 
Wts, and Trc kinases in fly cells. Significantly, our findings revealed that 
MOB1A carrying D63 to V (D63V) substitution disrupts the association 
with Wts, but not with Trc and Hpo, while MOB1A carrying K104/K105 to 
E (K104E/K105E) substitutions abrogate the interaction with Hpo, but not 
with Trc and Wts. These findings are fully consistent with the findings 
observed in mammalian cells. Our structure based sequence alignment of 
the conserved N-terminal regulatory domain of NDR/LATS kinases further 
showed that the H646 and F31 residues of LATS1 and NDR2, respectively, 
are conserved in Drosophila Wts and Trc, respectively, thereby suggesting 
that D63 of MOB1A also makes a hydrogen bond with the His residue of 
Wts that corresponds to H646 in human LATS1. Furthermore, our 
biochemical experiments showed that the positively charged K104 and 
K105 residues are essential for binding to Hpo. However, further structural 
studies are now required to provide insights into the complex formation of 
MOB1A with the fly Hippo core kinases. Collectively, these observations 
support our notion that the regulation of Hippo core signalling by MOB1A 
(Mats) is highly conserved from Drosophila to humans.    
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In sections 3.1, and 3.2, we characterized and defined the important 
residues that selectively impair the binding of MOB1A to the Hippo core 
kinases MST1/2(Hpo), LATS1/2(Wts), and NDR1/2(Trc) in mammalian 
(fly) cells. Considering that MOB1A(Mats) is regulated through 
phosphorylation by MST1/2(Hpo), we examined also the phosphorylation 
status of our selected MOB1A variants by MST1, MST2, and Hpo as a 
complementary approach to our characterisation of MOB1A variants. 
Significantly, our findings presented in section 3.3 show that all our 
MOB1A variants are normally phosphorylated on Thr12 and Thr35 by 
MST1, MST2, and Hpo like wild-type MOB1A. Considering that 
MOB1A(KEKE) does not stably interact with MST1/2 and Hpo, but is 
phosphorylated by MST1/2 and Hpo like wild-type MOB1A, we are 
tempted to conclude that MOB1A-MST1/2(Hpo) complex formation is not 
essential for MST1/2(Hpo)-mediated phosphorylation of MOB1A. Even 
more importantly, these findings suggest that changes in MST1/2(Hpo)-
mediated phosphorylation of MOB1A are very unlikely the cause of the 
observed alterations of binding patterns of our MOB1A variants. 
Taken together, our findings presented in sections 3.1, 3.2, and 3.3 
allowed us to establish novel research tools to study the biological 
significance of the interactions of MOB1A with the Hippo core kinases 
MST1/2(Hpo), LATS1/2(Wts), and NDR1/2(Trc) kinases in the context of 
mammalian and fly Hippo core signalling. 
        
4.2. Final discussion - from human cells and Drosophila 
melanogaster 
After characterizing the residues of MOB1A that selectively play crucial 
roles in binding to the Hippo core kinases MST1/2(Hpo), LATS1/2(Wts), 
and NDR1/2(Trc), we investigated the selected roles of MOB1A in tumour 
suppression in section 3.4. Significantly, we discovered that MOB1A 
functions as a tumour suppressor by inhibiting cell proliferation and 
anchorage-independent growth of human breast cancer cells. Our cell 
proliferation-based experiments showed that the association of MOB1A 
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with MST1/2 or LATS1/2 is not required for suppressing cell proliferation 
of human breast cancer cells. Our anchorage-independent growth 
experiments revealed that the interaction of MOB1A with MST1/2 is not 
essential for the suppression of anchorage-independent growth of breast 
cancer cells, while complex formation of MOB1A with LATS1/2 and 
NDR1/2 appear to be required for the tumour suppressive function of 
MOB1A in this setting. More specifically, our findings revealed that 
disruption of the interaction of MOB1A with the LATS1/2 or MST1/2 
kinases results in decreased YAP1 levels and suppression of cell 
proliferation, suggesting that the interaction of MOB1A with LATS1/2 or 
MST1/2, respectively, is dispensable for this tumour suppressive function of 
MOB1A. In contrast, our findings showed that disruption of the interaction 
of MOB1A with both LATS1/2 and MST1/2 does not suppress cell 
proliferation like wild-type MOB1A, although YAP1 protein levels are 
decreased like in cells expressing wild-type MOB1A. This finding indicates 
that the combined loss of binding to LATS1/2 and MST1/2 by MOB1A is 
impairing the tumour suppressive function of MOB1A without affecting the 
suppression of YAP1. Nevertheless, since disruption of the interaction of 
MOB1A with both LATS1/2 and MST1/2 still decrease proliferation and 
YAP1 levels when compared to controls, this finding further suggests that in 
addition to MST1/2 and LATS1/2 other YAP1 regulators are likely to be 
supported by MOB1A. In this context, it is quite likely that in our 
proliferation setting NDR1/2 maintain their function as YAP regulators, 
which would explain why YAP1 levels are consistently downregulated 
irrespective of the type of MOB1A variant that was expressed. 
In addition to addressing the roles of MOB1A in cancer cells, we 
also examined the roles of MOB1A in Drosophila melanogaster. Our 
findings presented in section 3.5 revealed, for the first time, that expression 
of wild-type human MOB1A can rescue for the homozygous lethality 
caused by Mats/dMOB1 loss-of-function. Moreover, our results uncovered 
that complex formation of MOB1A with Hpo is dispensable, while the 
interactions of MOB1A with Wts and Trc are required for normal fly 
embryogenesis/development. Our findings presented in section 3.5 further 
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show that complex formation of MOB1A with the Wts and Trc kinases is 
required for tissue growth control in the adult fly eye, while the 
Hpo/MOB1A interaction is dispensable in this context. Importantly, our 
findings in section 3.5 further revealed that Mats/dMOB1 loss-of-function 
in wing and eye imaginal discs leads to elevated Ex expression, which is a 
well-established readout for Yki activity (the counterpart of human YAP1). 
In this regard, we found that the upregulation of Ex can be reversed by 
expression of wild-type human MOB1A, further confirming that the 
functions of Mats/dMOB1 are conserved from Drosophila to humans. 
Moreover, our data indicate that MOB1A with a disruption in Hpo/MOB1A 
complex formation can still suppress the upregulation of Ex, while 
disruption of the interaction between Wts and MOB1A does not reverse 
elevated Ex expression in Mats mutant clones. Collectively, these findings 
revealed that stable Hpo/MOB1A complex formation is not important for 
the regulation of Yki activity, while Wts/MOB1A and possibly also 
Trc/MOB1A complex formations are required for tissue growth control by 
regulating Yki activity in our experimental settings.  
Taken together, our experimental results performed in both mammalian 
cells and Drosophila reveal that complex formation of MST1/2(Hpo) with 
MOB1A is dispensable, while interaction of MOB1A with LATS1/2(Wts) is 
required for tumour suppression (suppression of tissue overgrowth) in 
human cells and Drosophila. Our findings are fully consistent with the 
findings of Vrabioiu et al. (2015). Using chimeric sensor proteins, Vrabioiu 
et al. (2015) reported that Wts/Mats complex formation is required for Wts 
activation, while the Hpo/Mats interaction appears to be dispensable for the 
activation of Wts, and hence Hippo signalling. However, Ni et al. (2015) 
reported that MST/MOB1 complex formation is required for the activation 
of the LATS kinases. However, latter evidence (Ni, Zheng et al. 2015) is 
solely based on structural biology and biochemistry using truncated protein 
versions. Noteworthy, our results presented in this thesis do not support 
their notion, namely that MST/MOB1 complex formation is essential. One 
explanation of this discrepancy might be that they only studied truncated 
proteins and did not test the interaction patterns using full-length proteins in 
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tissue culture cells. In our research, we used full-length versions of all the 
proteins tested and investigated their functions in mammalian cells as well 
as Drosophila melanogaster. Thus, we are very tempted to conclude that 
evidence only based on structural and biochemical studies can be quite 
misleading, and therefore observations should also be confirmed cell 
biologically using even multicellular organisms if possible.  
 
4.3. Future outlook 
Studies of knockout mice revealed that MOB1 loss-of-function results in a 
range of different cancers in mice (Nishio, Sugimachi et al. 2016). Thus, a 
future key question should be the investigation of PPIs of MOB1 with the 
MST1/2, LATS1/2, and NDR1/2 kinases described herein in mouse tissues 
with MOB1 loss-of-function. Specifically, one should consider to use our 
MOB1A variants described herein to address which protein-protein 
interactions of MOB1 with the MST1/2, LATS1/2, NDR1/2 kinases are 
required for the suppression of cancer development. In this regard, we are 
confident that the use of the newly-developed gene engineering technology 
CRISPR-Cas9 (Jinek, Chylinski et al. 2012) has a great potential to lead the 
way. In addition to MOB1 functioning as a central regulator of Hippo core 
signalling, recent studies reported that MOB1 can be involved in the 
regulation of microtubule dynamics (Florindo, Perdigao et al. 2012). Thus, 
protein-protein interactions of MOB1 with the Hippo core kinases MST1/2, 
LATS1/2, and NDR1/2 might play important roles in regulating microtubule 
dynamics as well. It is noteworthy that MOB1 can also bind to PRAJA2 and 
DOCK8 proteins to regulate different cellular processes (Mou, Praskova et 
al. 2012, Lignitto, Arcella et al. 2013). On the one hand, PRAJA2 was 
shown to bind to and ultimately ubiquitylate MOB1, thereby playing a role 
in glioblastoma multiform growth (Lignitto, Arcella et al. 2013). On the 
other hand, phosphorylation of MOB1A by the MST1/2 kinases was shown 
to promote the binding of MOB1A to the DOCK8 guanyl nucleotide 
exchanger (Mou, Praskova et al. 2012). Consequently, MOB1 can be 
involved in different cellular processes in addition to Hippo signalling. 
Considering our findings, namely that MOB1 is tightly associated through 
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protein-protein interactions with the Hippo core kinases MST1/2, LATS1/2, 
and NDR1/2, one should consider to investigate whether any of the 
interactions of MOB1 with these kinases are potentially affecting DOCK8 
and PRAJA2-dependent signalling outputs. Thus, discovery of the key 
residues that are selectively required for binding to the MST1/2, LATS1/2, 
and NDR1/2 kinases should provide an excellent platform to address such 
key questions in the future. 
In my thesis, we discovered the key residues that is required for 
binding to the MST1/2, LATS1/2, and NDR1/2 kinases and established 
important and novel research tools to study the importance of protein-
protein interactions of MOB1A with the MST1/2, LATS1/2, and NDR1/2 
kinases in MOB1-regulated cellular processes. Moreover, we also managed 
to integrate human MOB1A(wt) into the Mats loss-of-function flies and 
showed that human MOB1A(wt) can rescue homozygous lethality caused 
by the Mats loss-of-function. Furthermore, we also successfully integrated 
our selective MOB1A variants into the Mats loss-of-function flies, thereby 
establishing novel research tools to study the importance of protein-protein 
interactions of MOB1A with the Hpo, Wts, and Trc kinases in different 
signalling concepts.  
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Supplementary Data 
Supplementary Table S1 Data collection and refinement statistics. 
Rmerge = Rmerge = hi |Ih,i – Ih|/hi Ih,i for the intensity (I) of observation i of 
reflection h. R factor = ||Fobs| - |Fcalc||/|Fobs|, where Fobs and Fcalc are the 
observed and calculated structure factors, respectively. Rfree = R factor 
calculated using 5% of the reflection data chosen randomly and omitted 
from the start of refinement. RMSD, root-mean-square deviations from ideal 
geometry. Data for the highest resolution shell are shown in parentheses. 
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Table S1: Data collection and refinement statistics 
Data collection  
Space group P212121 
Unit-cell parameters a=57.5 Å, b=94.4 Å, c =102.2 
Å; α=β=γ=90° 
Number of molecules/asymmetric unit 2 
Resolution range (Å) 50-2.10 (2.18-2.10) 
Completeness (%) 99.6 (100.0) 
Redundancy  
Total observations 
6.9 (6.4) 
226,859 
Unique reflections 32,723 
Rmerge (%) 10.0 (61.3) 
I/σI  16.3 (3.1) 
Refinement  
Rwork (%) 15.3 
Rfree (%) 24.4 
Overall B factor 42.3 
RMSD bond lengths (Å) 0.013 
RMSD bond angles (°) 1.507 
202 | P a g e  
 
Ramanchandran plot (favored, allowed, 
disallowed, % ) 
99.0, 0.6, 0.4 
Final model (Number of protein/solvent 
atoms) 
4,149/267 
 
 
 
  
203 | P a g e  
 
Supplementary Figure S1 PCR genotyping.  
 
 
 
Figure S1: PCR genotyping of the indicated flies. The primers Roo Internal 1 and 97 (specified in 
section 2.1.5) was used to confirm the Roo transposon. 
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Supplementary Figure S2 PCR genotyping.  
 
 
 
 
Figure S2: PCR genotyping of the indicated flies. The primers Neo2 f and hsp70_FRT r (specified 
in section 2.1.5) was used to confirm the FRT site. 
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Appendix 2 
 
Appendix Figure 1: The TAO1 kinase phosphorylate GCKIII kinases on their T-loop 
phosphorylation site in fly and human cells. 
(A) Lysates of Drosophila S2R+ cells expressing full-length HA-Tao1 wild-type (wt) or 
kinase-dead (kd) together with indicated full-length GckIII versions were subjected to 
immunoprecipitation (IP) using anti-HA 12CA5 antibody. Complexes were analysed by 
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immunoblotting using anti-myc (top) and anti-HA (top middle). Input lysates were analysed 
with anti-myc (bottom middle) and anti-actin (bottom). 
(B) S2R+ cells were transfected with indicated versions of fly Tao1 and GckIII, before 
whole cell extracts were processed for Western blotting using anti-T167-P (top), anti-myc 
(top middle), anti-HA (bottom middle) and anti-actin (bottom). 
(C) Lysates of S2R+ cells transiently expressing full-length HA-Tao1 variants were 
subjected to immunoprecipitation with anti-HA 12CA5 antibody. Immunopurified proteins 
were then processed for kinase assays without or with the indicated recombinant full-length 
and kinase-dead Mal-GckIII version. Following kinase reactions, the samples were 
examined by immunoblotting using the specified antibodies. Importantly, the anti-T167-P 
antibody specifically detected Tao1-mediated phosphorylation of GckIII on Thr167 
(compare lanes 3, 9 and 11). 
(D) Lysates of human HEK293 cells expressing full-length HA-GCKIII variants (MST3, 
MST4 or STK25) together with indicated full-length myc-TAO1 were subjected to IP using 
anti-HA, before Western blot analysis of complexes and input lysates using indicated 
antibodies. 
(E) HEK293 cells were transfected with indicated versions of human TAO1, before whole 
cell extracts were processed for Western blotting using the specified antibodies. 
Noteworthy, increased T-loop phosphorylation of human GCKIII kinases was observed 
upon TAO1 overexpression. 
(F) Lysates of HEK293 cells transiently expressing full-length human HA-TAO1 variants 
were subjected to immunoprecipitation with anti-HA. Immunopurified kinases were then 
processed for kinase assays without or with the indicated recombinant full-length and 
kinase-dead Mal-GCKIII versions (MST3, MST4 or STK25). Following kinase reactions, 
the samples were examined by immunoblotting using the specified antibodies. Importantly, 
TAO1-mediated T-loop phosphorylation of human GCKIII kinases was only observed 
when wild-type TAO1 was incubated with kinase-dead GCKIII kinases. Relative molecular 
weights are shown. 
 
 
To determine whether GckIII is potentially directly regulated by Tao1 in fly 
cells, we investigated Tao1/GckIII complex formation in Drosophila S2R+ 
cells (Appendix Fig. 1A). N-terminally tagged versions of HA-Tao1 and 
myc-GckIII were co-expressed, followed by immunoprecipitation using 
anti-HA. This revealed that irrespective of their activity status Tao1 and 
GckIII can form a complex in fly cells, as judged by the co-
immunoprecipitation of wild-type and kinase-dead variants (Appendix Fig. 
1A). Next, considering that Tao1 can function as upstream kinase of Hippo 
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(Poon, Lin et al. 2011), we sought to test whether Tao1 can also act as 
upstream kinase of the Hippo-like GckIII kinase. To do so, we pursued two 
lines of research. First, we examined in fly cells the level of T-loop 
(Thr167) phosphorylation on GckIII upon Tao1 co-expression (Appendix 
Fig. 1B). Second, we studied Tao1-mediated phosphorylation of 
recombinant full-length GckIII in vitro (Appendix Fig. 1C). The 
phosphorylation of kinase-dead GckIII was elevated upon Tao1 expression 
(Appendix Fig. 1B) and in vitro the T-loop phosphorylation of GckIII was 
dependent on Tao1 kinase activity (Appendix Fig. 1C). Significantly, these 
experiments collectively showed that fly Tao1 can phosphorylate GckIII on 
Thr167 in the activation T-loop in cells and in vitro (Appendix Fig. 1B and 
1C). 
 Considering that GckIII is conserved between flies and humans, we 
asked next whether human TAO1 can also interact with and phosphorylate 
MST3, MST4 and/or STK25, the three human counterparts of fly GckIII, 
hence collectively termed hGCKIII. The corresponding human cDNAs were 
expressed in human HEK293 cells and TAO1/hGCKIII complex formation 
was assessed by co-immunoprecipitation experiments (Fig. XD). 
Furthermore, the T-loop phosphorylation of endogenous hGCKIII was 
studied in cells transiently overexpressing HA-TAO1(wt) or HA-TAO1(kd) 
(Appendix Fig. 1E), and the phosphorylation of recombinant full-length 
kinase-dead hGCKIII versions by TAO1 was investigated in vitro 
(Appendix Fig. 1). These experiments jointly revealed, like observed for fly 
Tao1/GckIII (Appendix Fig. 1A-C), that human TAO1 and hGCKIII can 
form complexes (Appendix Fig. 1D), and even more importantly, that 
human TAO1 phosphorylates all three hGCKIII kinases on their T-loop 
regulatory site (Appendix Fig. 1E and 1F). Taken together, our data 
presented in Appendix Fig. 1 suggest that GCKIII kinases are bona fide 
substrates of TAO1 in fly and human cells. 
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